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ABSTRACT 
Inhibiting BCR-ABL kinase activity with tyrosine kinase inhibitors (TKIs) has been 
the frontline therapy for CML. Resistance to TKIs frequently occurs, but the 
mechanisms remain elusive.  
First, to uncover survival pathways involved in TKI resistance in CML, I 
conducted a genome-wide RNAi screen in human CML cells to identify genes 
governing cellular sensitivity to the first generation TKI called IM (Gleevec). I 
identified genes converging on and activating the MEK/ERK pathway through 
transcriptional up-regulation of PRKCH. Combining IM with a MEK inhibitor 
synergistically kills TKI-resistant CML cells and CML stem cells.  
Next, I performed single cell RNA-seq to compare expression profiles of CML 
stem cells and hematopoietic stem cells isolated from the same patient. Among 
the genes that are preferentially expressed in CML stem cells is PIM2, which 
encodes a pro-survival serine-threonine kinase that phosphorylates and inhibits 
the pro-apoptotic protein BAD. Inhibiting PIM2 function sensitizes CML stem cells 
to IM-induced apoptosis and prevents disease relapse in a CML mouse model.  
Last, I devised a CRISPR-Cas9 based strategy to perform insertional 
mutagenesis at a defined genomic location in murine hematopoietic Ba/F3 cells. 
As proof of principle, we showed its capability to perform unbiased, saturated 
point mutagenesis in a 9 amino acid region of BCR-ABL encompassing the so-
called “gatekeeper” residue, an important determinant of TKI binding. We found 
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that the ranking order of mutations from the screen correlated well with their 
prevalence in IM-resistant CML patients.  
Overall, my findings reveal novel resistance mechanisms in CML and provide 
alternative therapeutic strategies. 
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CHAPTER I: INTRODUCTION 
1.1 Chronic Myeloid Leukemia (CML) 
A Brief History of CML 
The first description of leukemia dates back to 1840s, David Craigie and his 
college John Hughes Bennett saw a few cases of patients experiencing fever, 
splenomegaly and leukocytosis, and subsequent death between 1841 and 
1845(Goldman, 2010). These characteristics suggest the possibility of first case 
of chronic myeloid leukemia (CML). Later in 1872, Ernst Neumann recognized 
the origination of leukemia from bone marrow(Goldman, 2010).   
 
The specific association of cytogenetic defect and leukemia was first established 
in 1960 when Nowell and Hungerford described a consistent abnormal minute 
chromosome in the blood of seven patients with chronic granulocytic 
leukemia(Nowell PC, 1960). Later, the finding of this minute chromosome was 
confirmed by others and became known as “Philadelphia chromosome” (Ph 
chromosome). With the improvement of chromosome banding techniques, 
Rowley further demonstrated in 1973 that the Ph chromosome comprised 
truncated version of chromosome 9 and 22 that originate from a reciprocal 
chromosomal translocation event, designated t(9;22)(Rowley, 1973).   
A seminal study from Groffen and colleagues in 1984 reported the presence of a 
“breakpoint cluster region” in 17 different CML patients, and this region 
constitutes a part of the BCR gene(Groffen et al., 1984). Meanwhile, Witte and 
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colleagues showed that c-Abl, encoded by ABL gene, was associated with 
abnormal kinase activity of in K562 CML cells, establishing a possible casual link 
between BCR and ABL(Konopka et al., 1984; Lozzio and Lozzio, 1975).  
Between 1984 and 1985, studies led by Eli Canaani from Weizmann Institute 
confirmed the presence of a BCR-ABL fusion transcript in cells from CML 
patients, revealing the major molecular abnormality in CML(Canaani et al., 1984; 
Shtivelman et al., 1985). In 1990, the casual relationship of BCR-ABL and CML 
was further established by Daley et al(Daley et al., 1990) and Kelliher et al 
(Kelliher et al., 1990), who demonstrated that retroviral transduction of BCR-ABL 
gene into murine stem cells could induce CML-like leukemia in mice, resembling 
the chronic phase of CML in patients.  
CML Pathology and Epidemiology 
CML is a myeloproliferative disease (MPD), characterized by unregulated growth 
of immature granulocytes in peripheral blood and bone marrows(Faderl et al., 
1999).  One obvious symptom of CML is the elevated white blood cell count, with 
majority of cell being mature neutrophils, myelocytes, basophils and eosinophils, 
usually with few blasts(Faderl et al., 1999).  While around 40% of CML patients 
are asymptomatic at diagnosis of the disease, other patients demonstrate 
splenomegaly(Redaelli et al., 2004; Sawyers, 1999). Uncontrolled granulocyte 
accumulation in the peripheral blood, and infiltration of lung and liver will finally 
lead to patient death(Daley et al., 1990).  
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The annual incidence of CML is about one to two cases per 100,000 people with 
a median onset age at 53 years(Redaelli et al., 2004). CML is typically present in 
chronic, accelerated and blast crisis phases(Faderl et al., 1999). Chronic phase 
CML usually has a long latency, which are typically 4-5 years, and majority of the 
cells in peripheral blood are neutrophils. Impairment of ATR signaling by BCR-
ABL promotes genomic instability and the accumulation of additional genetic 
lesions(Dierov et al., 2004). Additionally, BCR-ABL suppressed expression of a 
myeloid-specific transcription factor CEBPα by increasing stability of its 
translational regulator HNRNPE2, leading to differentiation arrest of CML 
cells(Melo and Barnes, 2007). These events lead to accumulation of immature 
blast cells in peripheral blood and CML progression. When some CML patients 
may go through a transient accelerated phase, which last for 6-9 months, other 
patients may directly enter blast crisis phase with more than 20% of blood cells 
being CML blasts(Schiffer et al., 2003). Without therapy, blast crisis CML patients 
may only survive for 3-6 months(Faderl et al., 1999).  
Conventional Therapy for CML 
In early 20th century, CML patients were predominantly treated with radiotherapy, 
which usually is directed to the spleen (Goldman, 2010). In 1960s, 
chemotherapies using busulfan and hydroxyurea often replaced radiotherapy as 
an alternative, but none of them were able to eradicate Ph+ cells(Goldman, 
2010). In early 1980s, interferon-α (IFNα) was introduced to treat CML patients in 
chronic phase. Unlikely busulfan and hydroxyurea, IFNα was capable of 
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achieving complete and durable Ph- hematopoiesis in a minority group of 
patients, and even can be discontinued without disease relapse in rare 
cases(Talpaz et al., 1986). A meta-analysis of seven randomized trials involving 
1,554 patients showed that IFNα treatment leads to ~57% of 5-year survival rate 
compared to 42% using chemotherapy(1997). Therefore, IFNα has been 
considered the major option for newly diagnosed CML patients.   
Up to now, the only proven cure for CML could be allogeneic bone marrow 
transplantation (BMT). A case was reported in 1979 using total body irradiation 
followed by transfusion of bone marrow cells from human leukocyte antigen(HLA) 
identical siblings(Fefer et al., 1979). In this case, patient remained Ph- in his 
marrows at follow-up interval of 22-31 months, therefore becoming the first case 
of CML that can be cured by bone marrow transplantation(Fefer et al., 1979). 
The 5 year overall survival rate of CML patients receiving allogeneic BMT are 
60% to 80%, while the leukemia-free survival rate are 55% to 70%(Goldman, 
2010). Majority of survivors show no evidence of leukemia or Ph chromosome, 
but certain patients do relapse within the first 3 years of transplant(Gaziev et al., 
2002). 
1.2 Molecular and Cellular basis of CML 
Ph Chromosome and BCR-ABL oncogene 
Since its first description by Nowell and Hungerford in 1960, Ph Chromosome 
has been shown to be present in >95% of CML patients, strongly suggesting the 
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causal relationship with CML. In addition, Ph chromosome was also found in 
~20% of acute lymphoblastic leukemia (ALL)(Kurzrock et al., 2003). Ph 
chromosome produces a constitutively active oncogenic tyrosine kinase, BCR–
ABL, by fusing Abelson kinase gene (ABL or ABL1) with the breakpoint cluster 
region gene (BCR)(Kurzrock et al., 1987).  
ABL gene is located on the long arm of chromosome 9 and encodes a 145kb 
protein product, c-Abl, which acts as a non-receptor tyrosine kinase(Rosenberg 
and Witte, 1988). c-Abl protein can shuttle between nucleus, where it binds to 
DNA and regulates cell cycle and genotoxicity, and cytoplasm, where it is 
involved in cytoskeleton remodeling and substrate phosphorylation(Van Etten, 
1999; Wang, 1998; Wetzler et al., 1993). Normal c-Abl function is tightly 
regulated, replacement with N-terminal BCR leads to high and constitutive c-Abl 
kinase activity in the cytoplasm, leading to oncogenic transformation (Pendergast 
et al., 1991; Pluk et al., 2002; Van Etten, 1999).  
BCR gene is located on the long arm of chromosome 22, and produces two 
major isoforms, 130kd and 160kd, respectively(Dhut et al., 1988; Stam et al., 
1987). Similar to c-Abl, Bcr protein also resides in both the cytoplasmic and 
nuclear compartments(Dhut et al., 1988; Laurent et al., 2000; Wetzler et al., 
1993). When ABL gene breaks at the identical location, BCR gene has several 
breakpoint region (m-bcr, M-bcr, µ-bcr)(Kurzrock et al., 2003). The first exon of 
BCR possesses several highly conserved Src-Homology-2 (SH2) binding 
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domain, which is important for assembling signal transduction 
complexes(Sadowski et al., 1986). This exon exists in all BCR-ABL fusion 
proteins and is thought to play a pivotal role in oncogenesis(Kurzrock et al., 
2003).  
The classic fusion event in CML is b2a2 or b3a2, which fuses exon2 (b2) or 
exon3 (b3) of BCR to exon 2 (a2) of ABL, leading to an oncoprotein of 210 kd 
molecular weight, dubbed p210 BCR-ABL(Melo, 1996). Depending on the 
junction, BCR-ABL has two other isoforms, p190 and p230. Among them, p210 
isoform is predominantly found in CML, and p230 was also present in a small 
percentage of CML. p190 is the major isoform found in BCR-ABL+ Acute 
Lymphoblastic Leukemia(Melo, 1996), and it was thought to have higher tyrosine 
kinase activity and therefore more transforming capability than p210 and p230(Li 
et al., 1999).  
In contrast to c-Abl and Bcr protein, BCR-ABL protein was found exclusively in 
the cytoplasm(Kurzrock et al., 2003). The fusion event brings together the 
functional domains of Bcr and Abl, therefore making a variety of cytoplasmic 
signaling proteins accessible to phosphorylation and activation by Abl. BCR-ABL 
could either directly activate these pathways by interacting with the key signaling 
molecule or by indirectly increased cytokine or growth factor secretion, therefore 
establishing an autocrine feedback loop.    
Oncogenic BCR-ABL signaling pathways 
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The growth and differentiation of hematopoietic cells is maintained by various 
cytokine-stimulated signaling pathway. However, oncogene BCR-ABL bypasses 
the requirement of these extracellular stimuli and drives cytokine-independent 
cell growth and proliferation while inhibiting apoptosis, leading to subsequent cell 
transformation and CML development (Ren, 2005). The key signaling pathways 
activated by BCR-ABL include, but not limited to, RAF/MEK/ERK, JAK/STAT, 
and PI3K/AKT pathway(Steelman et al., 2004) as described below. 
The RAF/MEK/ERK pathway is also known as mitogen-activated protein kinase 
(MAPK) pathway, and can be stimulated by mitogen, cytokines and growth 
factors(Steelman et al., 2004). MAPK pathway mediates signal transduction from 
cell surface to the nucleus(McCubrey et al., 2007).  One well-studied example is 
RAS mediated MAPK activation(Yan et al., 1998). Ras is a small GTP-binding 
protein. Once growth factor receptor encounters its ligand and becomes 
phosphorylated on tyrosine residues. A docking protein Grb2 will then be 
recruited by directly binding to the phosphotyrosine through its SH2 domain while 
forming a complex with a guanine nucleotide exchange factor (GEF), SOS, 
through its SH3 domain. RAS can be activated by SOS, which promotes 
exchanging of GDP to GTP, but inactivated by GTPase-Activating Protein (GAP), 
which catalyzes the removal of phosphate from GTP. The GTP-bound active 
conformation of RAS recruits RAF protein to the membrane through the Ras 
binding domain present in RAF. Subsequent phosphorylation events at several 
serine/threonine sites lead to RAF activation(Fabian et al., 1993). Then RAF 
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protein phosphorylates and activates of primary downstream target MEK, which 
further phosphorylates and activates ERK. Activated ERK transmits signal into 
nucleus by phosphorylating and activating downstream targets, such as the 40S 
ribosomal protein S6 kinase, c-Myc, and Elk1, to regulate protein translation and 
gene expression required for cell cycle entry and mitosis.  
BCR-ABL transformed cells have constitutively RAF/MEK/ERK pathway 
activation(Steelman et al., 2004). It was shown that BCR-ABL 
autophosphorylates itself at Y177 position, which serves as docking site for 
Grb2(Million and Van Etten, 2000). BCR-ABL further recruits scaffolding Gab2 
adaptor protein via Grb2/Gab2 complex as a signal amplifier to mediate 
downstream pathway activation, including RAF/MEK/ERK pathway(Lock et al., 
2000; Sattler et al., 2002). Y177F mutation abolishes this interaction and 
dramatically impairs myeloid leukemogenesis.  Gab2 knockout in mice blocks 
PI3K/AKT and RAF/MEK/ERK pathway activation and BCR-ABL 
transformation(Sattler et al., 2002). In addition, BCR-ABL could stimulate 
RAF/MEK/ERK pathway by directly regulating RAF1(Skorski et al., 1995).  
JAK/STAT pathway mediates sensing of extracellular stimuli, including cytokines, 
and transmitting the signal into nucleus by directly modulating transcription of 
gene involved in proliferation, differentiation and immunity(Leonard, 2001; 
Rawlings et al., 2004). JAK/STAT pathway consists of three components: cell 
surface receptor, Janus kinase(JAK), and STAT proteins(Steelman et al., 2004). 
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Ligand binding induces receptor homodimerization or heterodimerization, and 
this receptor aggregation facilitates transphosphorylation and subsequent 
activation of associated JAKs(Rawlings et al., 2004). Once activated, JAKs could 
phosphorylate additional tyrosine residues on the receptor, leading to recruitment 
and subsequent phosphorylation of SH2 domain-containing STAT proteins. 
Phosphorylation of STATs induces their dimerization through SH2 domain 
interaction, which promotes their movements into nucleus, DNA binding and 
transcription activation ability.  
Constitutive STATs activation has also been shown in CML cells and BCR-ABL+ 
ALL cells(Danial and Rothman, 2000). In cells containing p210 BCR-ABL, the 
major activated STAT protein is STAT1 and STAT5, while only p190 was 
reported to have the ability to activate STAT6(Ilaria and Van Etten, 1996). Unlike 
v-Abl, which mediates STAT5 activation via direct associating with JAK kinase at 
its c-terminal domain, there is no evidence showing physical interaction of BCR-
ABL with STATs. It was demonstrated that kinase inactive JAK2 fails to block 
STAT5 activity in BCR-ABL transformed Ba/F3 cells(Ilaria and Van Etten, 1996). 
SRC family kinases (e.g., Hck, and Lyn) can activate STAT5 independent of 
JAK2 during IL-3 signaling(Silva, 2004). Because SRC family kinases are often 
stimulated by BCR-ABL in CML cells, this leads to the characterization of Hck as 
an intermediate in BCR-ABL-dependent activation of STAT5 via its binding to 
BCR-ABL SH2 and SH3 domain(Klejman et al., 2002).   
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PI3K/AKT pathway was first discovered during the characterization of insulin 
signaling in early 1980s, and it has been shown to play a pivotal role in regulating 
cell growth, proliferation, and apoptosis(Hemmings and Restuccia, 2012; 
Vanhaesebroeck et al., 2012). PI3Ks (Phosphatidylinositol-3 kinases) constitute 
a lipid kinase family that can phosphorylate the 3’-OH group of inositol ring in 
inositol phospholipids(Steelman et al., 2004). As an example, activated insulin 
receptor could directly stimulate bound class I PI3K via its regulatory subunit to 
catalyze the conversion of phosphatidylinositol (3,4)-bisphosphate (PIP2) lipids to 
phosphatidylinositol (3,4,5)-trisphosphate (PIP3) in seconds. Then, protein 
kinase B (PKB, also known as AKT) binds to PIP3 at the plasma membrane via 
its pleckstrin-homology (PH) domain, leading to the conformation change and 
allowing 3-phosphoinositide-dependent protein kinase 1 (PDPK1) to access and 
phosphorylate the activation loop at T308 site. This phosphorylation event is 
thought to stabilize the activation loop and result in partial activation of PKB/AKT. 
Full activation of PKB/AKT requires a second phosphorylation event at S473 site 
in its hydrophobic C-terminal region by PDPK2(Feng et al., 2004; Sarbassov et 
al., 2005). Fully activated PKB/AKT regulates a number of cellular functions, 
including metabolism, survival, proliferation and protein synthesis, by 
phosphorylating both cytoplasmic and nuclear substrates(Hemmings and 
Restuccia, 2012). Notably, one of such phosphorylation event leads to inhibition 
of pro-apoptotic FOXO family proteins(Guertin et al., 2006).  
PI3K/AKT pathway activation contributes to another signaling downstream of 
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BCR-ABL to promote cell transformation(Steelman et al., 2004).  Activation of 
PI3K/AKT pathway by BCR-ABL depends on the binding of BCR-ABL SH2 
domain to the p85 regulatory subunit(Steelman et al., 2004). Cells expressing 
BCR-ABL Y177F mutant exhibited marked reduction of tyrosine phosphorylation 
in Gab2, and reduced association of PI3K with Gab2 and BCR-ABL(Sattler et al., 
2002). In addition, it was shown that elevated ROS level by BCR-ABL in 
TonB.210 cells also contributes to activation of PI3K/AKT pathway by activating 
AKT, GSK3β, as well as its downstream targets such as β-catenin, and Mcl-
1(Naughton et al., 2009). A negative regulator of PI3K/AKT pathway, PP2A, is 
also inhibited by BCR-ABL mediated SET protein expression, which is a potent 
physiological inhibitor of PP2A(Neviani et al., 2005).  
Cancer stem cells in CML 
Like normal stem cells, which can self-new and fuel the growth of normal 
proliferative tissues such as bone marrow, skin and intestinal epithelium, cancer 
stem cells are also thought to be capable of self-renewal and serve as the 
unlimited source of rapidly proliferating bulk cancer cells(Huntly and Gilliland, 
2005; Reya et al., 2001; Visvader and Lindeman, 2008). The concept of cancer 
stem cells was first introduced by the study in Acute Myeloid Leukemia (AML) 
(Bonnet and Dick, 1997), Bonnet and Dick transplanted the leukemic counterpart 
of normal HSCs, CD34+CD38- population, from AML samples into NOD/SCID 
mice and found that they possess the ability of leukemia initiation and 
differentiation into leukemic blast. The capability of transferring AML into 
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secondary recipients by serial transplantation confirmed the self-renewal nature 
of CD34+CD38- cell population(Bonnet and Dick, 1997). It is thought that cancer 
stem cells are phenotypically the same as normal stem cells(Tang, 2012). 
Cancer stem cells were thereafter reported in many solid tumors, including breast 
cancer(Al-Hajj et al., 2003), pancreatic cancer(Li et al., 2007), brain tumor(Singh 
et al., 2003), and lung cancer(Kim et al., 2005). 
Despite compelling evidence of the presence of cancer stem cells, there remain 
some controversies, particularly on their definition and origination. Many tumors 
are derived from a single transformed cell which acquired the ability to 
proliferation and form tumor in vivo(Bjerkvig et al., 2005). Such cancer initiating 
cells have often been designated as cancer stem cells. One misconception is 
that cancer stem cell must have arisen from a normal stem cells(Jordan, 2009). 
Although this argument is true in some cases, it does not generally apply to all 
cancer types. For example in acute myeloid leukemia, committed progenitor 
transformed by MLL-AF9 acquired self-renewal ability and became cancer stem 
cells(Krivtsov et al., 2006). Like normal stem cells, any given cancer cell will 
qualify as cancer stem cell if it could self-renew, differentiate and reconstitute the 
original heterogeneous cancer population. That said, functional assays to 
characterize in vivo self-renewal capacity will serve as the ultimate criteria to 
define a cancer stem cell population(Lathia, 2013).  
Although certain cell surface markers have been demonstrated to be associated 
	 13	
with enhanced cancer stem cell property, such as CD44/CD24(Al-Hajj et al., 
2003) for breast cancer stem cells, CD133 for glioblastoma stem cells(Singh et 
al., 2004), it is important not attaching the label of cancer stem cells solely based 
on these phenotypic traits.  Recent observation of cancer cell plasticity and cell 
phenotype switching also argues that cancer stem cells may not be a fixed state, 
but rather a transitional or adaptive state depending on environmental 
factors(Lathia, 2013). For example, in breast cancer, CD44low/CD24high non-stem 
cancer cells could be converted to CD44high/CD24low cancer stem cells in 
response to IL-6 mediated activation of inflammatory feedback loop(Iliopoulos et 
al., 2011).   
Regardless of these controversies, CML stem cells have been demonstrated to 
originate from early multipotent progenitor or stem cells(Savona and Talpaz, 
2008). Using CML mouse model, several groups have confirmed that only the 
BCR-ABL transduced Lin-Sca1+Kit+ (LSK) population, which are enriched for 
stem cells, are capable of full engraftment and reestablishment of functional 
hematopoiesis, and being serially transplanted, but not the more differentiated 
common myeloid progenitor (CMP), granulocyte-macrophage progenitors (GMP) 
or common lymphoid progenitor (CLP) (Hu et al., 2006; Huntly et al., 2004; 
Reynaud et al., 2011). Therefore, in chronic phase CML patient, BCR-ABL+ 
HSCs are the source of self-renewal capacity and provides proliferative and 
survival advantages.  
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1.3 Animal models in Chronic Myeloid Leukemia 
Multiple animal models have been developed to recapitulate the clinical 
phenotypes of CML and study CML leukemogenesis(Ilaria, 2004; Sontakke et al., 
2016). Among them, three models are widely used: retroviral transduction and 
bone marrow transplantation model(Daley et al., 1990; Kelliher et al., 1990; Li et 
al., 1999), BCR-ABL transgenic model(Honda et al., 1995; Huettner et al., 2000), 
and patient sample xenograft NSG mice model(Eisterer et al., 2005). 
 
Retroviral transduction mouse model 
In 1990, a retroviral transduction model was first reported to induce CML in 
mice(Daley et al., 1990). The retrovirus contains p210 isoform of BCR-ABL and 
was controlled by LTR promoter of myeloproliferative sarcoma virus(MPSV). 
Bone marrow cells from young BALB/c mice were harvested, infected with high 
titer virus, and transplanted into lethally irradiated syngeneic recipient mice. 
Some recipient mice developed a CML-like myeloproliferative disease with an 
average 9-week latency, and displayed typical clinical CML features, such as 
massive splenomegaly, increased peripheral white blood cell counts 
(15,000~500,000 cells/mm3), and extensive infiltration of the bone marrow, liver, 
spleen with granulocytes, and loss of normal splenic architecture. However, there 
were also some mice developing acute lymphoblastic leukemia or mixed lineage 
tumor with longer latency. The retroviral transduction strategy was further 
improved later by replacing MPSV LTR with MSCV LTR to ensure high level of 
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BCR-ABL expression in hematopoietic stem/progenitor cells(Hawley et al., 1994), 
leading to a nearly 100% of CML disease induction (Li et al., 1999; Pear et al., 
1998).  
Because of the technical convenience of this model, it has been widely used for 
studying genes involved in CML leukemogenesis and testing novel therapeutic 
strategies. 
 
BCR-ABL transgenic mouse model 
Although resembling most of the clinical characteristics of CML, the well 
established retroviral based model has short latency, usually 2-3 weeks, before 
the mice develop lethal phenotype, such as pulmonary hemorrhage, which is a 
disadvantage in evaluating genes involved in leukemia progression. 
Since 1990s, several BCR-ABL transgenic mouse models have also been 
developed using different regulatory elements to modulate BCR-ABL expression, 
including mouse “housekeeping gene” metallothionine-1(MT) gene promoter 
driving p210 BCR-ABL expression(Honda et al., 1995). However, this BCR-ABL 
transgenic model develops T cell leukemia rather than a CML-like MPD. To 
understand if BCR-ABL is required for both induction and maintenance of 
leukemia, Tenen group engineered a double transgenic mice line by crossing a 
tetracycline transactivator (tTA) repressive promoter controlled p210 BCR-ABL 
transgenic line with another line bearing mouse mammary tumor virus (MMTV) –
tTA transactivator(Huettner et al., 2000). After withdrawal of tetracycline, 100% of 
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the double transgenic progenies start expressing BCR-ABL and develop 
lymphoid leukemia. Lineage analysis of the leukemic cells from peripheral blood, 
bone marrow, or lymph node using flow cytometry, however, showed that 
majority of cells were positive for B cell surface antigen, such as B220, while no 
detection of T cell marker or myeloid markers, indicating its useful application to 
study BCR-ABL+ ALL(Huettner et al., 2000). All the above evidence suggests 
that the leukemic phenotype induced by BCR-ABL largely depends on the cell 
type expression of BCR-ABL. And a highly controlled expression of BCR-ABL in 
hematopoietic stem cells is required to establish a CML-like model given that 
CML is a stem cell based disease.  After a series of effort, an enhancer region 
identified in the 3’ region of Stem Cell Leukemia (SCL) gene was found to restrict 
heterologous LacZ expression in hematopoietic stem and progenitor cells and 
megakaryocytes, and were therefore employed to generate a new SCLtTA/BCR-
ABL transgenic mouse model(Koschmieder et al., 2005). In this model, BCR-ABL 
induction by withdrawal of tetracycline led to neutrophilia, splenomegaly and 
myeloid infiltration in different organs, and more importantly expansion of myeloid 
progenitor and hematopoietic stem cells, recapitulating many clinical features of 
human CML.  
Patient sample xenograft NSG mouse model 
Engrafting human CML patient cells into humanized mice may provide a more 
clinical and physiological relevant model to study CML disease and evaluate 
therapeutic strategies. Several initial trials in NOD/SCID mice using CML cells 
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from chronic phase patients failed to obtain efficient leukemic engraftment even 
with co-injection of recombinant cytokines(Lewis et al., 1998; Sirard et al., 1996). 
Recently, a new nonobese diabetic/severe combined immunodeficient mouse 
line was generated by incorporating a complete null mutation of the common 
cytokine receptor gamma chain (NOD/SCID/interleukin 2 receptor gamma(null) 
[IL2γ-/-]), known as NSG mice(Ishikawa et al., 2005) . These mice are able to 
efficiently support human blood HSC engraftment and multilineage 
differentiation(Ishikawa et al., 2005; Shultz et al., 2005). In contrast to NOD/SCID 
mice, which requires up to 7-10x10^6 CML CD34+ cells for engraftment, 1-
2x10^6 CD34+ cells are sufficient to establish engraftment and reconstitute 
hematopoiesis in NSG mice for at least 16 weeks.  
Modeling blast crisis CML 
In addition to the above strategies modeling chronic phase CML, several mouse 
models of blast crisis CML have been reported. Daley et al generated the first BC 
CML model by transplanting primary CML cells to secondary recipients in BALB/c 
mice(Daley et al., 1991). Albeit with low efficiency, they were able to observe 
retrovirally transduced primary CML cells progress from chronic into acute 
leukemia in a small number of recipients, with elevated level of immature blast 
cells from either lymphoid or myeloid lineage(Daley et al., 1991). Progression of 
CML into blast crisis stage is often accompanied by of secondary mutations that 
have synergistic effect with BCR-ABL(Melo and Barnes, 2007).  Effort has also 
been made by combining BCR-ABL expression with a defined second hit, such 
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as p53(Honda et al., 2000; Skorski et al., 1996), Dok1/Dok2 null 
mutation(Yasuda et al., 2004) or NUP98-HOXA9 overexpression(Dash et al., 
2002), driving rapid expansion of immature blast cells.  
Although the above mouse models displays many features resembling CML, they 
failed to recapitulate the entire disease development course in human subject. 
Most recently, Giotopoulos et al introduced a sleeping beauty transposon, 
GrOnc, into the chronic phase BCR-ABL transgenic mouse model(Giotopoulos et 
al., 2015). Induction of transposition leads to CML progression from an initial 
chronic phase stage to a blast crisis stage, with ~85% mice developing Blast 
crisis phase-like phenotype, ~10% mice demonstrating accelerated phase-like 
phenotype, and only ~5% remaining in chronic phase phenotype(Giotopoulos et 
al., 2015). Notably, the GrOnc transposon, in combination with BCR-ABL, 
promote myeloid but not lymphoid leukemogenesis, recapitulating many clinical 
and laboratory aspects of human CML blast crisis.  
1.4 Targeted Therapy in CML 
Development of Tyrosine Kinase inhibitors (TKIs) 
Given that over 95% of CML patients contain the Ph chromosome and express 
the BCR-ABL oncoprotein, it is noted that CML might respond to inhibition of 
BCR-ABL kinase activity(Druker, 2002).  
In the early 1990s, Brian Druker collaborated with Novartis expecting to identify 
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such a tyrosine kinase inhibitor that can be orally administrated, and they found 
that a 2-phenylaminopyrimindin derivative, CGP57-148B, now widely known as 
imatinib (IM), with a brand name Gleevec, capable of potently inhibiting BCR-
ABL and killing CML cells while leaving normal cells unaffected(Deininger et al., 
2005; Druker et al., 1996). 
IM inhibits BCR-ABL kinase activity by occupying the ATP-binding pocket 
through forming hydrogen bonds and blocking its access to ATP, thereby locking 
it at inactive confirmation and precluding subsequent substrate phosphorylation 
and activation of downstream signaling pathways(Schindler et al., 2000).  
Although IM shows great efficacy in controlling CML progression in chronic 
phase patients, it is less effective in patients with advanced disease, or even 
ineffective in blast crisis patients(Sawyers et al., 2002). Collectively, these 
unresponsive events were considered to be IM resistance(Shah, 2005). In certain 
cases, patients don’t respond to IM at all, which is called primary 
resistance(Quintas-Cardama et al., 2009) and is largely due to unknown genetic 
alterations that shift the dependence away from BCR-ABL for survival. IM is also 
vulnerable to MDR1, p-Glycoprotein, mediated drug efflux(Illmer et al., 2004). In 
other cases, which are regarded as secondary resistance(Quintas-Cardama et 
al., 2009), patients may respond to IM at first but lose established response 
overtime. These cases often involve BCR-ABL mutations that block IM binding.  
To overcome IM resistance, second generation inhibitors, represented by 
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Nilotinib and Dasatinib, and third generation inhibitor, represented by Ponatinib, 
were developed to recognize and inhibit a variety of BCR-ABL mutants. 
Unlike IM, which is discovered through drug screening, Nilotinib was developed 
with rational drug design based on the structure of ABL-IM complex to overcome 
resistance related to BCR-ABL mutations(Kantarjian et al., 2006). Nilotinib binds 
to the inactive confirmation of ABL kinase domain through lipophilic and weak 
van der wall interactions and blocks its catalytic activity(Manley et al., 2005), and 
is not dependent on OCT1 or P-glycoprotein for influx and efflux(White et al., 
2006). Nilotinib is 10-30 fold more potent than IM in inhibiting BCR-ABL activity 
and proliferation of BCR-ABL+ cells, and is effectively against 32/33 BCR-ABL 
mutations at physiologically relevant concentration(Kantarjian et al., 2007). 
Notably, a limited number of P-loop associated mutations, such as E255K and 
Y253H, causes resistance to Nilotinib, but can be suppressed by increased drug 
concentration(Jabbour et al., 2009). However, the loss of effectiveness against 
T315I mutation might be a consequence of the steric hindrance between the 
isoleucine-methyl group of BCR-ABL and 2-methylphenyl phenyl group of 
Nilotinib(Manley et al., 2005).  
In contrast to most TKIs, which bind to the inactive confirmation of BCR-ABL, 
Dasatinib exclusively targets the active confirmation of ABL kinase, but with less 
stringent conformation requirement and reduced selectivity(Eck and Manley, 
2009). It is noteworthy that this binding characteristic makes Dasatinib ~325-fold 
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more potent against wildtype BCR-ABL than IM and effectively against majority 
of BCR-ABL mutations except for T315I(Olivieri and Manzione, 2007). Dasatinib 
is also a highly potent inhibitor of SRC family kinases including FRG, FYN, HCK, 
LCK, LYN, and YES, and has activity against additional tyrosine kinases, such as 
KIT and PDGFR(Schittenhelm et al., 2006). This lack of selectivity is likely 
related to the similarity between the active conformation of BCR-ABL and SRC 
family kinases, therefore making Dasatinib a multi-target inhibitor of ABL and 
SRC kinases(Schittenhelm et al., 2006). 
Ponatinib is derived from AP23464, one of Ariad’s dual ABL/SRC inhibitor, and is 
the first TKI demonstrating effectiveness against T315I mutation(Cortes et al., 
2012). Ponatinib possesses a linear structure, which possibly helps it avoid steric 
clashes with hydrophobic gatekeeper residues and making it a potent inhibitor of 
most of know BCR-ABL mutations, particularly T315I(O'Hare et al., 2009).  
1.5 Drug resistance in CML 
BCR-ABL dependent TKI resistance 
Therapeutic efficacy of IM is often compromised by BCR-ABL mutations, and 
BCR-ABL gene amplification(Gorre et al., 2001). Clinically, at least 50% of IM 
resistant patients have detectable BCR-ABL mutations depending on the 
study(Lange et al., 2005). Up to now, there have been over 100 mutations found 
to be relevant to TKI resistance, most of these mutations are located at BCR-ABL 
kinase domain(Laboratory, 2007; Soverini et al., 2011) (Figure 1.1). Since these 
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mutant cells are still depending on BCR-ABL for survival, it is called BCR-ABL 
dependent TKI resistance(Bhamidipati et al., 2013).  
 
Newly diagnosed CML or Ph+ ALL patients were usually prescribed with IM as 
first line therapy, and only switched to second generation inhibitor, Nilotinib or 
Dasatinib, when disease become refractory to IM due to resistant 
mutations(Weisberg et al., 2007). Although many of these mutations could be 
overcome by second generation inhibitors, sequential treatment does not always 
guarantee long-term disease remission. Patients often relapse due to acquired 
mutations at other amino acid positions, which blocks new TKIs again(Cortes et 
al., 2007). One of such mutations is the notorious gatekeeper mutation, T315I, 
which does not respond to either drug(Weisberg et al., 2007). 
 
However, mutation from Threonine to Isoleucine at 315 AA position is not the 
only way causing resistance to Nilotinib or Dasatinib as revealed by several 
studies.  And substitution of 315 position to Methionine even leads to resistance 
to Ponatinib, which was designed to inhibit T315I mutation(Zabriskie et al., 2014). 
In addition to such mutations at single amino acid position, which is likely due to 
selection of polyclonal mutations or sequential mutations(Zabriskie et al., 2014), 
acquired mutations at the second or third amino acid sites in the same BCR-ABL 
protein molecule, dubbed “compound mutations”, is another major cause of 
acquired resistance and disease relapse(Shah et al., 2007; Zabriskie et al., 2014). 
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BCR-ABL independent TKI resistance 
The causes of TKI resistance in primary resistance cases are more diverse and 
complicated. Donato et al, established an IM resistant K562 cell line(K562R) by 
treating an IM sensitive K562 cell line with increasing dose of IM, and found that 
overexpression of an SRC family kinase, Lyn, being the main driver of 
resistance(Donato et al., 2003). This is further supported by the fact that K562R 
cells respond well to Dasatinib, which inhibits both BCR-ABL and SRC family 
kinases(Wu et al., 2008). Our recent work to identify genes involved in IM 
resistance using a genome-wide shRNA library revealed dozens of IM-sensitizing 
genes(Ma et al., 2014). Knocking down many of them using shRNA leads to IM 
resistance which is at least partially due to transcriptional upregulation of a PKC 
family member, PRKCH. Overexpression of PRKCH sustains the activity of 
MEK/ERK pathway upon IM treatment by directly phosphorylating and activating 
upstream CRAF. PRKCH/MAPK pathway was found to be a common resistance 
pathway in many BCR-ABL independent IM resistant cases. 
 
It is thought that BCR-ABL inhibition is the trigger of cell death due to quick loss 
of pro-survival signals while gaining pro-apoptotic signals(Sharma et al., 2006). 
However, cell signaling is always responding in a network fashion, and 
compensatory pathways may be transiently activated to slow down or circumvent 
cell death program(Logue and Morrison, 2012), there by causing TKI resistance. 
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One of such examples is BCL6, which is an oncogene suppressed by JAK/STAT 
pathway. Upon TKI treatment, JAK/STAT pathway losses the activation signal 
from BCR-ABL, and releases the brake on BCL6, which then acts as an anti-
apoptotic protein(Duy et al., 2011).  
 
TKI Insensitivity and Mechanisms of CML stem cells 
One attractive postulate of cancer therapy would be targeting these aberrant 
stem cells in order to prevent eradicate cancer. Although non-stem cancer cells 
are sensitive to variety of chemical or irradiation therapy, cancer stem cells are 
generally difficult to remove primarily due to its quiescent nature(Moore and Lyle, 
2011; Saito et al., 2010).  
IM, the first FDA approved tyrosine kinase inhibitor, inhibits BCR-ABL kinase 
activity and leads to CML cell death(An et al., 2010b), and has been the front-line 
therapy for chronic phase CML patients. Despite its great efficacy in suppressing 
CML progression, it can barely lead to a cure. Accumulating evidence reveals 
that CML stem cells remain alive even with effective inhibition of BCR-ABL 
activity by TKIs(Graham et al., 2002; Hamilton et al., 2012; Jiang et al., 2007), 
indicating that BCR-ABL itself is not an essential survival factor of CML stem 
cells in contrast to more differentiated CML cells. And CML often relapses after 
IM discontinuation and the relapse does not involve BCR-ABL mutation(Ross et 
al., 2013; Yhim et al., 2012), suggesting persistence of these residual CML stem 
cells.  
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Holyoke and colleagues first noted that IM treatment fails to kill all Lin-CD34+ 
cells isolated from peripheral blood of chronic phase CML patient(Graham et al., 
2002). They observed that IM was able to kill all proliferating cells but a 
significant portion of cells, particularly the non-dividing CD34+ cells, were 
unaffected although confirmed to be leukemic. Additionally, CD34+ cells derived 
from bone marrow cells of CML patients under long-term IM therapy also 
demonstrate the presence of BCR-ABL transcripts (Bhatia et al., 2003). After 
further separation of CD34+ cells into progenitor (CD34+CD38+) and stem 
cell(CD34+CD38-) population, Jiang and colleagues demonstrated that 
CD34+CD38- population showed significantly less sensitivity to IM treatment in 
the presence or absence of growth factors(Jiang et al., 2007). Druker and 
colleagues also showed that IM treatment is capable of inhibiting tyrosine 
phosphorylation using intracellular phospho-staining. CRKL and STAT5 
phosphorylation in FACS-isolated CD34+CD38- cells is also efficiently inhibited 
using immunohistochemistry(Corbin et al., 2011). However, cell viability is not 
significantly affected in the presence or absence of growth factors(Corbin et al., 
2011). 
 
Similar to what is observed in human CML stem cells, TKI also showed minimal 
effect on Leukemic Stem Cells (LSCs) from CML mouse model(Hamilton et al., 
2012; Ma et al., 2014). Oral administration of IM in CML mice significantly 
reduced the accumulation of leukemic cells in peripheral blood and prolongs 
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animal survival, however, it does not reduce the percentage or number of BCR-
ABL+ Lin-Sca1+Kit+ cells, and did not induce significant level of apoptosis in LSK 
cells either(Ma et al., 2014). Both in vitro and in vivo studies reported that second 
generation inhibitor, Dasatinib, is moderately effective in inducing apoptosis and 
suppressing LSCs expansion in CML mice, but remain incapable of eradicating 
LSCs(Hamilton et al., 2012). Most importantly, the side population (GFP+CD34-
c-Kit+Hoe- ) from bone marrow cells of TKI-treated CML mice could still be 
serially transplanted to recipient mice(Hu et al., 2006). And IM, even the second 
generation inhibitor Dasatinb, treated mice eventually succumbed to CML. 
Collectively, all these studies suggest that the residual CML stem cells are not 
addicted to BCR-ABL for their survival.  
Up to now, many studies have revealed critical pathways for maintenance of 
CML stem cells. For example, Wnt/β-catenin pathway has been shown to be 
required for the self-renewal and differentiation of normal HSC and also leukemic 
stem cells(Zhao et al., 2007).  Microarray analysis of gene expression in mouse 
HSCs, CML stem cells(Lin-Sca1+Kit+GFP+) treated with placebo or IM revealed 
Alox5 as a LSC specific maintenance gene(Chen et al., 2009). PRKCH mediated 
MAPK activation also contributes to IM insensitivity of CML stem cells(Ma et al., 
2014). Most recently, the gene expression and proteomic network analysis of 
CML stem cells demonstrates the deregulation of p53 and c-Myc signaling 
network(Abraham et al., 2016). Maintenance of p53 stability and inhibition of c-
Myc expression using small molecules markedly increased CML stem cell death, 
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and engraftment in NSG mice.  Other signaling pathways related to IM resistance 
of CML stem cells includes hedgehog(Zhao et al., 2009), TGF-FOXO(Naka et al., 
2010), BCL6(Hurtz et al., 2011), and HIF1α(Wang et al., 2011).  
 
1.6 Current technologies to study drug resistance in CML and CML stem 
cells. 
Genome-wide RNA interference screen 
RNA interference (RNAi) is a mechanism by which expression of a specific gene 
is post-transcriptionally inhibited. RNAi is mediated by a double-stranded RNA, 
which recognizes and induces sequence-specific degradation of the 
corresponding mRNA, resulting in silencing or “knocking down” the gene. The 
development of RNAi as a genetic tool initially held great promise for analyzing 
loss-of-function phenotypes in mammalian cells using high-throughput, unbiased, 
function-based genetic screens. However, it was not until the development of 
RNAi expression libraries about 10 years ago(Berns et al., 2004; Kittler et al., 
2004; MacKeigan et al., 2005; Paddison et al., 2004) that such large-scale 
screens became feasible. Using these and other RNAi libraries, many studies 
have uncovered previously unappreciated genes and mechanisms involved in 
diverse biological processes in mammalian cells, particularly in the context of 
cancer, such as unknown tumor suppressor genes (Gobeil et al., 2008; Zender et 
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al., 2008), synthetic lethal interactions (Luo et al., 2009), and potential drug 
targets (Ngo et al., 2006; Zuber et al., 2011).  
 
Today, a wide variety of RNAi libraries are commercially available. These 
libraries typically use a lentiviral vector to express a chimeric short hairpin RNA 
(shRNA), which is subsequently processed into a small interfering RNA (siRNA) 
to induce target mRNA degradation (Moffat et al., 2006; Paddison et al., 2002). 
Lentiviral-based libraries have high titers and broad trophism, making them 
suitable for use in a variety of mammalian cell types. Each shRNA in the library 
contains an easily sequenced barcode, which enable unambiguous identification 
of the shRNA. The genome-wide screen described in this protocol uses the 
human lentiviral shRNA library from The RNAi Consortium (TRC), which has 
~85,000 shRNA constructs with 3-5 shRNAs per gene, targeting ~22,000 human 
genes (Moffat et al., 2006; Root et al., 2006). To facilitate screening such a large 
number of shRNAs, we have divided the library into “pools”, with ~5000 shRNAs 
per pool for a total of 22 pools. 
 
BCR-ABL mutation-independent resistance to TKIs frequently occurs in CML 
(Donato et al., 2004; Khorashad et al., 2006; Quintas-Cardama et al., 2009). 
Identifying TKI resistance-related genes helps increase our knowledge of how 
resistance occurs and may lead to the development of better therapeutic 
strategies for CML. As an example, in chapter II, we employed a genome-wide 
	 29	
screening strategy in a human CML cell line to identify genes involved in 
resistance to the first generation TKI, IM (Ma et al., 2014).  
 
Single cell RNA-sequencing 
Global gene expression analysis has been widely used to profile cell 
differentiation, therapeutic and disease related gene expression changes(Golub 
et al., 1999; Gu et al., 2004). Microarray and RNA-sequencing (RNA-seq) is two 
major ways of achieving this purpose(Schena et al., 1995; Wang et al., 2009). 
Traditionally, in order to obtain reliable and reproducible data, microarray 
requires microgram level of total RNA as input material, while RNA-seq requires 
substantially less but still significant initial amount for depletion of ribosome RNA. 
In contrast to microarray, which are covered by pre-designed probes for a known 
number of genes, RNA-seq is more powerful in identifying splicing variants, 
isoforms and new genes. Additionally, mRNA-seq provides a larger dynamic 
range than microarray, therefore, more likely to capture subtle gene expression 
difference(Fu et al., 2009; Marioni et al., 2008).  
However, total RNA used for global gene expression analysis is typically 
extracted from bulk cell population comprising phenotypically similar but likely 
functionally distinct cells. The development of ultra-low input RNA-seq 
technology allows for transcriptome analysis at single cell level to address many 
new and longstanding questions, such as revealing functional heterogeneity 
within a phenotypically homogeneous population, refining lineage relationships 
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defined previously by cell surface marker system, and identifying rare cell types, 
etc(Patel et al., 2014; Tang et al., 2010; Zeisel et al., 2015).  
The first integrated study of single cell analysis dates back to 2002, when Klein 
and colleagues used microarray readout to study single micrometastic cells(Klein 
et al., 2002). In 2009, Surani and colleagues reported the first single cell RNA-
seq analysis using oocytes and blastomeres which are relatively easy to 
manipulate compare to more differentiated cells because of relative abundance 
of mRNA molecules(Tang et al., 2009).  
Up to now, multiple single cell mRNA-seq protocols have been developed for all 
cell types, such as smart-seq(Ramskold et al., 2012), CEL-seq(Hashimshony et 
al., 2012), STRT(Islam et al., 2011), Drop-seq/Indrop(Klein et al., 2015; Macosko 
et al., 2015), each having its own pros and cons. Smart-seq protocol was 
selected for the current thesis study and described in more detail below. Smart-
seq was first developed by Sandberg lab and published in 2012. What makes it 
stand out is its capability of generating more full-length cDNA. By further 
optimizing the conditions and essential reagents, an updated protocol, Smart-
seq2, was released with improved yield and length of cDNA libraries for 
individual cells(Picelli et al., 2013). In this improved protocol, single cells were 
collected and lysed in a relatively mild hypotonic lysis buffer, which does not 
interfere with RT reaction. Full-length cDNA synthesis and amplification was 
achieved through a template-switching reaction which relies on a Moloney 
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Murine Leukemia Virus (M-MLV) based reverse transcriptase and a Locked 
Nucleic Acids (LNA)-containing template switching oligo(Krivtsov et al.). M-MLV 
typically adds 2-5 non-templated cytosine to the cDNA 3’end(Schmidt and 
Mueller, 1999). Similar to the original TSO containing three riboguanosines, 
Smart-seq2 TSO carries two riboguanosines and one modified guanosine at last 
position to produce a LNA but with enhanced thermostability and binding 
strength. Once template switching and synthesis of full-length first-strand cDNA 
is done, an artificial sequence introduced at both end of the cDNA will serve as 
binding site of ISPCR primer for subsequent PCR pre-amplification. cDNA is 
amplified using a limited number of cycles, usually 18 cycles for a single 
mammalian cell or as many as needed to get enough material for following 
reactions. Given that only low nanogram level of cDNA could be obtained from a 
typical single cell, conventional biorupter or mechanic-based physical shearing 
and barcoding methods is not a practical option. In this ultralow input scenario, a 
TN5 transposase-based tagementation and barcoding strategy was employed to 
construct cDNA library for deep-sequencing(Gertz et al., 2012). Briefly, TN5 
transposase was preassembled with two double-stranded oligonucleotides 
carrying illumina adapter sequences. Incubation of TN5 transposases with 
cDNAs from each cell will result in unbiased fragmentation and insertion of 
adapter with unique barcodes at a single step. After PCR enrichment and 
purification, a library spanning 200-1kb but centralized at ~500bp could be 
obtained.  
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Illumina dual-index strategy provides an option of high-multiplexing by using 
index1 (i5) and index2 (i7) for the enrichment PCR then pooling 96~384 cDNA 
libraries together on a single lane for deep-sequencing. The new generation of 
illumina table-top sequencer, Nextseq, offers a fast and economical way of 
sequencing hundreds of cells on a single lane and a high yield of up to 500 
million total reads, usually with >70% alignment efficiency.  
Conventional study using genetically unrelated individuals shows extensive gene 
expression variation(Cheung et al., 2003). Variability of drug response among 
patients has long been known to be attributed to such individual variances(Roden 
and George, 2002). Profiling gene expression in paired normal and disease 
samples from the same patient would be helpful to circumvent such genetic 
variability, patient-specific and common drug targets could be identified through 
intra-sample and inter-sample comparison. However, this strategy has often 
been hampered by the inability to completely separate normal and disease cells 
due to factors, such as phenotypic similarity(Carter et al., 2010). 
 
In this case, single cell RNA-seq offers a unique advantage to clearly separate 
disease cells from normal cells based on definitive molecular markers of 
individual cells. As an example, in chapter III, we use CML as a model, and 
report clear separation of normal hematopoietic stem cells (HSCs) from CML 
stem cells (CMLSCs) based on a unique molecular marker in CML, the fusion 
oncogene BCR-ABL, and performed gene expression profiling in both population 
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using single cell RNA-seq.   
High-throughput and Saturated point mutagenesis 
Genetic mutation is one of the major evolution forces shaping the fitness a 
particular gene or even the whole organism(Kacser and Beeby, 1984; Mitchell-
Olds et al., 2007). While most mutations are neutral, and are passed onto the 
progenies by random genetic drift, certain mutations could be deleterious, and be 
depleted during evolution(Charlesworth et al., 1993; Kimura, 1979). However, 
upon environmental changes or the presence of selection pressure, such as 
addition of antibiotics or kinase inhibitors, some of the non-advantageous 
mutations may be adapted to the new condition, therefore enriched and 
preserved(Eyre-Walker and Keightley, 2007; Nielsen, 2005). Conventionally, 
random mutagenesis was performed using UV exposure in bacteria or 
carcinogen exposure in mammalian cells, but this mutagenesis is far from 
saturation(Sarasin, 2003; Witkin, 1976). It is usually more controllable over a 
small genomic region or a particular gene than a whole genome. Error-prone 
PCR(Fujii et al., 2004) or DNA-repair deficient bacteria(Greener et al., 1997) 
were often employed to reach a high level coverage of mutagenesis for such 
study. Despite extensive coverage, none of these methods were able to offer a 
fully controlled condition and equal representation of each mutation for 
systematic evaluation of the contribution of each mutation to the cell fitness or a 
particular phenotype.  
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To overcome these drawbacks, research group led by Dr. Bolon at UMass 
Medical School developed a method which they refer to as EMPIRIC(exceedingly 
methodical and parallel investigation of randomized individual codons) for 
systematic generation of all possible point mutations in regions of an important 
gene and quantification of the fitness effect of each mutants(Hietpas et al., 2011).  
In this method, a 10 amino acid(AA) region is randomized to all possible 
codons(Hietpas et al., 2012). Two complementary 40-base long oligonucleotides 
were synthesized with 30 bases for a 10aa region flanked by a 3-base cohesive 
end for annealing into expression vector. Each double-stranded oligo bears a 
degenerate codon(i.e., NNN) at desired position on both strands. The library size 
for a single randomized codon is 64, and 640 for the 10AA region. Typically, 10 
fold or greater coverage is required for confident assessment of all mutants in the 
library. To increase the throughput and recovery rate, hundreds of mutations in a 
single bulk competition experiment were analyzed at once by deep-sequencing 
to accurately measure the relative abundance of each mutation(Hietpas et al., 
2012).  
However, several drawbacks remain unsolved with the saturated mutagenesis 
strategy in mammalian cells because of the inherent characteristics of retroviral 
delivery method, particularly, inconsistent gene expression resulted from random 
integration(Day et al., 2000). 
CRISPR-Cas9 mediated genome editing for improved mutagenesis  
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Programmable endonucleases, such as zinc-finger nucleases (ZFNs), 
transcription activator-like effector nucleases (TALENs) or clustered regularly 
interspaced short palindromic repeat (CRISPR)-Cas9 based RNA-guided DNA 
endonucleases, offer a practical and accurate way of genome editing(Gaj et al., 
2013). Among them, the CRISPR-Cas9 system could easily target any genomic 
region of interest by customizing the short guide-RNA(sgRNA) sequence. 
 
The CRISPR-Cas9 system was first discovered and derived from bacteria, 
Streptococcus pyogenes(Hsu et al., 2014; Jinek et al., 2012), as a bacteria 
defense system for eliminating of exogenous DNA. Guide-RNA associated Cas9 
nuclease locates the target DNA sequence by searching for a PAM (NGG) 
element followed by formation of a heteroduplex between the guide and the 
complementary DNA sequence (Jinek et al., 2012). Once activated, a Cas9-
induced double strand break(DSB) is usually introduced between the 3rd  and 4th 
nucleotide position 5’ of the PAM sequence(Tsai et al., 2015). While in most 
cases, such DSB will be fixed by non-homologous end-joining(NHEJ) pathway, 
resulting in mini-insertion or deletion(indels) which could disrupt normal gene 
function by causing frame-shift and formation of pre-mature stop 
codon(Rothkamm et al., 2003). In the presence of a DNA template with suitable 
homology arms flanking the target region, a subset of DSB can be fixed by 
utilizing this exogenous donor DNA as a repair template via the homology 
directed repair (HDR) pathway(Liang et al., 1998).  This process results in tailor-
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made sequence alterations at the target locus that are dictated by the contents of 
the repair template (Cong et al., 2013; Sander and Joung, 2014).    
 
When the DSB is fixed by HDR pathway, only a single donor plasmid will be used 
as template due to the requirement of paired homology arms. This fact raises the 
possibility of introducing a library of pre-defined templates into a single genomic 
location in a cell population, with each cell fixed by only one template. Recently, 
Findlay et al successfully performed a saturated mutagenesis at a specific 
genomic locus, the first 6 bases of BRCA1 exon, using a random hexamer library 
by leveraging the CRISPR-Cas9 system and associated HDR 
mechanism(Findlay et al., 2014). This CRISPR-Cas9 based saturated 
mutagenesis strategy was conducted in a completely endogenous condition, 
therefore providing the most physiologically relevant information for mutation 
induced phenotypic variation. However, the short length of their donor library, 
only randomizing a hexamer region, poses a big limit on its application. 
As an example, in chapter VI, we describe the development of an improved and 
more flexible CRISPR-Cas9 HDR-based strategy for a large-scale saturation 
mutagenesis screen in Ba/F3 cells, its application to analyze fitness landscape 
and TKI resistance of BCR-ABL mutations, and its capability to reveal clinically 
relevant and meaningful mutations with minimal false positive rates.  
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1.7 Focus of this dissertation 
This dissertation focuses on drug resistance in CML.  Three major aspects of 
drug resistance are studied: 1, RNA inference screen was performed to study 
BCR-ABL independent drug resistance mechanism and exploit new therapeutic 
strategies. 2, Single cell RNA-seq was conducted to profile gene expression 
heterogeneity in primary CML stem cell population and reveal common 
therapeutic targets to eradicate CML stem cells. 3, An improved saturated point 
mutagenesis strategy was devised using CRISPR-Cas9 to more precisely 
evaluate contribution of each amino acid substitution to BCR-ABL function and 
fitness with or without drug selection pressure.  
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Figure 1.1. Schematic illustration of functional domains in BCR-ABL and 
location of clinically identified mutations associated with IM resistance. 
Mutations with 2-10% frequency are highlighted in bold, while those with >10% 
frequency are in red. P-loop: phosphate binding loop; IM binding: imatinib 
binding region; and A-loop: activation loop. Data were collated from (Hughes et 
al., 2006; Jones et al., 2009; Soverini et al., 2011)	
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CHAPTER II: A THERAPEUTICALLY TARGETABLE MECHANISM OF BCR-
ABL-INDEPENDENT IMATINIB RESISTANCE IN CHRONIC MYELOID 
LEUKEMIA 	
ABSTRACT 
Resistance to the BCR-ABL inhibitor imatinib mesylate (IM) poses a major 
problem for the treatment of chronic myeloid leukemia (CML). IM resistance often 
results from a secondary mutation in BCR-ABL that interferes with drug binding. 
However, in many instances there is no mutation in BCR-ABL, and the basis of 
such BCR-ABL-independent IM resistance remains to be elucidated. To gain 
insight into BCR-ABL-independent IM resistance mechanisms, we performed a 
large-scale RNA interference (RNAi) screen and identified IM-sensitizing genes 
(IMSGs) whose knockdown renders BCR-ABL+ cells IM-resistant. In these IMSG 
knockdown cells, RAF/MEK/ERK signaling is sustained after IM treatment due to 
upregulation of PRKCH, which encodes the protein kinase C (PKC) family 
member PKCη, an activator of CRAF. PRKCH is also upregulated in samples 
from CML patients with BCR-ABL-independent IM resistance. Combined 
treatment with IM and trametinib, an FDA-approved MEK inhibitor, synergistically 
kills BCR-ABL+ IMSG knockdown cells and prolongs survival in mouse models of 
BCR-ABL-independent IM-resistant CML. Finally, we showed that CML stem 
cells contain high levels of PRKCH and this contributes to their intrinsic IM 
resistance. Combined treatment with IM and trametinib synergistically kills CML 
stem cells with negligible effect on normal hematopoietic stem cells. Collectively, 
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our results identify a therapeutically targetable mechanism of BCR-ABL-
independent IM resistance in CML and CML stem cells. 
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INTRODUCTION 
Chronic myeloid leukemia (CML) is a hematopoietic malignancy characterized by 
an increase and unregulated growth of predominantly myeloid cells in the bone 
marrow, and their accumulation in the blood (Faderl et al., 1999). A hallmark of 
CML is the Philadelphia chromosome, resulting from a reciprocal translocation 
between the long arms of chromosomes 9 and 22 (Deininger et al., 2000; 
Kurzrock et al., 2003). This chromosomal translocation leads to expression of 
BCR-ABL, an oncogenic fusion protein with a constitutively activated ABL 
tyrosine kinase. BCR-ABL can transform myeloid progenitor cells and drives the 
development of 95% of CML cases. BCR-ABL promotes leukemogenesis by 
activating downstream signaling proteins that increase cell survival and 
proliferation (Colicelli, 2010). These pathways include, but are not limited to, the 
RAS/mitogen-activated protein kinase (RAF/MEK/ERK), phosphatidylinositol 3-
kinase/AKT (PI3K/AKT), and JAK/STAT signaling cascades (Steelman et al., 
2004).  
 
The first-line treatment for CML is imatinib mesylate (IM), which binds to 
the ABL kinase domain and inhibits phosphorylation of substrates (An et al., 
2010a). Although IM dramatically improves patient survival when used to treat 
early-stage disease, the drug is not curative. Resistance to IM can develop, 
especially in advanced-stage disease, leading to disease relapse and 
progression (von Bubnoff et al., 2003). Resistance to IM can result from multiple 
mechanisms that can be broadly classified as either BCR-ABL-dependent or 
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BCR-ABL-independent (Quintas-Cardama et al., 2009). BCR-ABL-dependent 
resistance is most commonly due to the acquisition of point mutations in the ABL 
kinase domain that interfere with IM binding and subsequent kinase inhibition 
(Jabbour et al., 2006; Shah et al., 2002; Weisberg et al., 2007). However, in 50% 
or more of IM-resistant CML patients there is no mutation in BCR-ABL (Donato et 
al., 2004; Khorashad et al., 2006), and the basis of such BCR-ABL-independent 
IM resistance is not understood.  
 
CML, like several other malignancies, is propagated by a small population 
of stem cells, elimination of which is likely required to achieve long-term 
remission and cure (Dean et al., 2005; Graham et al., 2002). An important 
limitation of IM treatment is that although IM inhibits BCR-ABL activity in CML 
stem cells, these cells do not depend on BCR-ABL activity for survival and are 
thus not eliminated (Corbin et al., 2011; Hamilton et al., 2012). These findings 
imply that CML stem cells use survival signals other than BCR-ABL to maintain 
viability in the presence of IM. Understanding the mechanism by which CML 
stem cells are intrinsically resistant to IM is essential for devising strategies to 
eradicate residual leukemia. To gain insight into how IM resistance can occur in 
the absence of BCR-ABL mutations, we performed an RNA interference (RNAi) 
screen to identify genes that regulate IM responsiveness. Our results reveal a 
survival pathway that promotes BCR-ABL-independent IM resistance and also 
contributes to the IM resistance of CML stem cells.   
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RESULTS	
A large-scale shRNA screen identifies IM-sensitizing genes 
To identify IM-sensitizing genes (IMSGs), IM-sensitive human CML K562 cells 
(Andersson et al., 1979) were stably transduced with pools of a genome-wide 
human short hairpin (shRNA) library (Silva et al., 2005) followed by IM treatment 
(Figure 2.1 a). Surviving cells from all pools were combined, and shRNAs 
corresponding to 89 genes were identified by sequence analysis. Validation 
experiments with individual shRNAs corresponding to those isolated from the 
primary screen, as well as second, unrelated shRNAs targeting the same genes, 
confirmed that knockdown of 25 genes conferred >2-fold increased K562 cell 
survival in the presence of IM relative to a control non-silencing (NS) shRNA 
(Figure 2.1 b and Figure 2.2 and Figure 2. 3 a). The extent of IM resistance after 
IMSG knockdown was roughly similar to that of the well-studied experimentally-
derived IM-resistant cell line K562R and an IM-resistant patient-derived cell line, 
SUPB15 (Figure 2.3 b). Quantitative real-time RT-PCR (qRT-PCR) confirmed in 
all cases that expression of the target gene was decreased in the corresponding 
K562 knockdown (KD) cell line (Figure 2.3 c-d).   
 
To confirm that our results are generalizable, we analyzed the validated 
candidates in KYO-1 cells, another IM-sensitive human CML cell line (Ohkubo et 
al., 1985). Figure 2.1 c shows that 21 of the 25 shRNA candidates validated in 
KYO-1 cells. Finally, we tested whether knockdown of the validated candidates 
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would also confer IM resistance in BCR-ABL+ mouse primary bone marrow cells. 
Toward this end, we induced CML-like disease in C57BL/6 mice with a BCR-
ABL-expressing retrovirus (Daley et al., 1990; Li et al., 1999). Primary bone 
marrow cells were harvested, infected with a mouse candidate IMSG shRNA, 
and tested for their ability to form colonies in methylcellulose containing IM. We 
found that knockdown of 19 candidate IMSGs (Figure 2.4 a) rendered BCR-ABL+ 
primary bone marrow cells IM-resistant (Figure 2.1 d). Equivalent results were 
obtained with a second, unrelated shRNA for each IMSG (Figure 2.4. b and c). 
 
To quantify IM resistance, we determined the IC50 for imatinib (IC50IM) of 
IMSG KD K562 cells. Knockdown of 11 IMSGs increased the IC50IM greater than 
5-fold (Figure 2.1 e and Figure 2.5), and we therefore focused on these IMSGs in 
our subsequent experiments. Notably, the IC50IMs of these 11 IMSG KD K562 
cell lines are similar to those of IM-resistant cell lines derived from CML patients 
(Quentmeier et al., 2011). These 11 IMSGs are involved in diverse biological 
processes including transcriptional regulation, signal transduction, protein 
metabolism and DNA/RNA metabolism (Table 2.1).   
 
Next, we tested whether knockdown of IMSGs would cause resistance to 
the second-generation tyrosine kinase inhibitor, dasatinib (Shah et al., 2004). As 
a control, we analyzed in parallel K562R cells, which are resistant to IM but 
sensitive to dasatinib due to over-expression of the Src family kinase (SFK) LYN 
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(Donato et al., 2003). All of the IMSG shRNAs that conferred IM resistance also 
caused resistance to dasatinib (Figure 2.1 f).  
 
Knockdown of IMSGs in BCR-ABL+ cells results in sustained 
RAF/MEK/ERK signaling after IM treatment 
We next performed a series of experiments to identify the regulatory pathway(s) 
through which IMSGs promote IM sensitivity. IMSG KD K562 cell lines were 
cultured in the presence or absence of IM followed by immunoblotting for 
characteristic markers of relevant cell signaling pathways. The results in Figure 
2.6 indicate that knockdown of IMSGs had no effect on total BCR-ABL. 
Moreover, in all IMSG KD K562 cell lines, IM inhibited BCR-ABL protein kinase 
activity, as evidenced by decreased BCR-ABL autophosphorylation and 
decreased phosphorylation of the BCR-ABL substrate CRKL (ten Hoeve et al., 
1994). We also monitored the effect of IMSG knockdown on SFK activity, whose 
elevation, as mentioned above, is responsible for IM resistance in K562R cells. 
None of the IMSG KD K562 cell lines had elevated SFK activity or expression, 
consistent with their resistance to dasatinib.  
 
We next analyzed the effect of IMSG knockdown on known downstream 
signaling pathways of BCR-ABL. All IMSG KD K562 cell lines had normal 
amounts of phosphorylated STAT5 and AKT, indicating that JAK/STAT and 
PI3K/AKT signaling pathways were not affected by IMSG knockdown. In 
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contrast, most of the IMSG KD K562 cell lines had increased RAF/MEK/ERK 
kinase pathway activity, as evidenced by elevated phosphorylation of ERK1/2. As 
expected, after IM treatment of control K562 cells, there was a substantial 
decrease in phosphorylated ERK1/2. However, all of the IMSG KD K562 cell 
lines had, to varying extents, sustained phosphorylation of ERK1/2 after IM 
treatment. Thus, in IMSG KD K562 cell lines, there is an alternative pathway that 
activates RAF/MEK/ERK signaling after inhibition of BCR-ABL. 
 
Previous studies have reported that the protein kinase C (PKC) pathway 
can stimulate RAF/MEK/ERK signaling (Takahashi et al., 1999; Ueda et al., 
1996; Uht et al., 2007). We therefore analyzed PKC pathway activity in IMSG KD 
K562 cells by monitoring phosphorylation of a universal PKC substrate, 
MARCKS (Aderem, 1992). Phosphorylation of MARCKS was elevated in all 
IMSG KD K562 cell lines, indicating increased PKC activity.  
 
PRKCH is upregulated in BCR-ABL-independent IM-resistant CML cell lines 
and patient samples 
Next, we sought to identify the PKC family member(s) responsible for the 
increased PKC activity. The qRT-PCR results in Figure 2.7 a show that PRKCH, 
which encodes PKCη, was upregulated in nearly all IMSG KD K562 cell lines. 
Similar results were obtained with a second shRNA targeting each IMSG (Figure 
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2.8 a). Immunoblot analysis confirmed that PKCη protein levels were also 
increased in the IMSG KD K562 cell lines (Figure 2.8 b).  
As a first step toward understanding the basis by which IMSGs regulate 
PRKCH expression, we further analyzed one of the IMSGs, ELF5, a known 
transcriptional repressor (Chakrabarti et al., 2012; Escamilla-Hernandez et al., 
2010). We used a chromatin immunoprecipitation assay and found that ELF5 
was directly bound at the transcription start site of PRKCH (Figure 2.9 a), 
consistent with the results of a study analyzing ELF5 occupancy genome-wide 
(Kalyuga et al., 2012). Moreover, we found that expression of a PRKCH 
promoter-luciferase reporter construct was increased by ELF5 knockdown and, 
conversely, decreased by ectopic expression of ELF5 (Figure 2.9 b and c). Thus, 
ELF5 is a direct transcriptional repressor of PRKCH, explaining why decreased 
ELF5 levels result in increased PRKCH expression. 
 
To verify that increased PKCη expression is responsible for the IM 
resistance, we derived K562 cell lines that over-expressed PRKCH 
(K562/PRKCH cells) to varying degrees. In several K562/PRKCH cell lines, 
PKCη levels were comparable to those found in IMSG KD K562 cells (Figure 
2.10 a). The elevated PRKCH expression resulted in a 10–20-fold increase in IM 
resistance (Figure 2.7 b). Conversely, knockdown of PRKCH abrogated the IM 
resistance of representative IMSG KD K562 cell lines (Figure 2.10 b).  
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 To determine the clinical relevance of these results, we analyzed PRKCH 
mRNA levels in IM-resistant CML patient samples harboring wild-type BCR-ABL. 
As a control, we also analyzed PRKCH mRNA levels in IM-resistant CML patient 
samples that contained a known IM-resistance mutation in BCR-ABL (Table 2.2). 
The results in Figure 2.7 c show that PRKCH mRNA levels were significantly 
(P<0.01) higher in IM-resistant CML patient samples containing wild-type BCR-
ABL compared to those with mutant BCR-ABL. In addition, we found that the 
average expression of three IMSGs (CLEC5A, ELF5, and WNT7B) was 
significantly (P<0.01, <0.05, <0.05, respectively) lower in IM-resistant CML 
patient samples containing wild-type BCR-ABL compared to those with mutant 
BCR-ABL (Figure 2.7 d). Moreover, in all 11 IM-resistant CML patient samples 
containing wild-type BCR-ABL, at least one IMSG was down-regulated >2-fold, 
and in 9/11 samples at least one IMSG was down-regulated >5-fold relative to 
the average expression in IM-resistant mutant BCR-ABL samples (Table 2.3).  
Finally, the results in Figure 2.7 e show that knockdown of PRKCH increased IM 
sensitivity of leukemic cells from BCR-ABL-independent IM-resistant CML 
patients. 
 
PKCη  increases RAF/MEK/ERK signaling through phosphorylation and 
activation of CRAF 
We next sought to understand in greater detail how PKCη increased 
RAF/MEK/ERK signaling. Figure 2.7 f shows that even a relatively modest 
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knockdown of PRKCH in IM-sensitive K562 cells decreased both phosphorylated 
MEK and ERK1/2 (see also Figure 2.11 a) and increased IM sensitivity (Figure 
2.10 b). Conversely, K562/PRKCH cells had increased levels of both 
phosphorylated MEK and ERK1/2 (Figure 2.7 f). Most importantly, K562/PRKCH 
cells maintained high levels of phosphorylated MEK and ERK1/2 after IM 
treatment (Figure 2.7 f). 
 
The finding that PKCη affected both phosphorylated MEK and ERK1/2 
indicated that PKCη functioned upstream of MEK by, for example, stimulating 
RAF activity. There are three known RAF kinases: ARAF, BRAF, and CRAF 
(Wellbrock et al., 2004). We found that in K562/PRKCH cells, knockdown of 
CRAF, but not ARAF or BRAF, decreased phosphorylatedERK1/2 (Figure 2.7 g 
and Figure 2.11 b). Most importantly, in IM-treated K562/PRKCH cells, 
knockdown of CRAF, but not ARAF or BRAF, resulted in loss of sustained 
phosphorylation of ERK1/2.   
 
To determine whether CRAF was a direct substrate of PKCη, we derived 
a glutathione-S-transferase (GST) fusion-protein containing a CRAF peptide 
bearing a potential PKC phosphorylation site at S497/S499 (Carroll and May, 
1994; Kolch et al., 1993). The in vitro kinase assay in Figure 2.7 h shows that 
wild-type PKCη, but not a kinase-dead mutant (K384R) (Suzuki et al., 2009), 
could phosphorylate the CRAF S497/S499 site. Our results are consistent with 
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several previous findings including phosphorylation of CRAF by PKC isoforms 
(Cai et al., 1997; Carroll and May, 1994; Kolch et al., 1993; Schonwasser et al., 
1998; Sozeri et al., 1992) and reduced activity of a CRAF S497A/S499A mutant 
(Cai et al., 1997; Kolch et al., 1993). 
 
IM and a MEK inhibitor synergistically kill BCR-ABL-independent IM-
resistant CML cells 
The results presented above show that BCR-ABL-independent IM resistance can 
result from increased PRKCH expression, leading to sustained RAF/MEK/ERK 
signaling after IM treatment. An implication of this conclusion is that simultaneous 
inhibition of BCR-ABL and RAF/MEK/ERK signaling might efficiently kill BCR-
ABL-independent IM-resistant CML cells. To investigate this possibility, we 
analyzed the effect of combining IM treatment with the FDA-approved MEK 
inhibitor trametinib (also called GSK1120212). We found that treatment with both 
IM and trametinib had a substantially greater effect than either drug alone in 
killing K562/PRKCH cells (Figure 2.12 a), representative IMSG KD K562 cell 
lines (Figure 2.12 b), and BCR-ABL+ mouse primary bone marrow cells over-
expressing Prkch (Figure 2.12 c). In most instances, the effect of combined drug 
treatment was synergistic. The modest effect of trametinib alone on K562 cell 
lines likely reflects stimulation of RAF/MEK/ERK signaling by BCR-ABL. Finally, 
treatment with both IM and trametinib had a significantly (P<0.01) greater effect 
than either drug alone in killing primary leukemic cells from BCR-ABL-
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independent IM-resistant CML patients (Figure 2.12 d and Figure 2.13 a), 
Moreover, these leukemic cells were killed more effectively by combined 
treatment with IM and trametinib than by IM and a JAK-STAT or PI3K inhibitor, 
and neither of these latter two drug combinations were significantly more 
effective than IM alone (Figure 2.13 b). 
 
IM and a MEK inhibitor prolong survival in mouse models of BCR-ABL-
independent IM-resistant CML 
Based upon the cell culture results, we analyzed the ability of this drug 
combination to prolong survival in mouse models of BCR-ABL-independent IM-
resistant CML. Briefly, mouse primary bone marrow cells were transduced with a 
retrovirus co-expressing BCR-ABL and either Prkch (Figure 2.14 a) or an shRNA 
targeting one of two representative IMSGs, Clec5a or Elf5 (Figure 2.14 b-d), 
followed by transplantation into lethally irradiated syngeneic mice. We found that 
combined treatment with IM and trametinib was substantially more effective than 
either drug alone at suppressing leukemic progression, as evidenced by a 
reduced white blood cell count (Figure 2.12 e and f), and prolonged survival 
(Figure 2.12 g and h). 
PRKCH modulates proliferation of BCR-ABL+ cells, disease progression, 
and IM sensitivity 
The finding that knockdown of PRKCH in K562 cells reduced phosphorylated 
ERK1/2 (Figure 2.7 f) raised the possibility that PRKCH might modulate the 
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proliferation and survival of BCR-ABL+ cells and thus affect disease progression. 
To investigate this possibility, we transduced mouse primary bone marrow cells 
with a retrovirus co-expressing BCR-ABL and a Prkch shRNA (Figure 2.15 a). 
Prkch knockdown decreased phosphorylated ERK1/2, similar to the results in 
K562 cells. Figure 2.15 b shows that knockdown of Prkch (Figure 2.16 a) 
reduced the ability of untreated BCR-ABL+ mouse primary bone marrow cells to 
form colonies in methylcellulose (see also Figure 2.16 b). Moreover, the colony 
formation assay in Figure 2.15 c shows that knockdown of Prkch markedly 
increased the IM sensitivity of BCR-ABL+ mouse primary bone marrow cells. 
 
We next transplanted the Prkch KD bone marrow cells into syngeneic 
mice to induce CML-like disease and analyzed the effect of Prkch knockdown on 
leukemic progression. We found that in untreated mice Prkch knockdown 
resulted in a lower white blood cell count (Figure 2.15 d), reduced spleen size 
(Figure 2.15 e), decreased infiltration of the lung and spleen by leukemic cells 
(Figure 2.15 f), and an increase in survival (Figure 2.15 g). Thus, in the absence 
of IM treatment, PRKCH promotes disease progression, although this effect may 
be relatively minor. More importantly, knockdown of Prkch markedly increased 
survival of IM-treated mice with CML-like disease (Figure 2.15 g).  
 
IM-resistant murine and human CML stem cells contain high levels of 
PRKCH   
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We considered the possibility that PRKCH might contribute to the intrinsic 
resistance of CML stem cells to IM. To investigate this idea, we induced CML-like 
disease in mice and isolated BCR-ABL+ murine stem cells (Lin-Sca1+Kit+), 
progenitor cells (Lin-) and mature cells (Lin+Gr1+) by fluorescence activated cell 
sorting (FACS) (Hamilton et al., 2012; Neering et al., 2007). The qRT-PCR 
results in Figure 2.17 a show that IM-resistant murine CML stem cells ((Hamilton 
et al., 2012; Zhang et al., 2010; Zhang et al., 2012) and see below) had 
substantially higher expression of Prkch compared to murine CML progenitor and 
mature cells, both of which are IM-sensitive ((Hamilton et al., 2012; Li et al., 
2012) and Figure 2.18).  
 
We next asked whether PRKCH expression was also high in human CML 
stem cells. We isolated CML stem cells (CD34+CD38-) and CML progenitor cells 
(CD34+CD38+) (Corbin et al., 2011; Jiang et al., 2007; Lobo et al., 2007) from 
newly diagnosed CML patients. The qRT-PCR results in Figure 2.17 b show that 
IM-resistant human CML stem cells ((Bhatia et al., 2003; Chomel et al., 2011; 
Corbin et al., 2011; Graham et al., 2002; Pellicano et al., 2014) and see below) 
had substantially higher expression of PRKCH compared to human CML 
progenitor cells, which are IM-sensitive (Corbin et al., 2011; Jiang et al., 2007). 
Analysis of a published expression profiling study comparing highly enriched 
human CML stem and progenitor cell populations (Gerber et al., 2013) revealed 
similar differences in PRKCH expression (Figure 2.17 c). Microarray analysis 
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indicates that PRKCH expression is much higher in hematopoietic stem cells 
than in mature myeloid cells (Bagger et al., 2013; Konuma et al., 2011), 
suggesting that high PRKCH expression may be a marker of stemness.  
 
High Prkch expression contributes to the IM resistance of CML stem cells 
We performed several experiments to determine whether the high Prkch 
expression in murine CML stem cells contributes to their IM resistance. We first 
assessed the contribution of Prkch, and as a comparison BCR-ABL, to 
RAF/MEK/ERK signaling in murine CML stem cells. Prkch KD bone marrow cells 
were isolated from leukemic mice, permeabilized and incubated with an antibody 
against phosphorylated ERK1/2 or, as a negative control, IgG isotype antibody, 
and then analyzed by FACS to determine the phosphorylated ERK1/2 levels in 
CML progenitor and stem cells. Figure 2.19 a shows that knockdown of Prkch 
reduced phosphorylated ERK1/2 in both CML progenitor and stem cells (see also 
Figure 2.20 a). 
 
 To evaluate the role of BCR-ABL, bone marrow cells were isolated from 
leukemic mice and treated with either IM or trametinib, and phosphorylated 
ERK1/2 was monitored as described above. Figure 2.19 b shows, as expected, 
that trametinib reduced phosphorylated ERK1/2 in both CML progenitor and stem 
cells (see also Figure 2.20 b). In contrast, IM reduced phosphorylated ERK1/2 in 
IM-sensitive CML progenitor cells, but not in IM-resistant CML stem cells. 
	 55	
Collectively, these results indicate that in CML stem cells, PKCη has a more 
prominent role than BCR-ABL in promoting RAF/MEK/ERK signaling. 
 
We next performed a series of experiments to determine whether Prkch 
affects survival of CML stem cells after IM treatment. In the first experiment, 
mouse primary bone marrow cells were transduced with a retrovirus co-
expressing BCR-ABL and either Prkch or a control NS shRNA, followed by 
transplantation into lethally irradiated syngeneic mice. BCR-ABL+ murine stem 
cells (Lin-Sca1+Kit+) were isolated from the mice and IM sensitivity determined 
in a colony formation assay. The results in Figure 2.19 c show that Prkch 
knockdown markedly increased the IM sensitivity of CML stem cells. In the 
second experiment, mice with CML-like disease were treated with either vehicle 
or IM in parallel for two weeks, and then sacrificed at the same time followed by 
quantification of CML stem cells by FACS analysis. Figure 2.19 d shows, as 
expected, that IM treatment had little effect on the number of CML stem cells 
expressing a control NS shRNA, confirming that murine CML stem cells are IM-
resistant. In contrast, IM treatment markedly reduced Prkch KD CML stem cells. 
Annexin V staining revealed that IM treatment induced a higher level of apoptosis 
in Prkch KD compared to control CML stem cells (Figure 2.21 a and b). Finally, 
combined treatment with IM and trametinib synergistically killed murine CML 
stem cells (Figure 2.19 e), which was due, at least in part, to the induction of 
apoptosis (Figure 2.21 c and d). By contrast, treatment with IM and trametinib 
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had negligible effect on normal murine hematopoietic stem cells (Figure 2.22 a).  
 
Knockdown of PRKCH also increased the IM sensitivity of IM-resistant 
human CML stem cells (Figure 2.19 f). Moreover, treatment with both IM and 
trametinib had a substantially greater effect than either drug alone in killing 
human CML stem cells (Figure 2.19 g), and a negligible effect on normal human 
hematopoietic CD34+ cells and hematopoietic stem cells (CD34+CD38-) (Figure 
2.22 b). Collectively, these results indicate that PRKCH is expressed at relatively 
high levels in both mouse and human CML stem cells and this contributes to their 
IM resistance. 
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DISCUSSION	
In this study, we have identified a molecular pathway whose increased activity 
promotes BCR-ABL-independent IM resistance and also contributes to the IM 
resistance of CML stem cells. Our major conclusions are summarized in the 
schematic model in Figure 2.23 and discussed below. In typical IM-sensitive CML 
cells, BCR-ABL is the major contributor to RAF/MEK/ERK signaling. Thus, treatment 
with IM substantially reduces RAF/MEK/ERK signaling, leading to inhibition of 
proliferation and induction of apoptosis. In BCR-ABL-independent IM-resistant CML 
cells, elevation of PKCη, due to decreased expression of one or more IMSGs, 
results in phosphorylation and activation of CRAF, thereby augmenting 
RAF/MEK/ERK signaling. After treatment with IM, RAF/MEK/ERK signaling is 
sustained, resulting in drug resistance.  
 
A previous study analyzing IM resistance resulting from mutations in BCR-
ABL found that IM treatment "paradoxically" increased RAF/MEF/ERK signaling 
through a RAS-directed pathway (Packer et al., 2011). Although the IM resistance 
mechanism we describe, like that in (Packer et al., 2011), involves increased 
RAF/MEK/ERK signaling, there are several important differences. For example, in 
our experiments the increased RAF/MEK/ERK signaling is not dependent upon RAS 
but rather initiated by PKCη, is constitutive and not induced by IM, and, as 
discussed below, is also relevant to the intrinsic IM resistance of CML stem cells. In 
addition, several reports have described experimentally derived BCR-ABL-
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independent IM-resistant CML cell lines in which RAF/MEK/ERK signaling is 
increased by a mechanism that was not determined (Aceves-Luquero et al., 2009; 
Hentschel et al., 2011; Nambu et al., 2010), or have provided other evidence that 
RAF/MEK/ERK signaling can contribute to IM resistance (Chang et al., 2007; Chu et 
al., 2004; Mizuchi et al., 2005; Pellicano et al., 2011). 
 
The mechanistic basis by which IMSGs regulate PRKCH expression is largely 
unknown. We showed that one of the IMSGs, ELF5, is directly bound at the 
transcription start site of PRKCH, and can decrease PRKCH expression. Thus, 
ELF5 is a direct transcriptional repressor of PRKCH, explaining why decreased 
ELF5 levels result in increased PRKCH expression. Whether other IMSGs function 
directly or indirectly to regulate PRKCH expression remained to be determined. 
 
It is likely that our RNAi screen, like other large-scale RNAi screens 
(Mullenders and Bernards, 2009), was not saturating, and thus there are probably 
other IMSGs and regulators of PRKCH expression that remain to be identified. Our 
results suggest that a variety of diverse perturbations can increase PRKCH 
expression. A previous expression profiling study revealed that the level of PRKCH 
in CML cells increased after one week of IM treatment (Bruennert et al., 2009), 
perhaps due to selection of and enrichment for cells with high PRKCH expression. 
This finding may also be explained by induction of PRKCH expression by IM 
treatment, although we found in IMSG KD K562 cell lines and CML stem cells that 
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PRKCH is highly expressed in the absence of IM. In addition to its role in IM 
resistance, we found that elevated Prkch expression also accelerates disease 
progression in a mouse model of CML. Consistent with this idea, in a previous 
expression profiling study, PRKCH levels were found to increase during disease 
progression in CML patients. In the same study, the expression of seven of nine 
IMSGs analyzed decreased during disease progression (Radich et al., 2006). 
 
The IM-resistance mechanism we describe is therapeutically targetable, 
which we demonstrate by showing that combined treatment with IM and the FDA-
approved MEK inhibitor trametinib synergistically kills BCR-ABL+ IMSG KD cells and 
prolongs survival in several mouse models of BCR-ABL-independent IM-resistant 
CML. However, analysis of patient-derived CML cell lines suggests there may be 
variable responsiveness to MEK inhibition (Jing et al., 2012). Our results are also 
relevant to another current challenge of CML treatment: the intrinsic resistance of 
CML stem cells to IM. We found that both human and murine CML stem cells 
contain high levels of PRKCH and provide evidence that this is responsible, at least 
in part, for their IM resistance. We further showed that the high PRKCH levels in 
CML stem cells promote RAF/MEK/ERK signaling, which helps explain why CML 
stem cells are not dependent upon BCR-ABL for survival (Corbin et al., 2011; 
Hamilton et al., 2012). Collectively, these results provide a rationale for our finding 
that CML stem cells, but not normal hematopoietic stem cells, are efficiently killed by 
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combined treatment with IM and trametinib, and suggest a therapeutic strategy for 
their eradication. 																				
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MATERIALS AND METHODS 
Cell lines and culture 
BCR-ABL+ positive human CML cell lines K562 (ATCC), K562R (kindly provided 
by Nicholas J. Donato, University of Michigan) and KYO-1 (Leibniz Institute 
DSMZ-German Collection of Microorganisms and Cell Cultures; ACC 601) were 
maintained in RPMI 1640 medium containing 10% fetal bovine serum (FBS), 4 
mM L-glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin. 32D/BCR-
ABL cells (kindly provided by Tomasz Skorski, Temple University) were 
maintained in RPMI 1640 with 10% FBS. 
 
RNAi screen 
The RNAi Consortium (TRC) lentiviral human shRNA library (Open 
Biosystems/Thermo Scientific) was obtained through the University of 
Massachusetts RNAi Core facility. Twenty-two lentivirus pools, each comprising 
~5000 shRNA clones, were generated with titers of ~2x107 cfu/ml, as previously 
described (Gazin et al., 2007). 2x106 K562 cells were transduced at a multiplicity 
of infection <1 with the lentiviral stocks in 6-well plates, and 2 days later 
puromycin selected (1 µg/ml) for 5 days. Cells were then treated with 20 µM IM 
(LC Laboratories) for 7 days, and washed twice with fresh medium until >99% of 
control cells (those expressing a non-silencing shRNA) died off. Surviving cells 
from all shRNA pools were combined and allowed to recover in IM-free medium 
with 1 µg/µl puromycin for 4 days. Live cells were sorted out with a Dead Cell 
	 62	
Removal kit (Miltenyi Biotec) and harvested, and genomic DNA was prepared for 
sequencing identification of the integrated shRNA as previously described (Gazin 
et al., 2007).  
 
Cell viability assay 
To validate candidates, K562 or KYO-1 cells were stably transduced with a 
lentivirus carrying an individual shRNA (clone IDs are listed in Table 2.4) and 
puromycin selected for 5 days. 2.5x103 IMSG KD K562 cells or 1x104 IMSG KD 
KYO-1 cells were plated in 96-well plates, and IM (10 µM for K562 cells or 0.1 
µM for KYO-1 cells) or vehicle (DMSO) was added for 3 days. MTT reagent 
(Promega) or Alamar Blue (Invitrogen) was added to each well in 1:10 volume 
and incubated, and absorbance at 570 nm was recorded using a VICTOR3 
(PerkinElmer) or SpectraMAX M5 (Molecular Devices) plate reader. 
For other cell viability assays, IMSG KD K562 cells or K562/PRKCH cells were 
treated for 3 days with a range of IM concentrations as indicated (Figure 2.1 e 
and Figure 2.7 b), or 0.1 µM IM, 1.5 nM trametinib or both (Figure 2.12 a and b), 
and analyzed as described above. For Figure 2.1 e and Figure 2.7 b and Figure 
2.5, data were plotted in GraphPad Prism and a dose response curve was fit with 
nonlinear regression to calculate IC50IM. For Figure 2.1 f, IMSG KD K562 cells 
were treated with 10 µM IM or 500 nM dasatinib (ChemieTeK), and cell viability 
was analyzed as described above. The curve was fit with linear regression, and 
correlation coefficient was calculated using GraphPad Prism 6. 
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Colony formation assay 
For Figure 2.1 d, mouse primary bone marrow cells were harvested from CML 
mice as described below, and subjected to two rounds of infection with a mouse 
IMSG shRNA lentivirus (clone IDs are listed in Table 2.4). Two days later, 5x104 
IMSG KD cells were mixed with cytokine-free methylcellulose-based medium 
(MethoCult M3234; STEMCELL Technologies) and 0.5 µM IM and plated in 35 
mm dishes. Colonies were counted under a brightfield microscope at day 7. For 
Figure 2.12 c, primary bone marrow cells were transduced for two rounds with a 
retrovirus expressing Prkch, generated by PCR amplifying mouse Prkch cDNA 
(an MGC clone; Open Biosystems/Thermo Scientific) using forward (5’-
ATAGGTTAACGCCACCATGTCGTCCGG CACGATGA-3’) and reverse (5’-
ATAGGAATTCCTACAGTTGCAATTCCGGTGA-3’) primers, digesting the PCR 
product with HpaI and EcoRI, and cloning it into MSCV-IRES-GFP (Addgene 
plasmid 20672). Two days after transduction, 5x104 cells were mixed with 
methylcellulose and 0.5 µM IM, 2 nM trametinib (ChemieTek) or both. For Figure 
2.15 b and c, primary bone marrow cells were collected from Prkch knockdown 
CML mice (generated using a retrovirus co-expressing BCR-ABL and a Prkch 
shRNA; see below), and 1x105 cells were plated in methylcellulose in the 
absence (Figure 2.15 b) or presence of 0.1 µM IM (Figure 2.15 c). For Figure 
2.19 c, primary bone marrow cells were collected from either NS or Prkch 
knockdown CML mice, BCR-ABL+ murine stem cells (Lin-Sca1+Kit+) were 
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isolated from the mice by FACS, and IM sensitivity determined as described 
above for Figure 2.15 b and c.  
 
Immunoblot analysis 
After 5 days puromycin selection, ~1x106 IMSG KD K562 cells were plated into 
6-well dishes and treated with 10 µM IM for 36 hours. Cells were harvested and 
lysed with RIPA buffer (10x, 200 mM HEPES pH 6.8, 1400 mM NaCl, 25 mM 
MgCl2, 25 mM CaCl2, 10% NP40, and 5% sodium deoxycholate) plus 
phosphatase (Sigma) and protease inhibitors (Roche). Blots were probed with 
the following primary antibodies, all obtained from Cell Signaling Technology: 
BCR-ABL PathScan (p-BCR-ABL, p-STAT5, p-CRKL) (#5300S), total BCR-ABL 
(#2862S), p-ERK1/2 (#4377S), total ERK1/2 (#4695S), t-STAT5 (#9358S), p-
AKT (#4060S), t-AKT (#4685S), p-SFK (#2105S), t-LYN (#2796S), t-CRKL 
(#3182S), p-MARCKS (#8722S), t-MARCKS (#5607S), ARAF (#4432S), BRAF 
(#9433S), CRAF (#9422S). The PKCη antibody (Santa Cruz Technology; C-15) 
was diluted in 5% skim milk at 1:150. The β-actin antibody (Sigma; AC-74) was 
diluted in 5% BSA at 1:5000. Blots were developed with Pico/Femato super 
signal (Sigma) and visualized using autoradiography or a Bio-Rad ChemiDoc MP 
Imaging System. 
 
RNA preparation and qRT-PCR 
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Total RNA was isolated from cells using TriPure Isolation Reagent (Roche) 
followed by treatment with turbo DNase (Ambion) to remove contaminating 
genomic DNA. Reverse transcription was performed using MMLV reverse 
transcriptase (Zhao et al.) followed by qPCR with Fast SYBR Green Master Mix 
(Applied Biosystems) and primers listed in Table 2.5. The expression of each 
gene was normalized to that of GAPDH. Knockdown efficiency was calculated 
relative to that obtained with a control non-silencing shRNA. 
 
In vitro kinase assay 
A plasmid expressing Flag-tagged PKCη was generated by PCR amplifying 
PRKCH from a cDNA clone (Open Biosystems/Thermo Scientific) and cloning 
the PCR product into expression vector p3xFlag-Myc-CMV-25 (Sigma). The 
kinase-dead K384R mutant was generated by PCR-based site-directed 
mutagenesis using PfuTurbo DNA polymerase (Agilent). Plasmids were 
transfected individually into 293T cells, and proteins were immunopurified from 
cell lysate using an anti-Flag antibody (Sigma). In vitro phosphorylation reactions 
were set up in a 20 µl reaction volume as follows: 1 µl 32P-γ-ATP (10 mCi), 1 µl 
10 µM ATP, 0.2 mM microcystin, 4 µl 5X kinase buffer [23 mM MOPS, 11.5 mM 
β-glycerophosphate, 23 mM MgCl2, 4.6 mM EGTA, 1.8 mM EDTA, 0.25 mM DTT 
(pH 7.0)], 60 nM purified Flag-PKCη diluted in 1X kinase buffer, and 10 µM 
substrate (GST or GST fused to a peptide corresponding to amino acids 491-505 
of CRAF, purified from E. coli) diluted in 1X kinase buffer. Reactions were 
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incubated for 30 min at 30°C and stopped using 2X Laemmli Sample Buffer. 
Incorporation of the radiolabel into the peptide was monitored by 
autoradiography. 
 
Flow cytometry analysis 
Fifteen days after induction of CML-like disease (see below), bone marrow cells 
were flushed out of mouse femur and tibia bones with RBC lysis buffer (155 mM 
NH4Cl, 12 mM NaHCO3, 0.1 mM EDTA), spun down at 1,000 rpm for 10 min, and 
washed once with PBS. 2-5x106 cells from each sample were aliquoted for 
staining. A cocktail of primary antibodies [APC-conjugated Sca-1 antibody 
(eBioscience), PE-conjugated c-Kit antibody (eBioscience) and Biotin-conjugated 
Lineage antibody cocktail (Miltenyi Biotec)] was added to each sample in a total 
volume of 100 µl, incubated on ice for 30 min, washed once by adding PBS (1 
ml) and spin down at 1,000 rpm for 10 min. The secondary antibody (APC-
eFluor780-conjugated Straptavidin; eBioscience) was added in a total volume of 
100 µl, incubated for 20 min on ice, and then washed once with PBS. FACS 
analysis was performed immediately using an LSR II flow cytometer (BD 
Biosciences). The Lin+ population was separated from the Lin- population by 
magnetic beads (Miltenyi Biotec). GFP+Lin-Sca1+Kit+ and GFP+Lin- cells 
(hereafter referred to as Lin-Sca1+Kit+ and Lin- cells) were then FACS sorted 
from the Lin- population, and GFP+Lin+Gr1+ cells (hereafter referred to as 
Lin+Gr1+ cells) were FACS sorted from the Lin+ population. 
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For Lin-Sca1+Kit+ apoptosis staining, 5 µl Annexin-V antibody [eFluor450-
conjugated Annexin V (eBioscience)] was added to each sample after the last 
wash and incubated for 20 min in the dark at room temperature. Samples were 
washed once, and 2 µl 7AAD (eBioscience) was added within 4 h before FACS 
analysis.  
 
For intracellular phosphorylated ERK1/2 analysis, bone marrow cells 
isolated from leukemic mice were treated with 5 µM IM or 10 nM trametinib for 3 
hours, fixed in 4% paraformaldehyde (Electron Microscopy Sciences) for 10 min 
at 37°C, washed twice with wash buffer (0.05% BSA in 1x PBS), spun down, and 
resuspended in 100 µl wash buffer. Ice-cold methanol (900 µl) was added to the 
cells while gently vortexing to reach a final concentration of 90% methanol for 
permeabilization. Samples were incubated on ice for 30 min, washed twice, and 
resuspended in 100 µl wash buffer. IgG control antibody (Cell Signaling) was 
added (at 1:100 dilution) for 10 min at room temperature for blocking, followed by 
addition of 2 µl conjugated IgG control (Pacific Blue-conjugated IgGXP Rabbit 
mAb, Cell Signaling) or phospho-ERK antibody (Pacific Blue-conjugated P-
p44/42(T202/Y204)XP Rabbit mAb, Cell Signaling). Samples were gently mixed 
and incubated at room temperature for 1 hour. Thirty minutes after the start of the 
incubation, a cocktail of primary antibodies for cell surface markers was added, 
incubated for a further 30 min, washed once with PBS, and incubated with the 
secondary antibody for 20 min on ice. Samples were then washed once with 
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wash buffer prior to FACS analysis. Relative phosphorylated ERK1/2 staining 
was calculated by first subtracting the IgG background staining and then 
normalizing the absolute fluorescence intensity (median) of the treatment group 
(Prkch knockdown or IM or TM treatment) to that of the control group (NS shRNA 
or DMSO). 
 
Construction of BCR-ABL/shRNA or BCR-ABL/Prkch co-expression 
plasmids 
shRNAs were subcloned from an effective TRC Elf5 or Clec5a shRNA plasmid 
(see Table 2.4) into the MluI site downstream of GFP in the retroviral vector 
MSCV-BCR-ABL-IRES-GFP (Li et al., 1999) (using forward [5’-
ATAGACGCGTTTCTTGGCTTTATATATCTTGTGG-3’] and reverse [5’-
ATAGACGCGTCAAAGTGGATCTCTGCTGTC-3’] primers, where underlining 
indicates the MluI site) to ensure the shRNA would be expressed in the same 
transcript as BCR-ABL and GFP. Similarly, mouse Prkch cDNA was subcloned 
into MSCV-BCR-ABL-IRES-GFP as described above to generate an MSCV-
BCR-ABL-IRES-mPRKCH-IRES-GFP triple gene expression construct. Virus titer 
was tested in NIH 3T3 cells. Briefly, 5x104 cells were plated in each well of a 6-
well plate, and virus was added at 1:1 dilution with fresh DMEM medium (10% 
FBS) plus Polybrene (Qiagen) and then cultured for 48 hours. FACS was 
performed to analyze GFP percentage. Only those viruses showing ≥90% 
infection were used for in vivo CML induction. 
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Mouse models of CML 
Mice with CML-like disease were generated as previously described (Li et al., 
1999). Briefly, wild-type male C57BL/6 mice 6–8 weeks of age (Jackson 
Laboratory) were tail-vein injected with 5-fluorouracil (200 mg/kg; Sigma) for 4 
days to enrich for slow-cycling hematopoietic stem cells. At day 5, bone marrow 
cells were harvested and pre-incubated overnight in the presence of IL-3, IL-6 
and SCF (all from PeproTech) to increase infection efficiency. At days 6 and 7, 
bone marrow cells were infected with a BCR-ABL retrovirus by co-sedimentation 
method at 3,000 rpm for 90 min at room temperature. Four hours after the 
second round of retroviral infection, 0.5x106 bone marrow cells were injected into 
the tail vein of syngeneic recipient mice that had been lethally irradiated (twice at 
550 R). Mice were randomly allocated to each group after bone marrow 
transplantation. 
 
For drug treatment, mice were orally gavaged twice a day with IM 
(dissolved in filtered ddH2O [vehicle]) at 100 mg/kg and/or once a day with 
trametinib (dissolved in 0.5% hydroxypropylmethycellulose and 0.2% Tween-80 
in filtered ddH2O [vehicle]) at 2 mg/kg.  
 
White Blood Count 
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Peripheral blood (~25 µl) was collected from mouse tail veins into Microtainer 
tubes (BD Biosciences), and analyzed using a Hemavet 950 FS (Drew Scientific, 
Inc) cell counter within 3 hours after blood collection.  
 
Acquisition and storage of CML patient samples 
After informed consent in accordance with IRB-approved protocols, bone marrow 
aspirate or peripheral blood samples were collected from CML patients. For 
samples provided by the Druker lab and Emory University, mononuclear cells 
were isolated by Ficoll gradient and, depending on the number of viable cells 
available, cells were stored as pellets or guanidinium thiocynate (GTC) lysates 
(resuspended in Qiagen RLT lysis buffer + β-mercaptoethanol) at -80°C, or 
resuspended in fetal bovine serum (FBS) + 10% DMSO, frozen slowly overnight, 
and then transferred to liquid nitrogen for long-term storage. For samples 
provided by UMMS, white blood cells were isolated by red cell lysis, and cells 
were resuspended in FBS + 10% DMSO, frozen slowly overnight, and then 
transferred to liquid nitrogen for long-term storage. All samples were provided in 
a de-identified manner. Samples from normal donors were purchased from a 
commercial vendor (AllCells or Lonza).  
 
Analysis of human CML patient samples 
To analyze gene expression in IM-sensitive and IM-resistant CML patient 
samples, RNA was obtained in the form of purified RNA or extracted 
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independently from GTC lysate or Trizol stock, and qRT-PCR was performed as 
described above.  
 
To culture primary cells derived from CML patients and normal individuals 
for functional experiments, frozen patient cells were first warmed for 10 min at 
37°C. 1 ml of pre-warmed thawing medium (IMDM with 5% FBS, 0.1 mg/ml 
DNase, and 400 U/ml heparin) was added slowly, followed by 10 ml of wash 
medium (IMDM with 5% FBS, 0.1mg/ml DNase). After passing through a 70 µm 
filter, cells were spun at 300 g for 10 min. Cell pellets were then resuspended in 
an adequate amount of culture medium (IMDM with 20% BIT [STEM CELL 
technology], 20 ng/ml IL-3, 20 ng/ml IL-6, 20 ng/ml FLT3, 100 ng/ml G-CSF, and 
100 ng/ml SCF [PeproTech]) and incubated overnight at 37°C. Cells were then 
either directly used, or further enriched for the CD34+ population using CD34 
MicroBead Kit UltraPure (Miltenyi Biotec).  
 
For PRKCH knockdown, a volume of PRKCH shRNA-GFP lentivirus equal 
to the volume of cells was used to infect cells at 2,000 g for 90 min at room 
temperature. After culturing for an additional 16-24 hours, cells were pelleted at 
300 g for 10 min and resuspended in culture medium with 1% of initial cytokines, 
a more physiologically relevant concentration. Cells were then treated with 
DMSO, 5 µM IM, 5 nM trametinib, or both drugs for 4 days. The cell viability of 
the target population was then calculated by multiplying the percentage of target 
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population, which was obtained by FACS analysis, and the total number of live 
cells, which was determined by trypan blue staining.  
 
To analyze PRKCH expression in human CML stem cells (CD34+CD38-) 
and progenitor cells (CD34+CD38+), freshly thawed CML cells or CD34+-
enriched CML cells were directly stained for CD34 and CD38 cell surface 
markers. The target population was isolated by FACS and total RNA was 
extracted by Trizol for qRT-PCR analysis as described above. For bioinformatic 
analysis, CEL files were downloaded from Gene Expression Omnibus (GEO 
accession GSE43754), and PRKCH expression analysis was performed using 
the R program 'RMA' in the BioConductor 'oligo' package (Carvalho and Irizarry, 
2010) with full probeset annotation. 
 
Chromatin immunoprecipitation 
K562 cells (1x107) were crosslinked with 1% formaldehyde for 12 min at room 
temperature, followed by addition of 0.125 mM glycine for 10 min. Cells were 
washed twice and lysed in ChIP lysis buffer (50 mM HEPES pH 8.0, 150 mM 
NaCl, 1 mM EDTA, 0.1%Na-deoxycholate, 1% TritonX-100, 0.1%SDS, plus 
protease inhibitor) for 15 min on ice. The lysate was sonicated for 12 rounds (30 
seconds on, 1 minute 30 seconds off, power output 6.0) using Sonicator 3000 
(Qsonica), and clarified by centrifugation. 50 µl 50% protein-G agarose bead 
slurry was used to pre-clear 5 mg of chromatin for over 4 hours at 4°C. For ChIP 
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experiments, 500 µg pre-cleared chromatin were incubated overnight with either 
5 µg anti-ELF5 antibody ((N-20) X, Santa Cruz) or IgG, followed by addition of 50 
µl 50% protein-G agarose bead slurry and incubation for 4 hours at 4°C. Beads 
were pelleted by centrifugation and washed twice with ChIP lysis buffer, once 
with high salt lysis buffer (ChIP lysis buffer adjusted to 1M NaCl), thrice with LiCl 
wash buffer (50 mM HEPES pH 8.0, 250 mM LiCl, 1 mM EDTA, 0.5% 
deoxycholate, 0.5% NP40, plus protease inhibitor), and once with Tris-EDTA 
buffer. After the last wash, the supernatant was removed and 400 µl elution 
buffer (1% SDS, 0.1% NaHCO3) was added and incubated for 15 min at 65°C 
with occasional vortexing. Beads were pelleted, and the supernatant was 
transferred to a new tube and reverse-crosslinked overnight at 65°C. RNase A (2 
µl of 10 mg/ml) was added to each ChIP sample and incubated for 1 hour at 
37°C, followed by addition of 5 µl Protease K (20 mg/ml, Promega) and 
incubation for 2 hours at 55°C. DNA was phenol:chloroform extracted and 
isopropanol precipitated, and subjected to qPCR  with the following primers: 
TSS-for (5’-AGGAGGAGAAGCAAGAGGAG-‘3’) and TSS-rev (5’-
CCGACCGTCCCTTCCAAG-3’), 500-for (5’-GACCTTTCCTGCTCTATGTG-3’) 
and 500-rev (5’-CTGCAGAGGCTAATTACACAG-3’), and 1000-for (5’-
CATAGCAGCGTAGGCTAAAA G-3’) and 1000-rev (5’-
CGGAAGAAATTGCCTCTTCTAG-3’). Fold enrichment was calculated by setting 
the IgG control to a value of 1.  
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Luciferase reporter assays 
A 2 kb genomic DNA region upstream of the PRKCH transcription start site was 
PCR amplified from a BAC clone (RP11-1069E8) using forward and reverse 
primers (5’-ATAGGCTAGCGTTCTGAACAGGGCCTTAGAG-3’ and 5’-
ATAGAAGCTTGATGCGGACCCTCAAATAGC-3’, respectively), digested with 
NheI and HindIII, and ligated into the firefly luciferase reporter vector 
PGL4.14[luc2/Hygro] (Promega). 2 µg of this reporter and 40 ng of pRL-TK 
Renilla luciferase control reporter vector (Promega) were co-transfected into 
ELF5 knockdown or ELF5-overexpressing K562 cells by electroporation. After 48 
hours of culturing, cells were lysed and centrifuged. Supernatants were 
incubated with luciferase substrate (Promega), and the luciferase activity was 
recorded by VICTOR3 (PerkinElmer) plate reader.  
 
Statistics 
All quantitative data were collected from experiments performed in at least 
triplicate, and expressed as mean ± standard deviation. Animal experiments were 
expressed as mean +/- standard error of the mean. Statistical analyses were 
performed using R, a system for statistical computation and graphics (Ihaka and 
Gentleman, 1996). Relative cell viability data and cell death data were first 
arcsine transformed to homogenize the variance. Colony number and cell 
number data were first log transformed. Levene's test was performed to test for 
homogeneity of variance. When the assumption of homogeneity of variances was 
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met, ANOVA was performed followed by predetermined contrasts within the 
ANOVA framework. When the assumption was violated, a non-parametric 
counterpart of ANOVA (Kruskal–Wallis test for completely randomized design or 
Friedman rank sum test for randomized complete block design) was performed. 
In some instances, P values were adjusted to counteract the problem of multiple 
comparisons (Benjamini and Hochberg, 1995). Significant differences were 
considered when P<0.05; *P≤0.05 and **P≤0.01.  
 
Statistical analysis for drug synergy was performed using R (Ihaka and 
Gentleman, 1996) to assess whether the combined effects from IM and 
trametinib were additive (responses were equal to the sum of the single-drug 
effects), synergistic (greater than the sum of the single-drug effects) or 
antagonistic (less than the sum of the single-drug effects). Two-way analysis of 
variance (ANOVA) was used to test for the main effects of IM and trametinib and 
their interaction on cell viability and apoptosis. Benjamini and Hochberg (BH)-
adjusted P value was calculated to counteract the problem of multiple 
comparisons (Benjamini and Hochberg, 1995). The difference between observed 
effects and the expected additive effects for the cell lines exposed to both drugs 
were compared as previously described (Slinker, 1998). The difference was 
estimated as the interaction coefficient in ANOVA. For cell viability, if there was a 
significant positive difference (interaction coefficient > 0 and BH-adjusted P value 
< 0.05), then the impact from the combined drugs was classified as antagonism; 
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if there was a significant negative difference (interaction coefficient < 0 and BH-
adjusted P value < 0.05), then the impact from the combined drugs was classified 
as synergistic; if there was no significant difference, then the impact from the 
combined drugs was classified as additive. For apoptosis, if there was a 
significant positive difference, then the impact from the combined drugs was 
classified as synergism; if there was a significant negative difference, then the 
impact from the combined drugs was classified as antagonism. 															
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Figure 2.1. A large-scale shRNA screen identifies IMSGs. (a) Schematic 
summary of the screen. (b) Relative viability of IMSG KD K562 cells in the 
presence of IM, as measured by MTT assay (n=4). The results were normalized 
to that obtained with DMSO-treated cells, which was set to 1. IMSG shRNAs that 
conferred >2-fold increase in cell survival (indicated by the red line) relative to the 
NS control shRNA were considered positive. (c) Relative viability of IMSG KD 
KYO-1 cells in the presence of IM, as measured by MTT assay (n=4). The results 
were normalized and positives determined as described in (b). (d) Colony 
formation assay monitoring survival of BCR-ABL+ mouse primary bone marrow 
cells expressing an IMSG shRNA in the presence of IM (n=3). IMSG shRNAs 
that conferred >2-fold increase in colony number (indicated by the red line) 
relative to the NS control shRNA were considered positive. (e) Relative IC50IM of 
IMSG KD K562 cells (n=4). (f) Cell viability, as measured by MTT assay, of IMSG 
KD K562 cells treated with 500 nM dasatinib or 10 µM IM for 3 days (n=4). K562 
cells expressing an NS shRNA (K562/NS) and IM-resistant K562 cells (K562R) 
were analyzed as controls. Data are represented as mean ± SD. *P≤0.05, 
**P≤0.01.   
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Figure 2.2 IM sensitivity of non-validating candidates isolated from the 
primary shRNA screen. MTT assay showing relative viability of IMSG KD K562 
cells in the presence of IM. The results were normalized to that obtained with 
DMSO-treated cells, which was set to 1. The red line indicates a 2-fold increase 
in cell survival relative to that of the non-silencing (NS) control shRNA; none of 
the shRNAs shown here were considered positive. The NS control is the same 
as that used in Figure 2.1 b. Data are represented as mean ± SD (n=4). *P≤0.05, 
**P≤0.01.   
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Figure 2.4. IM sensitivity after candidate IMSG knockdown in mouse 
primary bone marrow cells. (a) qRT-PCR analysis monitoring knockdown 
efficiencies of mouse IMSG shRNAs in mouse primary bone marrow cells (n=3). 
(b) Colony formation assay monitoring survival of BCR-ABL+ mouse primary 
bone marrow cells expressing an IMSG shRNA in the presence of IM (n=3). 
IMSG shRNAs that conferred >2-fold increase in colony formation relative to that 
of the NS control shRNA (indicated by the red line) were considered positive. (c) 
qRT-PCR analysis monitoring knockdown efficiencies, in mouse primary bone 
marrow cells, of a second set of mouse IMSG shRNAs unrelated to those used in 
(A) but the same as those used in (b) (n=3). Data are represented as mean ± SD. 
*P≤0.05, **P≤0.01.   
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Figure 2.5. Relative IC50IM of candidate IMSG KD K562 cells. The NS control 
used here is the same as that used in Figure 2.1 e, which was derived from the 
same experiment. Data are represented as mean ± SD (n=4).  
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Figure 2.7. IMSG knockdown increases RAF/MEK/ERK signaling through 
upregulation of PKCη , an activator of CRAF. (a) qRT-PCR analysis 
monitoring expression of different PKC isotypes in IMSG KD K562 cells. Each 
colored dot represents an individual IMSG KD K562 cell line. Error bars indicate 
median with interquartile range. The results were normalized to that obtained 
with the NS control shRNA, which was set to 1. The red lines indicate >2-fold 
change in gene expression relative to that obtained with the NS shRNA. (b) 
Relative IC50IM in K562 cells expressing empty vector and in two independently 
derived K562 clonal cell lines ectopically expressing PRKCH (n=4). Data are 
represented as mean ± SD. (c) qRT-PCR analysis monitoring expression of 
PRKCH in BCR-ABL wild-type IM-sensitive patient samples (n=11), and BCR-
ABL mutant (n=11) or BCR-ABL wild-type (n=11) IM-resistant CML patient 
samples. Error bars indicate median with interquartile range. (d) qRT-PCR 
analysis monitoring expression of three IMSGs in BCR-ABL mutant (n=11) or 
BCR-ABL wild-type (n=11) IM-resistant CML patient samples. For ELF5, BCR-
ABL mutant (n=9). Error bars indicate median with interquartile range. (e) 
Relative viability, as measured by trypan blue cell counting, of primary leukemic 
cells from BCR-ABL independent IM-resistant CML patient samples (n=5) 
expressing a NS or PRKCH shRNA and treated with DMSO or IM. The results 
were normalized to that obtained with DMSO-treated cells expressing a NS 
shRNA, which was set to 1. Data are represented as mean ± SEM. *P≤0.05, 
**P≤0.01.   (f) Immunoblot analysis monitoring RAF/MEK/ERK activity (as 
measured by p- and t-MEK and p- and t-ERK1/2) in PRKCH KD K562 cells (left) 
and in K562/PRKCH-1 cells in the absence or presence of IM (right). (g) 
Immunoblot analysis monitoring p- and t-ERK1/2 levels in K562/PRKCH-1 cells 
expressing an ARAF, BRAF or CRAF shRNA, treated with DMSO or IM for 1 h. 
(h) (Tsai et al.) Schematic of CRAF showing the kinase domain bearing a 
potential PKC phosphorylation site at S497/S499. (Bottom) In vitro 
phosphorylation assay. Wild-type (WT) or kinase-dead mutant (Mut; K384R) 
PKCη was used in an in vitro phosphorylation reaction containing either GST or a 
GST-CRAF(aa491-505) fusion-protein. The phosphorylated product was 
visualized by autoradiography. The Coomassie-stained gel shows the abundance 
of each protein. 
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Figure 2.12. Combined treatment with IM and a MEK inhibitor has beneficial 
effects. (a and b) Cell viability, as measured by MTT assay, of K562/PRKCH-1 
(a; n=4) or IMSG KD K562 cells (b; n=3 or 4) treated with 0.1 µM IM, 1.5 nM 
trametinib (TM) or a combination of the two drugs, as indicated. The results were 
normalized to that observed with DMSO, which was set to 1. Data are 
represented as mean ± SD. Asterisks indicate comparisons between the 
combined drug treatment and single drug treatments. Combined drug treatment 
was synergistic (S), additive (A) or antagonistic (G). (c) Colony formation assay 
monitoring survival of BCR-ABL+ mouse primary bone marrow cells ectopically 
expressing Prkch and treated with IM, TM or a combination, as described in (a) 
(n=3). Data are represented as mean ± SD. (d) Relative viability, as measured by 
trypan blue cell counting, of primary leukemic cells from BCR-ABL-independent 
IM-sensitive (n=3) or -resistant (n=6) CML patients treated with 5 µM IM, 5 µM 
TM or a combination. The results were normalized to those obtained by DMSO 
treatment of the same samples [IM-S or IM-R (IM-SR)], which was set to 1. Error 
bars indicate median with interquartile range. Matched samples from the same 
patient are indicated by dots of the same color. (e and f) White blood cell (WBC) 
count of leukemic mice derived by transplantation of BCR-ABL+ mouse primary 
bone marrow cells ectopically expressing Prkch (e) or knocked down for an 
IMSG (F), and treated at day 7 with either IM, TM or a combination of the two 
drugs as indicated (n=4 or 5 mice per group). Data are represented as mean ± 
SEM. The same NS control is used in the two graphs shown in (f), which were 
derived from a single experiment. (g and h) Kaplan-Meier survival curves of 
leukemic mice derived as described in (E and F). The indicated cohorts of mice 
(n=5 for Prkch overexpression and n=6 for IMSG knockdown) were treated with 
either vehicle, IM (100 mg/kg twice a day), TM (2 mg/kg once a day), or both IM 
and TM by oral gavage starting at day 7 (indicated by the arrow). The same NS 
control is used in the curves shown in (H), which were derived from a single 
experiment. *P≤0.05, **P≤0.01.   
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Figure 2.21. Synergistic induction of apoptosis in murine CML stem cells 
by IM and trametinib. (a) Apoptosis assay. CML mice (n=5) were orally gavaged 
with vehicle or IM. BCR-ABL+ bone marrow cells were stained with a 
Lin/Sca1/Kit antibody cocktail, then with Annexin V and 7-AAD followed by 
FACS. Data are represented as mean ± SEM. (b) FACS analysis showing 
representative Annexin V/7-AAD staining of murine CML stem cells expressing a 
NS shRNA or one of two unrelated Prkch shRNAs isolated from mice treated with 
vehicle or IM. These data provided the basis for the bar graph in (a). (c) 
Apoptosis assay. Mice were orally gavaged with vehicle (n=6), IM (n=6), TM 
(n=5) or both (n=5). BCR-ABL+ bone marrow cells were stained as described in 
(a). Data are represented as mean ± SEM. (d) FACS analysis showing 
representative Annexin V/7-AAD staining of murine CML stem cells isolated from 
mice treated with vehicle, IM, TM or a combination of IM and TM. These data 
provided the basis for the bar graph in (c). *P≤0.05, **P≤0.01.   
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Table 2.1. List of 11 IMSGs obtained from the genome-wide RNAi screen. All 
candidates were validated with a second, unrelated shRNA. Knockdown 
conferred IM resistance in BCR-ABL-transformed primary bone marrow cells and 
increased IC50IM greater than 5-fold in K562 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
              
            
             
 
 
Biological process Gene symbol Gene name 
Cell signaling CLEC5A C-type lectin domain family 5, member A 
STK11 Serine/threonine kinase 11 
WNT7B Wingless-type MMTV integration site family, 
member 7B 
DNA/RNA metabolism DNASE1L1 Deoxyribonuclease I-like 1 
EXOSC7 Exosome component 7 
RPP38 Ribonuclease P/MRP 38kDa subunit 
Protein metabolism BAP1 BRCA1 associated protein-1 (ubiquitin carboxy-
terminal hydrolase) 
Transcriptional regulation ELF5 E74-like factor 5 (ets domain transcription factor) 
Immunity CD22 CD22 molecule 
Unknown MEGF8 Multiple EGF-like-domains 8 
TMEM140 Transmembrane protein 140 
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Table 2.3. Relative expression of IMSGs in IM-resistant BCR-ABL-wt CML 
patient samples. Relative expression was calculated by determining the 
average expression of a given gene in all 11 mutant BCR-ABL patient samples, 
and dividing by the expression of the gene in the individual wild-type BCR-ABL 
sample. Thus, the value represents the fold down-regulation in wild-type BCR-
ABL samples.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
            
             
                 
            
      
 
Sample 
ID 
Relative expression  
BAP1 CD22 CLEC5A DNASE1L1 ELF5 EXOSC7 MEGF8 RPP38 STK11 TMEM140 WNT7B PRKCH 
WT-1 0.498 3.723 13.781 1.231 9.882 1.299 3.806 0.541 0.607 3.559 15.608 0.204 
WT-2 1.294 5.749 2.379 1.198 8.263 3.765 9.764 1.872 2.876 7.013 10.095 0.688 
WT-3 1.086 0.651 12.468 1.058 1.963 3.295 0.915 0.784 1.710 1.780 1 552 0.176 
WT-4 0.723 1.042 1.828 1.401 1.208 5.210 1.713 7.357 .0842 0.478 1.191 0.858 
WT-5 0.437 0.976 2.717 1.268 0.953 .0332 1.431 0.437 3.192 0.503 4.125 0.116 
WT-6 1.222 0.655 2.400 0.918 0.790 1.807 0.696 2.904 2.692 0.404 1 341 0.287 
WT-7 7.906 16.193 22 845 2.368 13.862 0.195 5.888 5.464 1.770 3.420 96.887 2.075 
WT-8 5.844 3.436 3.760 2.744 13.486 2.027 3.055 1.708 5.362 3.521 10.836 1.735 
WT-10 0.574 0.569 7.508 0.852 1.954 2.260 1.537 0.102 0.795 0.438 2 595 2.107 
WT-11 3.589 2.881 12.961 1.870 5.556 0.682 15.511 7.422 1.651 8.578 31.855 0.565 
WT-12 1.509 2.863 2.445 1.921 5.634 1.999 3.179 0.611 2.273 1.422 1 549 0.208 
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Table 2.4. List of clone IDs for shRNAs obtained from Open Biosystems 
/Thermo Scientific. 
 
             
 
Human Gene First shRNA Second shRNA 
ABCB6 TRCN0000060318  
ADARB2 TRCN0000051893  
AIFM3 TRCN0000064545   
AKR1C1 TRCN0000036544  
AKR1C3 TRCN0000026540  
ANO2 TRCN0000138764   
ARAF TRCN0000000571 TRCN0000000568 
ASAH3L TRCN0000050685   
BAP1 TRCN0000007373 TRCN0000007372 
BAZ2A TRCN0000015571  
BCAP29 TRCN0000060447 TRCN0000060444 
BMI1 TRCN0000020158   
BMP6 TRCN0000058615  
BRAF TRCN0000006291 TRCN0000006292 
C6orf224 TRCN0000140490   
CCL14 TRCN0000057850  
CD22 TRCN0000057623 TRCN0000057625 
CELA1 TRCN0000003679 TRCN0000003681 
CHRNA1 TRCN0000060992  
CLEC5A TRCN0000054035 TRCN0000054034 
CMYA5 TRCN0000129695  
CRAF TRCN0000001067 TRCN0000001068 
CUBN TRCN0000055649  
CYP46A1 TRCN0000063810   
DGKD TRCN0000000672  
DNASE1L1 TRCN0000049688 TRCN0000049690 
DPM1 TRCN0000036188 TRCN0000036186 
DUSP13 TRCN0000003064   
EBF1 TRCN0000013828 TRCN0000013830 
EFEMP2 TRCN0000053336  
EFNA3 TRCN0000058722  
EHD2 TRCN0000053473  
ELF5 TRCN0000013875 TRCN0000013877 
EXOSC7 TRCN0000051072 TRCN0000051070 
E2F4 TRCN0000013809 TRCN0000013810 
FAHD1 TRCN0000050068   
FAM92A1 TRCN0000136349  
GDAP1L1 TRCN0000136540  
GFRA2 TRCN0000060710   
GHRH TRCN0000083152  
GRK5 TRCN0000000842  
GTF3C4 TRCN0000013402   
IDH3A TRCN0000027270 TRCN0000027310 
IDS TRCN0000051546   
IFT140 TRCN0000147721   
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Table 2.4. List of clone IDs for shRNAs obtained from Open Biosystems 
/Thermo Scientific. (Continued) 
IL1A TRCN0000059211   
ITCH TRCN0000002087  
KCNC4 TRCN0000044942  
KCNH3 TRCN0000044593  
KIR2DL2 TRCN0000061458  
LEP TRCN0000058353  
LGALS9 TRCN0000057446  
LILRA3 TRCN0000056945 TRCN0000056946 
LMO7 TRCN0000006490  
LRAT TRCN0000035998  
MED8 TRCN0000052951  
MEGF8 TRCN0000055555 TRCN0000055554 
MEP1A TRCN0000050903  
MMP7 TRCN0000051847 TRCN0000051844 
MOV10 TRCN0000049978   
NCBP1 TRCN0000059506  
OBFC2A TRCN0000134695  
OR2D2 TRCN0000060969   
PAG1 TRCN0000123270  
POLR1C TRCN0000052904  
PRKCH TRCN0000006296 TRCN0000006295 
PRSS1 TRCN0000052119  
PSMD10 TRCN0000058074  
RASL10B TRCN0000047610  
RCVRN TRCN0000053264 TRCN0000053263 
RFK TRCN0000037600  
RIN2 TRCN0000062647   
RPP38 TRCN0000049875 TRCN0000049876 
RPS6KB1 TRCN0000003162  
SEC23IP TRCN0000064955   
SGK493 TRCN0000037531  
SH3TC1 TRCN0000062611  
SOX18 TRCN0000017449  
STK11 TRCN0000000408 TRCN0000000409 
STYXL1 TRCN0000003054 TRCN0000003052 
TCEAL1 TRCN0000013415 TRCN0000013413 
TM4SF18 TRCN0000122444  
TMEM140 TRCN0000138719 TRCN0000138320 
TRAF4 TRCN0000034239 TRCN0000034241 
TRIM24 TRCN0000021262  
UBAP2L TRCN0000007681 TRCN0000007679 
WDR45L TRCN0000148944  
WDR92 TRCN0000053730  
WNT7B TRCN0000061877 TRCN0000061875 
ZACN TRCN0000060205 TRCN0000060204 
ZFP82 TRCN0000016086  
ZHX1 TRCN0000020354  
ZKSCAN3 TRCN0000017750  
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Table 2.4 List of clone IDs for shRNAs obtained from Open Biosystems 
/Thermo Scientific. (Continued) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mouse Gene   
Bap1 TRCN0000030719 TRCN0000030721 
Bcap29 TRCN0000099810 TRCN0000099811 
Cd22 TRCN0000067945 TRCN0000067946 
Cela1 TRCN0000092406 TRCN0000092407 
Clec5a TRCN0000067713 TRCN0000067715 
Dnase1l1 TRCN0000108731 TRCN0000108730 
Dpm1 TRCN0000111999 TRCN0000111996 
Ebf1 TRCN0000086578 TRCN0000086580 
Elf5 TRCN0000081940 TRCN0000081938 
Exosc7 TRCN0000051070 TRCN0000051068 
E2f4 TRCN0000085633 TRCN0000085634 
Idh3a TRCN0000041785 TRCN0000041786 
Megf8 V3LMM_497156 V3LMM_457695 
Mmp7 TRCN0000031250 TRCN0000031251 
Prkch TRCN0000022812 TRCN0000022811 
Rcvrn TRCN0000053267 V3LMM_504872 
Rpp38 TRCN0000099598 TRCN0000099599 
Stk11 TRCN0000024146 TRCN0000024147 
Styxl1 TRCN0000071409 TRCN0000071412 
Tceal1 TRCN0000108607 TRCN0000108608 
Tmem140 TRCN0000177850 TRCN0000178239 
Traf4 TRCN0000067747 TRCN0000067743 
Ubap2l TRCN0000007677 TRCN0000007679 
Wnt7b TRCN0000071779 TRCN0000071780 
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Table 2.5. List of primer sequences used for quantitative real-time RT-PCR. 
 
 
         
 
 Forward primer sequence (5’ ! 3’) Forward primer sequence  (5’ ! 3’) 
Human Gene 
BAP1 ATCTGGGTCCTGTCATCAGC GCTGCCTTGGATTGGTCTG 
BCAP29 AACTAGTAGAAGACCAGGAG CGAAAGTCTCTCTGACTGC 
CD22 CACCTCAATGACAGTGGTCAG TGGATCGGATACCCATAGCAG 
CELA1 TCCAGCTCCTCCTACTGG CAGAATACTTGCCATTCACC 
CLEC5A AGGTGGCGTTGGATCAACAA TTAGGCCAATGGTCGCACAG 
DNASE1L1 CTGCACACCACTCCTAAGGC CAGGCGCTTTTTGGTCAGT 
DPM1 ATGGATGCTGATCTCTCACACC CCATTTCCTTTGTAGCGAGTTCC 
EBF1 CCTGGTGTTGTGGAAGTCACA GCTCAACGAACCCACCATC 
ELF5 GCTGATTCCAACTGCTTGAAAAC CAGTTTTCTTCAGGAGATAGAAGC 
EXOSC7 CCAAATGAAGGCTACTTGGAGT TAGAGGGTGTTAGCGATCTCG 
E2F4 ATCGGGCTAATCGAGAAAAAGTC TGCTGGTCTAGTTCTTGCTCC 
IDH3A AGCCGGTCACCCATCTATGAA TAGAGACACATGGTCGGACAT 
LILRA3 GCTCACTCAGCTCCAACC TCACCAGCCTTGGATTCG 
LYN TTCTGGTCTCCGAGTCACTCA GCCGTCCACTTAATAGGGAACT 
MEGF8 CGCCTGTCTTCGTCACGTC CTGCTGAAAGGTGAGCAAGT 
MMP7 GTGGAGTGCCAGATGTTGC ATCGATCCACTGAATATGCG 
PRKCH GTGACTTGATGTTCCACATTCAG ATTGTCCAGTTTCAGATCTCTATAG 
RCVRN CACGCCGGAAAAGCGAGC GGATCAGTCGCAGAATTTCC 
RPP38 GACTTTGTGGACGAAGTAAGAGC GCTTTCCAGAGGTTCAGTCTC 
STK11 CTGCAAGCAGCAGTGAGG AACCGGCAGGAAGACTGAG 
STYXL1 GACCCCAAGATTCAGAAGG TCCGGGGAATCTTCTATCC 
TCEAL1 TCGTTCTCGCCCGCAATTTAG GATAAGGACGGCTCCGTTTTG 
TMEM140 TCGGCTTCTATAACTTCTGCCT CTGTTGCACTGGGCTAGGAG 
TRAF4 TGCCTATCCGCTGCATCC TTCATGGGGCAGCGATTAGC 
UBAP2L ATAGCAGCGGCAATACGTGG GAAGACACATTAGAGGCAGTGAA 
WNT7B GAAGCAGGGCTACTACAACCA CGGCCTCATTGTTATGCAGGT 
ZACN GAGAGGGGAACAGCGAGAG CAGTCTCAGGCCAGCTTCTC 
Mouse Gene 
Bap1 TAGTCCTCCCAGCAAATGTAAG GTCTTCCTCCTCCTGCATAG 
Bcap29 TTCTGTCTGCCCTTTATTCCTCC TCTTACTTCTCTCACGGCATCT 
Cd22 AAGCTGGATGTCCATTATGCTC TCTGTAGGAGGTGACGTCTG 
Cela1 TCTGGATGCCAGGGTGATTC TATTCATCCAGGAAATGTAAGCAG 
Mclec5a GAAACTGGGATTTTCACCAAGG TCCTGAAGATACTTCAGTTTCTC 
Dnase1l1 TATGTGTATATCTACAGGTCTGAC ACCACACTTGGAAGAGTTTTGC 
Dpm1 GTAATTTTGATATTGTCTCTGGAAC CTTCTTTTCGGTATAATCTGAAGC 
Ebf1 CTCACCCTATGCCATTGTGC CGAAAGCACTCTTCTGTTTCAC 
Elf5 TGCCTTTGAGCATCAGACAG TACTGGTCGCAGCAGAATTG 
Exosc7 GTGATGACCTTGGCACAGAG CATTCCAGCAGCAGCACATC 
E2f4 ACATCTGAGATTGCAGTGAGTG TACTACTATCCAGCAGTGCAG 
Idh3a TGGGTGTCCAAGGTCTCTC CTCCCACTGAATAGGTGCTTTG 
Megf8 CTGCCAGTGTTCTAGGAAACTAC ATGTGAGTAACGGCCACTAGG 
Mmp7 TGAGGACGCAGGAGTGAAC CGTCCTTTGTAAGACTGAAGTC 
Prkch TCCGGCACGATGAAGTTCAAT TACGCTCACCGTCAGGTAGG 
Rcvrn ACGACGTAGACGGCAATGG CCGCTTTTCTGGGGTGTTTT 
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Table 2.5. List of primer sequences used for quantitative real-time RT-PCR. 
(Continued) 
 		
 
 
 
 
 
 
 
 
 
 
 
 
 		
Rpp38 CTTCTGCTCAGGGTTTTCAAG ATGTCTTCTCTCTCCAAGGTG 
Stk11 AGTATGACTGTAGTGCCCTAC CAGGACCTGTCCAGGCAC 
Styxl1 CTGCTTTTCTGCGAGCCAAC TGTCGTTTTGATCGGACATCC 
Tceal1 GTATCCGCCCTCAATTCATAG CTCCGTTTTGCCTTCCAATGC 
Tmem140 CAGCGTTGGTTTTTGTCTCCC GAGGAGAGCGTAGAACATCAG 
Traf4 CCCGGCTTCGACTACAAGTTC TCAGGGCATTTGAAGACTCCT 
Ubap2l TGCTACAACTTCAGGAAAAGCTC GTCTGGAGCATCTGTAAATCATC 
Wnt7b CCCGATGCCATCATTGTGATC GTAGGGAGTCGAGAGGCTG 
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CHAPTER III: SINGLE-CELL RNA-SEQ REVEALS A TARGETABLE 
IMATINIB-RESISTANCE PATHWAY IN LEUKEMIC STEM CELLS 
 
ABSTRACT 
Chronic myeloid leukemia (CML) is a hematopoietic malignancy that is 
predominantly caused by a chromosomal translocation that leads to expression 
of the oncogenic fusion protein BCR-ABL(Faderl et al., 1999). The first-line 
treatment for CML is the BCR-ABL inhibitor imatinib mesylate (IM). CML, like 
several other malignancies, is propagated by a small population of stem cells 
whose eradication is required to achieve long-term remission and cure(Dean et 
al., 2005; Graham et al., 2002). Unfortunately, CML stem cells (CMLSCs) do not 
depend on BCR-ABL activity for survival and are thus not eliminated by IM 
treatment(Corbin et al., 2011; Hamilton et al., 2012). Pro-survival genes that are 
preferentially expressed in CMLSCs compared to normal hematopoietic stem 
cells (HSCs) represent potential therapeutic targets for selectively eradicating 
CMLSCs. However, the discovery of such preferentially expressed genes has 
been hampered by the inability to completely separate CMLSCs from 
HSCs(Jiang et al., 2008), which display the same set of surface markers(Carter 
et al., 2010; Sloma et al., 2010). To overcome this challenge, and to minimize 
confounding effects of individual differences in gene expression profiles(Cheung 
et al., 2003), here we perform single-cell RNA-seq on CMLSCs and HSCs that 
were isolated from the same patient and distinguished based on the presence or 
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absence of BCR-ABL. Among genes preferentially expressed in CMLSCs is 
PIM2, which encodes a pro-survival serine-threonine kinase that phosphorylates 
and inhibits the pro-apoptotic protein BAD(Yan et al., 2003). We show that IM 
resistance of CMLSCs is due, at least in part, to maintenance of BAD 
phosphorylation by PIM2. Combined treatment with IM and a PIM2 inhibitor 
synergistically increases apoptosis of CMLSCs, suppresses colony formation, 
and significantly prolongs survival in a mouse CML model with a negligible effect 
on HSCs. Importantly, BCR-ABL independent IM-resistant CML cells are also 
sensitive to this combination therapy. Our results reveal a therapeutically 
targetable mechanism of IM resistance in CMLSCs and bulk CML cells. The 
experimental approach we describe can be generally applied to other 
malignancies that harbor oncogenic fusion proteins or other characteristic genetic 
markers. 
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RESULTS 
To distinguish CMLSCs and HSCs, which display the same set of surface 
markers (CD34+CD38-CD90+CD45RA-)(Carter et al., 2010; Sloma et al., 2010), 
we first captured ~600 CD34+CD38-CD90+CD45RA- cells (~200 from each of 
three CML patient samples) and then used single-cell nested PCR to detect the 
presence (CMLSCs) or absence (HSCs) of the BCR-ABL transcript (Figure 3.1 a 
and Figure 3.2). Once CMLSCs and HSCs had been identified, we then carried 
out single-cell RNA-seq on ~48 CMLSCs and ~48 HSCs from each patient.  
 
 Typically, we obtained ~2.5 million mapped reads (>70% average 
mapping efficiency) and detected ~5,000 genes (transcript per million [TPM]>1) 
per cell (Figure 3.1 b and Figure 3.3 a-c). To ensure quality of the analysis, we 
excluded those cells with low-sequencing depth (fewer than 0.5 million mapped 
reads) and low coverage (<2,000 genes). Comparison of our single-cell RNA-seq 
data to published RNA-seq results from HSCs(Woll et al., 2014) revealed that 
both CMLSCs and HSCs have an HSC-like signature (Figure 3.1 c). Notably, 
there were substantial differences in HSC and CMLSC gene expression patterns 
among the three CML patients (Figure 3.3 d), underscoring the contribution of 
individual variation. 
 
Previous single-cell RNA-seq studies have found that the average gene 
expression of as few as 30 single cells highly correlates with that of the 
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population control typically derived from >10,000 cells(Shalek et al., 2014). 
Because our analysis involved a pure population that consisted of a relatively 
small number of cells, we asked whether our small sample size was sufficient to 
mimic a larger population control. Consistent with the previous studies, we found 
that random sampling with increasing number of cells achieved a high correlation 
at ~30 cells (Figure 3.3 e), confirming the validity of using ~48 cells to represent 
each population group.  
 
 The correlation of overall gene expression among single cells from the 
same patient ranged from 0.27–0.61 with a median of 0.43, indicative of 
significant heterogeneity (Figure 3.1 d and Figure 3.3 f). Notably, the inter-patient 
correlation was significantly lower than the intra-patient correlation (Figure 3.1 d 
and Figure 3.3 f). Thus, there was greater heterogeneity between CML patients 
than between CMLSCs and HSCs of the same patient, which could also be 
visualized by multidimensional scaling (MDS) (Figure 3.1 e). The MDS analysis 
also revealed that the CMLSC and HSC populations could not be clearly 
distinguished from one another, indicating that BCR-ABL did not substantially 
affect global gene expression. 
 
 Despite the heterogeneity of the gene expression pattern, we were able to 
identify genes that were significantly more highly expressed in CMLSCs than in 
HSCs (Figure 3.4a, Figure 3.5a). About 50% of these differentially expressed 
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genes had modest total expression levels (10<TPM≤100) (Figure 3.4b and 
Figure 3.5b). Two cell surface markers, CD33 and CD47, were expressed at 
significantly higher levels in CMLSCs than in HSCs and could potentially be used 
to isolate CMLSCs (Figure 3.4c). Gene Set Enrichment Analysis (GSEA) 
revealed that compared to HSCs, CMLSCs preferentially expressed genes 
associated with active cell division (Figure 3.4d).  
 
 Systematic inter-patient comparison revealed that one of genes 
preferentially expressed in CMLSCs compared to HSCs was PIM2 (Figure 3.4c). 
Intra-patient comparison confirmed that PIM2 was more highly expressed in 
CMLSCs compared to HSCs in all three CML patients (Figure 3.4e). We also 
found that in mice, Pim2 was expressed at a significantly higher level in BCR-
ABL-positive CML Lin-Sca1+Kit+ (LSK) cells and long-term HSCs than in their 
normal BCR-ABL-negative counterparts (Figure 3.6).  
 
 PIM2 is a member of a family of serine/threonine protein kinase found to 
have oncogenic potential in several malignancies(Nawijn et al., 2011). PIM 
kinases promote cell survival by phosphorylating the pro-apoptotic BH3-only 
protein BAD at S112(Yan et al., 2003). Phosphorylation of BAD prevents it from 
interacting with and inhibiting anti-apoptotic BCL-2 family proteins, thereby 
promoting cell survival(Yang et al., 1995). The availability of small molecule PIM 
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inhibitors(Keeton et al., 2014) and the finding that Pim-/- mice are viable and 
fertile(Mikkers et al., 2004), makes PIM2 an attractive therapeutic target.  
 
 Previous studies have shown that IM treatment of IM-sensitive CML cells 
leads to reduced phosphorylation of BAD, which is responsible, at least in part, 
for cell death(Kuroda et al., 2006). The IM resistance of CMLSCs raised the 
question of whether BAD phosphorylation was maintained following IM treatment. 
To address this issue, we FACS sorted IM-resistant CMLSCs and, as a control, 
IM-sensitive CML progenitors from patient samples and performed intra-cellular 
staining for phosphorylated BAD (pBAD). As an additional control we also 
analyzed IM-sensitive human CML K562 cells(Andersson et al., 1979). 
Consistent with previous studies(Kuroda et al., 2006), we found that IM treatment 
of IM-sensitive CML progenitors and K562 cells resulted in a substantial 
decrease of pBAD levels (Figure 3.4f, left and middle panels). By contrast, IM 
treatment of CMLSCs did not significantly affect pBAD levels (Figure 3.4f, right 
panel and Figure 3.7). Notably, however, treatment with a small molecule PIM 
family inhibitor, AZD1208(Keeton et al., 2014), substantially reduced pBAD levels 
in CMLSCs, CML progenitors and K562 cells (Figure 3.4f and Figure 3.7).  
 
 IM is not a PIM2 inhibitor, raising the question of why PIM2 fails to 
maintain pBAD levels following IM treatment of IM-sensitive CML cells. Previous 
studies have shown that PIM2 expression is promoted by STAT5(Adam et al., 
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2015). Because the JAK/STAT pathway is downstream of and stimulated by 
BCR-ABL(Sillaber et al., 2000), we hypothesized that BCR-ABL upregulates 
PIM2, and thus IM treatment would result in reduced PIM2 levels. Consistent with 
this hypothesis, PIM2 levels were much higher in BCR-ABL-transformed mouse 
Ba/F3 (Ba/F3-BCR-ABL) cells than in parental Ba/F3 cells (Figure 3.8 a). 
Moreover, treatment of Ba/F3-BCR-ABL cells with IM led to a large reduction in 
PIM2 levels (Figure 3.8 a). Likewise, IM treatment of K562 cells and CML 
progenitors significantly reduced PIM2 mRNA (Figure 3.4g) and PIM2 protein 
levels (Figure 3.8 b). Finally, inhibition of the JAK/STAT pathway by the small 
molecule inhibitor pimozide(Nelson et al., 2011) also resulted in decreased PIM2 
levels in Ba/F3-BCR-ABL (Figure 3.8 c) and K562 cells (Figure 3.8 d). 
 
 By contrast to the results in IM-sensitive CML cells, IM treatment of IM-
resistant human CMLSCs and mouse CML LSK cells did not significantly reduce 
PIM2 levels (Figure 3.4 g and Figure 3.8 e, f). Intracellular staining of 
phosphorylated CRKL, a cellular marker of BCR-ABL activity(ten Hoeve et al., 
1994), confirmed complete inhibition of BCR-ABL activity by IM in CMLSCs 
(Figure 3.8 g). Consistent with our results, mining of two published expression 
profiling studies(Zhang et al., 2013; Zhang et al., 2010) revealed that IM 
treatment did not affect PIM2 levels in human CMLSCs (Figure 3.8 h, i). 
However, RNA interference-mediated knockdown of BCR-ABL with a short 
hairpin RNA (shRNA) resulted in reduced PIM2 levels (Figure 3.8 j, k). Thus in 
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CMLSCs PIM2 expression and its regulation of the BAD/BCL-2 pathway is 
dependent upon BCR-ABL but independent of BCR-ABL kinase activity. 
 
 The results described above suggested that PIM2 could be a therapeutic 
target for elimination of CMLSCs and we performed a series of experiments to 
test this idea. We found that RNA interference-mediated knockdown of PIM2 with 
a short hairpin RNA (shRNA) sensitized CMLSCs to IM treatment (Figure 3.9 a), 
which was due, at least in part, to increased apoptosis (Figure 3.9 b and Figure 
3.10 a). Similar results were obtained when PIM2 was inhibited with AZD1208 
(Figure 3.9 c, d and Figure 3.10 b). Notably, combined treatment with IM and 
AZD1208 had synergistic effects on cell viability and apoptosis (Figure 3.9 c, d). 
In addition, combined treatment with IM and AZD1208 synergistically suppressed 
colony formation of human primary CML CD34+ cells (Figure 3.9 e and Figure 
3.10 c), and long-term culture initiation cells (Figure 3.9 f). Notably, however, the 
combined drug treatment had negligible effect on viability of HSCs (Figure 3.9 g). 
 
A recent study demonstrated selected elimination of CML stem cells with 
dual targeting of p53 and c-Myc signaling(Abraham et al., 2016). However, this 
strategy is not evaluated in most primitive CD34+CD38-CD90+ CMLSCs(Zhang 
et al., 2016). We therefore performed a side-by-side comparison using the 
combination of PIM2 inhibitor and IM versus the combination of p53 activator 
(RITA) and c-Myc inhibitor (CPI-203). Our combination proved to be equally 
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effective in killing CD34+ CML cells and CD34+CD38- CMLSCs while 
demonstrating significantly higher efficacy in killing most primitive CD34+CD38-
CD90+ CMLSCs (Figure 3.11).  We also think our strategy could be superior in 
treating those CML patients harboring p53 mutation, for whom the combination of 
p53 activator and c-Myc inhibitor may not work. 
 
 We next asked whether combined IM and AZD1208 treatment could 
eradicate CMLSCs in an established mouse model of CML (Figure 3.12 a). We 
found that two weeks of combined treatment with IM and AZD1208 significantly 
delayed the relapse of CML disease compared to either drug along or vehicle-
treated mice (Figure 3.13   a). FACS analysis demonstrated that combined drug 
treatment synergistically increased apoptosis in the CML LSK population (Figure 
3.13   b and Figure 3.12 b), and significantly reduced the total number of CML 
LSK cells (Figure 3.13   c), short-term HSCs and long-term HSCs (Figure 3.13   
d), but spared normal LSK cells (Figure 3.13   e). 
 
 To confirm the effect of combined IM and AZD1208 treatment on 
CMLSCs, we harvested bone marrow from CML mice treated with vehicle, one 
drug, or both drugs, and transplanted an equal number of total CML cells into 
secondary recipients (see Figure 3.12 a). We found that expansion of CML cells 
in the peripheral blood was significantly slower in mice treated with both drugs 
(Figure 3.12 c). Most importantly, mice receiving bone marrow from donors 
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treated with IM and AZD1208 survived significantly longer (Figure 3.13   f), 
indicative of a reduced number of transplantable CMLSCs. 
 
From both literature and previous work of our group (Hurtz et al., 2011; 
Jiang et al., 2007; Ma et al., 2014), we realized that bulk CML cells with BCR-
ABL independent IM resistance and CMLSCs could share the same IM 
resistance mechanisms. We sought to understand if targeting PIM2 could 
sensitize BCR-ABL independent IM resistant CML cells as well. Knocking down 
PIM2 or pharmacologically inhibiting PIM2 function significantly increased IM 
induced apoptosis in and reduced cell viability of an in vitro established BCR-ABL 
independent/ mutation-free IM resistant cell line, K562R cells (Figure 3.14 a-c). 
We further demonstrated that combined treatment with IM and AZD1208 
markedly kills primary cells from BCR-ABL independent IM resistant CML 
patients (Figure 3.14 d). Overall, these evidences emphasized that PIM2 is 
required for maintenance of BCR-ABL independent IM resistance.  
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CONCLUSIONS	
Our major conclusions are summarized in the model of Figure 3.13   g and 
discussed below. In IM-sensitive CML cells, BCR-ABL promotes PIM2 
expression, and inhibition of BCR-ABL by IM results in reduced levels of PIM2, 
decreased pBAD, and cell death. In IM-resistant CMLSCs, IM treatment does not 
lead to a reduction in PIM2 levels or loss of pBAD, and survival is maintained by 
anti-apoptotic BCL-2 family members. Our model is consistent with previous 
studies showing that a pan-BCL-2 inhibitor can sensitize CMLSCs to IM, 
demonstrating a role for the BCL-2 pro-survival pathway in IM resistance(Airiau 
et al., 2012; Goff et al., 2013). Most importantly, we have shown that IM 
resistance of CMLSCs and bulk CML cells can be overcome by combining IM 
with a PIM2 inhibitor to inactivate BCL2-mediated pro-survival. Our results reveal 
a therapeutically targetable mechanism of IM resistance in CMLSCs and bulk 
CML cells. Interestingly, a recent study reported that the pan-PIM inhibitor SGI-
1776 enhances the ability of IM to induce apoptosis in IM-sensitive CML 
cells(Curi et al., 2015). Notably, however, this study did not investigate the 
effects of SGI-1776 on IM-resistant CMLSCs. 
 
Although PIM2 expression is increased in CMLSCs compared to HSCs, 
suggesting upregulation by BCR-ABL, paradoxically IM treatment does not 
reduce PIM2 expression. Consistent with our results, previous studies have 
identified several genes that are up- or down-regulated in BCR-ABL-positive cells 
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but whose expression is not normalized by IM treatment(Chen et al., 2009; Chen 
et al., 2014; Zhang et al., 2012). One possibility is that these genes are up- or 
down-regulated by BCR-ABL, but their expression is maintained through a 
mechanism that is independent of BCR-ABL kinase activity and thus is not 
affected by IM. Consistent with this possibility, we find that PIM2 expression is 
decreased when BCR-ABL protein levels are reduced, either through shRNA-
mediated knockdown of BCR-ABL in CMLSCs (Figure 3.8 k), or through 
tetracycline-induced loss of BCR-ABL in mouse LSK cells (Figure 3.6 c). Further 
elucidation of such BCR-ABL kinase-independent mechanisms may provide 
insight into the basis of IM-resistance in CMLSCs. 
 
 Pro-survival genes that are preferentially expressed in cancer cells are 
potential therapeutic targets. In principle, such genes can be identified by 
comparing gene expression profiles of normal and cancer cells. However, this 
strategy is often impeded by the inability to completely separate normal and 
cancer cells and the confounding effect of individual variation in gene expression 
profiles. Here, using CML as a model system, we describe a novel strategy by 
which HSCs and CMLSCs can be distinguished based on the presence or 
absence of a characteristic genetic marker, BCR-ABL. Moreover, by comparing 
single-cell RNA-seq results of HSCs and CMLCs isolated from the same patient 
we eliminate the potential masking effect of often substantial differences in gene 
expression among individuals(Cheung et al., 2003). The experimental approach 
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we have described can be generally applied to other malignancies that harbor 
oncogenic fusion proteins or other characteristic genetic markers. 
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MATERIALS AND METHODS 
CML patient samples 
Frozen samples isolated from patients with chronic phase CML (Table 3.1) were 
obtained from the UMass Cancer Center Tissue Bank, Department of Pathology, 
or the Druker Lab at Oregon Health and Science University Knight Cancer 
Institute, which procured samples with approval from the Institutional Review 
Board (Gazin et al., 4422). Human CML samples were selected on the basis of 
sample availability and a requirement to achieve statistical significance. Samples 
were thawed at 37°C. To avoid clumping during centrifugation, cells were 
immediately transferred to 20 ml IMDM medium (STEMCELL Technologies) 
containing 20% fetal bovine serum (Atlanta Biologicals) and 0.1 mg ml-1 DNaseI 
(Sigma) and incubated in a 37°C water bath for 15-20 min. Cells were then 
pelleted at 300g for 10 min, and either stained for HSC isolation or subjected to 
cell culture (see below).  
 
Single-cell RNA-seq 
Samples were enriched for CD34+ cells using magnetic beads (Miltenyi Biotech). 
CD34+ cells were then stained with Pacific Blue-conjugated CD34 (cat. no. 48-
0349), APC-conjugated CD38 (cat. no. 17-0389), PE-conjugated CD90 (cat. no. 
12-0909), and FITC-conjugated CD45RA (cat. no. 11-0458) antibodies, and 7-
AAD (all from eBioscience). The HSC population (CD34+CD38-CD90+CD45RA-) 
was then sorted at single-cell mode into 96-well plates containing lysis buffer (4 
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µl of 0.2% TritonX-100, 2 U µl-1 RNase in nuclease-free water). Plates were 
immediately spun at 800 g for 1 min and put on dry ice. Single HSC lysates were 
processed immediately for cDNA synthesis according to a revised Smart-seq2 
protocol(Picelli et al., 2014; Trombetta et al., 2014). Samples were processed 
immediately after collection or within two weeks to avoid severe degradation.  
 
 To identify wells that had successfully captured single cells, cDNAs were 
analyzed for expression of two housekeeping genes, B2M and GAPDH, by qPCR 
(see Table 3.2 for primer sequences). The quality of cDNA was also evaluated 
using an Agilent 2100 Bioanalyzer. Only cDNAs showing expression of 
housekeeping genes and the expected fragment distribution (peaking at ~2 kb, 
with minimal noisy peaks below 500 bp; see Figure 3.2) were used for 
subsequent experiments. The typical concentration of cDNA obtained ranged 
from 0.1–11 ng µl-1 in a volume of 20 µl.  
 
   For library construction, cDNAs were diluted to 0.1–0.3 ng µl-1 and 
barcoded following the Smart-seq2 protocol using a Nextera XT Index Kit 
(Illumina). A multiplexed library was generated using a Nextera XT DNA Library 
Prep Kit (Illumina). The fragment distribution of a typical library is shown in Figure 
3.2. Before deep sequencing, the amplifiable fraction of the library was quantified 
using a KAPA Library Quantification Lit (Kapa Biosystems) according to the 
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manufacturer’s instructions. Finally, 2x75 bp paired-end deep-sequencing was 
performed using an Illumina NextSeq 500 instrument. 
 
Single-cell RNA-seq data analysis 
Raw reads from the RNA-seq experiment were first assessed for their quality 
using fastqc (version 0.10.1) 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc), followed by 
alignment to the reference human genome (hg19) using tophat (version 
2.0.14)(Kim et al., 2013), with default settings except the parameter read-
mismatches was set to 2. HTseq-count (version 0.6.1p1)(Anders et al., 2015) 
was used to quantify gene expression. Cells with <500,000 aligned reads or 
<2000 expressed genes (at least 1 count per million [CPM]) were excluded from 
subsequent analysis. The remaining 283 cells were used for identifying 
differentially expressed genes between BCR-ABL- and BCR-ABL+ cells using the 
Voom method of Bioconductor package limma (version 3.26.5)(Law et al., 2014) 
after TMM (trimmed mean of M-values) normalization(Robinson and Oshlack, 
2010). Genes with a Benjamini-Hochberg (BH)(Benjamini and Hochberg, 1995) 
adjusted P-value < 0.01 and fold change > 1.5 were considered as significantly 
(both statistically and biologically) differentially expressed genes. In addition, 
differential gene expression analysis for individual patients (Figure 3.4 e) was 
conducted with the Tuxedo suite(Trapnell et al., 2012), i.e., Cufflinks (version 
2.2.1)(Trapnell et al., 2010) for assembling transcript and quantifying gene 
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expression as FPKM (Fragments Per Kilobase of transcript per Million mapped 
reads), and Cuffdiff2 for differential expression analysis and P-value 
determination. RSEM (version RSEM/1.2.11)(Hentschel et al., 2011; Li and 
Dewey, 2011) was used to calculate TPMs (Transcripts Per Million).  
 
 The HSC signature was defined as a set of genes differentially expressed 
in HSCs (Lin-CD34+CD38-CD90+CD45RA-) compared to non-stem cells, i.e. 
MEP and GMP (fold change > 2, P < 0.001) in the dataset GSE55689(Woll et al., 
2014) using limma package(Law et al., 2014). The MDS plot of Figure 3.1 e was 
generated using limma package(Law et al., 2014). Heatmap and Venn diagrams 
were drawn with pheatmap and Vennerable packages, respectively. For the pie 
chart of Figure 3.4, the number of genes in each category was first calculated in 
each individual cell (see Figure 3.3 b), and then all the cells were combined to 
obtain the average distribution. 
 
Nested PCR to identify BCR-ABL transcripts in single cells 
Two-step nested PCR was performed as follows using primers listed in Table 
3.2. The first round of PCR (10 µl total volume, 1 µl of undiluted single-cell cDNA 
as template) consisted of 1 cycle of 95°C for 3 min; 25 cycles of 95°C for 30 sec, 
58°C for 30 sec, and 68°C for 30 sec; extension at 68°C for 5 min; and 4°C hold. 
The second round of qPCR (10 µl total volume, 1 µl of 10x diluted first-round 
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PCR product as template) consisted of 1 cycle of 95°C for 3 min; 40 cycles of 
95°C for 3 sec and 60°C for 30 sec.  
 
Gene Set Enrichment Analysis (GSEA) 
GSEA was performed using GSEAPreranked module from GSEA v2.2.2 
package(Mootha et al., 2003; Subramanian et al., 2005) with all genes pre-
ordered based on log2 fold change. GSEA analysis was performed using the 
gene set: EGUCHI_CELL_CYCLE_RB1_TARGETS (systematic name: M4455). 
 
Ultra-low cell number qRT-PCR 
Due to the scarcity of the CMLSC population, it is usually difficult to collect 
enough cells from a frozen CML patient sample for qRT-PCR. To generate cDNA 
from ~200 cells, we employed a modified single-cell Smart-seq2 protocol. First, 
to accommodate the volume of sorted cells (<0.6 µl), the lysis buffer volume was 
increased from 4 µl to 8 µl, and the reaction volume was doubled in all 
subsequent steps. Second, rather than using 20 rounds post-amplification cycles 
for single-cell cDNA synthesis, only 15 rounds were used for 200 cells. To ensure 
all qRT-PCR experiments were carried out under the same conditions, the 
method was not only used for analysis of PIM2 expression in CMLSCs 
(CD34+CD38-CD90+ [Figure 3.4 g] and CD34+CD38- [Figure 3.8 e)] cells), but 
also in CML progenitor (CD34+CD38+) cells (Figure 3.4 g), and mouse CML LSK 
cells (Figure 3.6 c and 3.8 f) and LT-HSCs (Figure 3.6 d).  
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CML patient sample culturing 
Cell pellets were re-suspended in binding buffer (1x PBS with 0.2% BSA and 2 
mM EDTA) to enrich for bulk live cells or CD34+ cells alone. Cells were then 
cultured in IMDM medium plus 20% BSA, insulin and transferrin (Ma et al.) 
(STEMCELL Technologies) and the following cytokines: 100 ng ml-1 SCF, 100 ng 
ml-1 G-CSF, 20 ng ml-1 FLT3L, 20 ng ml-1 IL-3, and 20 ng ml-1 IL-6 (all from 
Prospec). For imatinib-induced apoptosis and cell viability experiments, cells 
were cultured in the presence of cytokines for 24 h, then cells were switched to 
IMDM plus 20% BIT with less than 10% of cytokines for the rest of culturing. 
From our FACS analysis (see Figure 3.2), we found that the HSC population 
(CD34+CD38-CD90+CD45RA-) was almost exclusively CD34+CD38-CD90+, 
which has also been used previously to define HSCs(Zhang et al., 2016). We therefore 
used CD34+CD38-CD90+ cells as an alternative for CMLSCs in the functional 
experiments for convenient FACS analysis. 
 
Phospho-flow analysis 
Human primary CD34+ cells were cultured for 2 days to expand the population, 
and then IM-sensitive CML progenitor cells (CD34+CD38+) and IM-resistant 
CMLSCs (CD34+CD38- and CD34+CD38-CD90+) were FACS sorted and further 
cultured for ~16 h in the presence of DMSO, IM (ChemieTek; 5 µM), or AZD1208 
(Active Biochem; 5 µM). K562 cells (ATCC) were cultured for ~16 h in the 
presence of DMSO, IM (5 µM), or AZD1208 (5 µM). Cells were then collected, 
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fixed, and processed as previously described(Ma et al., 2014) for staining of PE-
conjugated phospho-BAD (S112) (cat. no. 11865) and PE-conjugated rabbit IgG 
(cat. no. 5742) (both from Cell Signaling Technology). To assess efficient 
inhibition of BCR-ABL activity by IM, K562 or FACS sorted CMLSCs, were 
treated for 4 h with DMSO or IM, and then processed as above and stained with 
Alexa Fluor 488 conjugated pCRKL antibody (cat. no. 560789, BD Biosciences) 
and Alexa Fluor 488 conjugated IgG (cat. no. 557703, BD Biosciences). Fixed 
cells were used either immediately, or stored at 4°C for two weeks. 
 
Immunoblot analysis 
Ba/F3-BCR-ABL cells were generated by transducing Ba/F3 (originally 
purchased from ATCC) cells with a lentiviral vector expressing doxycycline-
inducible BCR-ABL (constructed by replacing the shRNA cassette and TurboRFP 
reporter in pTRIPZ [GE Dharmacon] with BCR-ABL[p210]). Cells were 
maintained in RPMI plus 10% fetal bovine serum in the presence of 1 µg/ml 
doxycycline (Sigma). To assay PIM2 expression upon BCR-ABL or JAK/STAT 
inhibition, Ba/F3-BCR-ABL cells were subjected to doxycycline withdrawal, or 
treatment with 5 µM IM or 0, 5 or 10 µM pimozide (Calbiochem). K562 cells were 
treated with 10 µM IM or 0, 2, 5 or 10 µM pimozide. After ~16 h of treatment, 
protein extracts were prepared and analyzed by immunoblotting for PIM2 (human 
PIM2: Cell Signaling Technology, cat. no. 4730; mouse PIM2: Santa Cruz, sc-
13514) and ACTB (Sigma, cat. no. A2228).  
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shRNA-mediated knockdown in primary CML samples and K562R cells 
Bulk live patient cells were enriched using a Dead Cell Removal Kit (Miltenyi 
Biotec) and cultured overnight at 37°C. For PIM2 knockdown, cells were 
transduced with a pLKO-GFP lentivirus (constructed by excising the puromycin-
resistance gene from pLKO.1 [Addgene plasmid #10878] and replacing it with 
PCR-amplified GFP) carrying either a control non-silencing shRNA or human 
PIM2 shRNA (TRCN0000001629 and TRCN0000001630) using two rounds of 
spin infection, with ~12-16 h in between. Cells were further cultured for 24 h to 
allow for expression of the shRNA. Cells were treated with IM (5 µM) for an 
additional 24 h for apoptosis analysis or 48 h for cell viability determination. For 
BCR-ABL knockdown, cells were transduced with pLKO-GFP carrying a non-
silencing or BCR-ABL shRNA (TRCN0000000790). Following two rounds of spin 
infection, cells were further cultured for 48 h and then FACS sorted to isolate 
CD34+CD38- cells. Conventional qRT-PCR was performed to analyze 
expression of BCR-ABL and PIM2. For K562R cells, one round of viral 
transduction is enough to achieve >90% infection rate. Cells were cultured in 
RPMI1640 + 10% FBS, and drug treatment started at day 4.  
 
Relative cell viability and apoptosis assays 
Bulk primary human cells were stained with PE-cy7-conjugated CD34 (cat. no. 
25-0349), APC-conjugated CD38, and PE-conjugated CD90 antibodies, Pacific 
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Blue-conjugated Annexin V, and 7-AAD, and immediately analyzed by FACS. For 
relative cell viability, the percentage of the HSC fraction was determined by 
FACS analysis, and the total cell number was determined by trypan blue cell 
counting. The number of viable cells was determined as [Total viable cell 
number] x [percentage of CMLSCs]. For mouse CML LSK cells, apoptosis and 
viability were determined as previously described(Ma et al., 2014). For analysis 
of mouse ST-HSCs and LT-HSCs, total mouse bone marrow cells were stained 
with a cocktail of primary antibodies [APC-conjugated Sca-1 (cat. no. 17-5981), 
PE-conjugated c-Kit (cat. no. 12-1171), Pacific blue-conjugated CD48 (cat. no. 
48-0481), PE-cy7-conjugated CD150 (cat. no. 25-1502) antibodies (all from 
eBioscience), and Biotin-conjugated Lineage antibody cocktail (Miltenyi Biotec)], 
followed by staining with APC-eFluor780-conjugated streptavidin secondary 
antibody (eBioscience; cat. no. 47-4317) as previously described(Ma et al., 
2014). Representative staining is shown in Figure 3.6 a. After initially culturing for 
24 h, cells were treated with DMSO, IM (5 µM), AZD1208 (5 µM) or a 
combination of IM and AZD1208 for an additional 24 h for apoptosis analysis or 
48 h for cell viability determination. 
 
To perform side-by-side comparison of combination therapies, we used a fixed 
concentration of IM (5uM) and AZD1208(5uM), and the combination of p53 
activator (RITA, ) and c-Myc inhibitor (CPI-203) at three highest concentrations 
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as listed in Abraham SA et al, Nature, 2016.  FACS analysis was done and cell 
viability was determined at either 48 hour or 72 hour treatment. 
Colony formation and LTC-IC assays 
For colony formation assays, ~500 CD34+ cells or bulk cells with equivalent 
number of CD34+ cells were plated on 35 mm dishes in MethoCult H4435 
Enriched medium supplemented with recombinant human cytokines (STEMCELL 
Technologies). Total colonies were counted at day 14.  
 
 For LTC-IC assays, M2-10B4 mouse fibroblast cells (ATCC) were 
irradiated with ~8,000 cGy, and then plated on collagen-coated 35 mm dishes 
and incubated overnight. ~3,000 CD34+ cells or bulk cells containing equivalent 
number of CD34+ cells were plated in MyeloCult H5100 medium (STEMCELL 
Technologies) with hydrocordisone (STEMCELL Technologies) with weekly half 
medium change for 6 weeks according to the manufacturer’s protocol. Cells were 
collected and plated in MethoCult H4535 medium (STEMCELL Technologies) 
containing DMSO, IM (5 µM), AZD1208 (5 µM) or a combination of IM and 
AZD1208, and assayed for colony formation as described above.  
 
CML mice 
All animal protocols were approved by the Institution Animal Care and Use 
Committee at UMMS (A-2300). Animal sample sizes were selected based on 
precedent established from previous publications and an understanding that at 
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least n=5 is generally required to achieve statistical significance. Mice were 
randomly allocated to each group for drug treatment after bone marrow 
transplantation, and were subsequently analyzed in a non-blinded fashion. 
Animals were excluded from the study based on pre-established criteria (death 
within 10 days with no evidence of enlarged spleen, indicative of bone marrow 
engraftment failure); based on these criteria, one mouse in the IM+AZD1208-
treated group was excluded (Figure 3.13 c-e).  
 
 CML was induced in male 6-8 week old C57BL/6 mice (The Jackson 
Laboratory) using retrovirus transduction as previously described(Ma et al., 2014; 
Zhang et al., 2016). At day 7 of bone marrow transplantation, mice were 
randomly grouped (n=5 per group) and treated with vehicle (0.5% 
hydroxypropylmethycellulose and 0.2% Tween-80 in filtered ddH2O), IM (100 mg 
kg-1), AZD1208 (30 mg kg-1, resuspended in H2O and sonicated to disrupt 
clumps, then resuspended in 0.5% hydroxypropylmethycellulose and 0.2% 
Tween-80 in filtered ddH2O) or a combination of IM and AZD1208 for about 2 
weeks until the first vehicle-treated mouse died. Mice were monitored for 
survival. 
 
 For apoptosis and stem cell viability analysis, CML mice (n=6 per group) 
were treated for 2 weeks, and sacrificed to harvest bone marrow cells for 
analysis as described previously(Ma et al., 2014). BCR-ABL+ (GFP+) and BCR-
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ABL- (GFP-) mouse stem cells (Lin-Sca1+Kit+) were isolated from the mice by 
FACS as described previously(Ma et al., 2014). For secondary transplantation, 
all the bone marrow cells from the same group of mice were combined, and the 
percentage of GFP-positive cells was determined by FACS. An equal number of 
total bone marrow cells were transplanted into lethally irradiated secondary 
recipients. Mice were monitored for accumulation of CML cells (GFP+ cells) in 
peripheral blood and survival.  
 
 To analyze Pim2 expression in CML LSK cells and LT-HSCs (Figure 3.6 c 
and 3.8 f), Tet-off SCL-tTA/BCR-ABL transgenic mice were used, which were 
bred as previously described(Koschmieder et al., 2005). To induce CML, BCR-
ABL transgenic mice were subjected to tetracycline-water withdrawal starting at 8 
weeks old, and CML development was monitored by FACS analysis of peripheral 
Gr1+/Mac1+ cells, which typically reached 20-30% after 2 weeks of induction. 
Mice were treated with vehicle or imatinib (100 mg kg-1) for 2 more weeks and 
then sacrificed, and bone marrow was collected for FACS sorting of LSK cells 
and LT-HSCs. To revert the CML phenotype, CML mice were re-administered 
with tetracycline water (0.5g L-1) for 4 weeks to suppress BCR-ABL expression, 
CML reversion was monitored by FACS analysis of peripheral Gr1+/Mac1+ cells. 
As a normal control, mice of the same age but maintained with tetracycline-water 
since birth were used. Ultra-low cell number qRT-PCR was used to determine 
Pim2 expression. 
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Statistical Analysis 
To achieve statistical significance, all qRT-PCR data were collected from 
experiments performed in technical triplicate; each experiment was repeated at 
least twice and statistically significant results were obtained in independent 
biological replicates. Differences between groups were assayed using a two-
tailed student t-test using GraphPad Prism. In cases where the assumption of the 
t-test was not valid a non-parametric statistical method was used (e.g., Mann-
Whitney test). Significant differences were considered when P<0.05. Data are 
presented as mean ± SD or SEM, as indicated in the legend.  
 
 Statistical analysis for drug synergy was performed using R, a system for 
statistical computation and graphics(Ihaka and Gentleman, 1996), to assess 
whether the combined effects from IM and AZD1208 were synergistic (greater 
than the sum of the single-drug effects) or non-synergistic. The number of 
surviving cells were log transformed before performing two-way analysis of 
variance (ANOVA) to test the main effect and the interaction of the two drugs 
with Randomized Complete Block Design or Completely Randomized Design. 
The percentage of viable cells was transformed using logit function followed by 
two-way analysis of variance (ANOVA) with the Randomized Complete Block 
Design or Completely Randomized Design, and the BH-adjusted P-value was 
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calculated to counteract the problem of multiple comparisons(Benjamini and 
Hochberg, 1995). 
 To determine whether or not IM and AZD1208 exerted synergistic impacts 
on decreasing cell survival, we compared the difference between observed 
effects with the expected additive effects for the mouse/patient samples exposed 
to both drugs(Slinker, 1998). The difference was estimated as the interaction 
coefficient in the ANOVA. If there was a significant negative difference (i.e., 
interaction coefficient < 0 and BH adjusted P-value < 0.05), then the impact from 
the combined drugs was classified as synergistic; otherwise, the impact from the 
combined drugs was classified as non-synergistic. For apoptosis, if there was a 
significant positive difference, then the impact from the combined drugs was 
classified as synergistic; otherwise, the impact from the combined drugs was 
classified as non-synergistic. When there was no statistically significant 
synergistic effect, combined drug treatments were compared with imatinib 
treatment alone using a pre-determined contrast under the framework of ANOVA. 
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Figure 3.1. Single-cell RNA-seq analysis of CMLSCs and HSCs. a, Schematic 
of the single-cell RNA-seq analysis. b, Number of genes expressed at a low 
(1<TPM≤10), modest (10<TPM≤100), or high (100<TPM) level in single CMLSCs 
and HSCs isolated from three CML patients. Error bars indicate SD; n=~96 
biological replicates. c, Gene expression signature in single HSCs and CMLSCs. 
A published RNA-seq dataset from HSCs, granulocyte-macrophage progenitors 
(GMPs), and megakaryocyte-erythrocyte progenitors (MEPs) was used to define 
an HSC-specific gene signature, and all 283 single-cell RNA-seq data were 
mapped to this signature. d, Box plot showing the distribution of the Spearman 
correlation coefficient of the global transcription profile of every pair of single cells 
within the same patient (intra-patient correlation) and between any pair of cells 
from different patients (inter-patient correlation). HSCs and CMLSCs were 
analyzed separately and then combined. Boxed areas span the first to the third 
quartile, and whiskers represent maximum or minimum observations within 1.5 
inter-quartile range (IQR). P < 0.001. e, Multidimensional scaling plot showing the 
inter-relationship of gene expression profiles of 283 single HSCs and CMLSCs 
from three CML patients. The distance between any two cells reflects the 
similarity of their expression profiles.  
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Figure 3.2. Single-cell RNA-seq workflow. Primary CML patient samples were 
enriched for CD34+ cells using magnetic beads. Enriched CD34+ cells were 
stained with CD34, CD38, CD90, and CD45RA cell surface markers, and single 
HSCs (CD34+CD38-CD90+CD45RA-) were collected and converted into cDNA 
using a revised Smart-seq2 protocol. cDNA quality was checked on a 
Bioanalyzer; a representative single HSC cDNA size distribution is shown in the 
inset on the top right. qPCR was performed to detect the expression of 
housekeeping genes B2M and GAPDH. Because the expression level of BCR-
ABL is typically low in primary CML cells, particularly in the stem cell population 
from chronic phase CML patients, nested PCR was performed to enhance 
specificity and sensitivity for detection of BCR-ABL. Nested qPCR for BCR-ABL 
was first optimized in human CML K562 cells. Briefly, cDNAs were prepared from 
16 single K562 cells and, following confirmation of expression of housekeeping 
genes, two-step nested PCR was carried out to detect BCR-ABL. The inset on 
the bottom left shows that all 16 single K562 cells showed positive amplification 
(>1,000-fold over background) with no detectable signal in the water (H2O) 
control, confirming the validity of this approach. Nested qPCR was then 
performed for single HSCs from CML patients. For every plate of single cells 
(~96 cells), 16 water control samples were also included; if any of the water 
controls was positive, the nested PCR was discarded and repeated. Typically, 
70~80% of single HSCs showed a positive BCR-ABL signal, which had a ~1,000-
fold reduced intensity compared to control K562 cells; a typical amplification from 
a plate of single HSCs is shown (inset, middle right). For each sample, we 
analyzed ~200 single cells and could obtain 40~60 HSCs that were negative for 
BCR-ABL. We combined ~96 BCR-ABL+ and BCR-ABL- cells to generate a 
cDNA library for deep-sequencing; a representative 96 index cDNA library size 
distribution is shown in the inset on the bottom right. 
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Figure 3.3. Quality controls for single-cell RNA-seq data. a,b, Box plots 
showing the number of total mapped reads (a) or the percentage of mappable 
reads (b) in all single HSCs and CMLSCs from each CML sample. Boxed areas 
span the first to the third quartile, and whiskers represent maximum or minimum 
observations within 1.5 inter-quartile range (IQR). c, Number of genes expressed 
at a low (1<TPM≤10), modest (10<TPM≤100), or high (100<TPM) level across all 
single cells in each patient. The results from BCR-ABL+ and BCR-ABL- cells are 
presented separately. Error bars indicate s.d.; n=~48 biological replicates. d, 
Venn diagrams showing the number of common detectable genes in HSCs and 
CMLSCs from three CML patients. A detectable gene is defined as one with 
TPM>1 in more than 50% of single cells. e, Box plot showing the distribution of 
the Spearman correlation coefficient of the global transcription profile of an 
increasing number of randomly sampled HSCs from the CML1 patient sample. 
The results show that the correlation reaches above 0.9 at ~30 cells. Boxed 
areas span the first to the third quartile, and whiskers represent maximum or 
minimum observations within 1.5 IQR. f, Box plot showing the distribution of the 
Spearman correlation coefficient of the global transcription profile of every pair of 
single cells within the same patient (intra-patient correlation) and between any 
pair of cells from different patients (inter-patient correlation). The results from 
BCR-ABL+ and BCR-ABL- cells were analyzed separately. Boxed areas span the 
first to the third quartile, and whiskers represent maximum or minimum 
observations within 1.5 IQR. ***P<0.001. 
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Figure 3.4. IM resistance in CMLSCs is due to PIM2-mediated maintenance 
of BAD phosphorylation. a, Heatmap showing the population average of 
differentially expressed genes between all single HSCs and CMLSCs in three 
CML patients. Only those differentially expressed genes with adjusted P<0.01 
and fold change ≥2 are shown. b, Pie chart showing the average distribution of 
differentially expressed genes at low (1<TPM≤10), modest (10<TPM≤100), and 
high (100<TPM) levels in all single cells. c, Volcano plot showing the significance 
(y-axis) and differential expression (x-axis) for all genes identified by the RNA-
seq analysis. Genes with P<0.01, fold change>1.5 and average (CPM)>1 are 
highlighted in yellow, genes with 0.01≤P<0.05, fold change>1.5 and average 
(CPM)>1 are in dark grey, and genes that are not significantly changed are 
indicated by light grey. d, GSEA showing CMLSCs are significantly enriched for 
genes involved in cell cycle progression. The heatmap shows individual gene 
expression from both CMLSCs and HSCs from three CML patients. ES, 
enrichment score, FDR, false discovery rate. e, FPKM value of PIM2 from intra-
patient comparison in three CML samples. Error bars indicate SEM; n=~48 
biological replicates. f, Phospho-flow analysis showing intra-cellular staining of 
pBAD (S112) levels in DMSO, IM, or AZD1208 treated K562 cells, CML 
progenitor cells (CD34+CD38+), and CMLSCs (CD34+CD38-CD90+). IgG was 
used for control staining. The upper panel shows a representative staining 
histogram for each population and the mean value of the population. The lower 
panel shows the quantification of n=3 biological replicates. Error bars indicate 
SEM. g, qRT-PCR monitoring PIM2 expression following IM treatment in K562 
cells, CML progenitors, and CMLSCs (CD34+CD38-CD90+). Error bars indicate 
SD; n=3 technical replicates of a representative experiment (out of two 
independent experiments). S denotes the combined drug treatment was 
synergistic. *P ≤ 0.05, **P ≤ 0.01. 
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Figure 3.5. Gene expression patterns and statistics in single cells. a, 
Heatmap showing the differentially expressed genes of 283 individual single 
HSCs (BCR-ABL-) and CMLSCs (BCR-ABL+) in three CML patients. Only those 
differentially expressed genes with adjusted P < 0.01 and fold-change ≥2 are 
shown. b, Box plot showing the distribution of the number of differentially 
expressed genes (P <0.01 and logFC≥1) at a low (1<TPM≤10), modest 
(10<TPM≤100), or high (100<TPM) level in all single cells. Boxed areas span the 
first to the third quartile, and whiskers represent maximum or minimum 
observations within 1.5 IQR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

	 152	
Figure 3.6. Pim2 expression is elevated in mouse CMLSCs. a, FACS plot 
showing the gating of murine Lin-Sca1+Kit+ (LSK) cells, multi-potent progenitor 
(MPP, LSKCD48+CD150-) cells, short-term HSCs (ST-HSC, LSKCD48-CD150-), 
and long-term HSCs (LT-HSC, LSKCD48-CD150+). b, qRT-PCR analysis 
showing relative Pim2 mRNA levels in murine LSK cells expressing vector or 
BCR-ABL; the data were mined from a published expression profiling study 
(GSE10912(Chen et al., 2009)). Error bars indicate SD; n=2 biological replicates. c, 
qRT-PCR analysis showing relative Pim2 mRNA levels in murine LSK cells from 
normal mice (Tet-off SCL-tTA/BCR-ABL transgenic mice given tetracycline-water 
since birth), CML mice (Tet-off SCL-tTA/BCR-ABL transgenic mice subjected to 
tetracycline-water withdrawal at 8 weeks of age), or reverted normal mice (Tet-off 
SCL-tTA/BCR-ABL transgenic mice subjected to tetracycline-water withdrawal 
from 8-12 weeks of age, then given tetracycline-water for 4 weeks to revert CML 
phenotype). Error bars indicate SEM; n=4 mice per group. d, qRT-PCR analysis 
showing the relative Pim2 mRNA level in LT-HSCs from control (normal) and 
BCR-ABL transgenic mice. Error bars indicate SEM; n=3 mice per group. 
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Figure 3.8. Pim2 expression is regulated by BCR-ABL and the JAK/STAT5 
pathway, and is not affected by IM treatment in CMLSCs. a, Immunoblot 
showing PIM2 levels in Ba/F3 cells expressing a doxycycline inducible BCR-ABL 
fusion protein. Cells were maintained in doxycycline (Dox) and subjected to Dox 
withdrawal or treatment with IM. β-actin (ACTB) was monitored as a loading 
control. b, Immunoblot showing PIM2 levels in K562 cells in the absence or 
presence of IM. The results of (a) and (b) show that PIM2 expression depends on 
BCR-ABL kinase activity. c,d, Immunoblots showing PIM2 levels in Ba/F3-BCR-
ABL cells (c) or K562 cells (d) treated with the STAT5 inhibitor, pimozide. The 
results of (c) and (d) show that PIM2 expression is regulated by the JAK/STAT5 
pathway. e, qRT-PCR analysis showing relative PIM2 mRNA levels in DMSO 
and imatinib-treated primary CML CD34+CD38- cells. Error bars indicate SD; 
n=3 technical replicates of a representative experiment (out of two experiments). 
f, qRT-PCR analysis showing relative Pim2 mRNA levels upon IM treatment in 
LSK cells from CML mice. CML mice were treated with vehicle or IM for two 
weeks, bone marrow was harvested, and LSK cells were sorted by FACS. Error 
bars indicate SEM; n=3 mice per group. g, Phospho-flow analysis showing intra-
cellular staining of phosphorylated CRKL (pCRKL) (Y207) levels in CMLSCs 
(CD34+CD38-, CD34+CD38-CD90+), or as a control K562 cells, treated with 
DMSO or IM (5 µM). IgG was used for control staining. The upper panel shows a 
representative staining histogram for each population and the mean value of the 
population. The lower panel shows the quantification of n=3 biological replicates. 
Error bars indicate SEM. The results show that IM treatment completely 
abolishes BCR-ABL activity. h,i, Relative PIM2 mRNA levels in CD34+CD38- 
CMLSCs treated in the presence or absence of IM. The data were mined from 
published expression profiling studies GSE43225(Zhang et al., 2013) (h) and 
GSE20876(Zhang et al., 2010) (i). Matched samples from the same patient are 
indicated by dots of the same color. Error bars indicate s.d.; n=3 biological 
replicates. The results shown that PIM2 expression is not affected by IM 
treatment in CD34+CD38- CMLSCs. j,k, qRT-PCR analysis in CD34+CD38- 
CMLSCs monitoring expression of BCR-ABL (j) or PIM2 (k) following knockdown 
of BCR-ABL. Error bars indicate SD; n=3 technical replicates. **P ≤ 0.01, *P ≤ 
0.05. 
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Figure 3.9. Impairment of PIM2 function by shRNA or small molecule 
inhibitor sensitizes CMLSCs to IM treatment. 
 
 
 
 
 
 
 
 
NS
PI
M2
-1
PI
M2
-2
0
10
20
30
40
P
er
ce
nt
ag
e 
of
 A
nn
ex
in
 V
+ 
C
M
LS
C
s
DMSO
IM
*
shRNA
CMLSCs
DM
SO IM
AZ
D1
20
8
IM
 + 
AZ
D1
20
8
0.0
0.2
0.4
0.6
0.8
1.0
1.2
R
el
at
iv
e 
ce
ll 
vi
ab
ilit
y
CMLSCs
DM
SO IM
AZ
D1
20
8
IM
 + 
AZ
D1
20
8
0
10
20
30
40
50
P
er
ce
nt
ag
e 
of
 A
nn
ex
in
 V
+ 
C
M
LS
C
s
CMLSCs
DM
SO IM
AZ
D1
20
8
IM
+A
ZD
12
08
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
R
el
at
iv
e 
ce
ll 
vi
ab
ili
ty
HSCs
CM
L1
CM
L2
CM
L3
CM
L4
0
20
40
60
80
100
120
140
160
N
um
be
r o
f c
ol
on
ie
s
DMSO
IM
AZD1208
IM + AZD1208
DM
SO IM
AZ
D1
20
8
IM
+A
ZD
12
08
0.0
0.2
0.4
0.6
0.8
1.0
1.2
R
el
at
iv
e 
co
lo
ny
 fo
rm
at
io
n
a b
c d e
f g
NS
PI
M2
-1
PI
M2
-2
0.0
0.2
0.4
0.6
0.8
1.0
1.2
R
el
at
iv
e 
ce
ll 
vi
ab
ilit
y DMSO
IM
*
shRNA
CMLSCs
 
Primary CML CD34+ cells
LTC-ICs
**
**
** ** **
**
**
S
S
S
**
	 157	
Figure 3.9. Impairment of PIM2 function by shRNA or small molecule 
inhibitor sensitizes CMLSCs to IM treatment. a,b, Relative cell viability (a) or 
apoptosis (b) of CMLSCs from CML patient samples expressing an NS or PIM2 
shRNA and treated with DMSO or IM. In (a), the results were normalized to that 
obtained in DMSO-treated cells, which was set to 1. Error bars indicate SEM; 
n=4 biological replicates. c,d, Relative cell viability (c) and apoptosis (d) of 
CMLSCs from CML patient samples treated with DMSO, IM, AZD1208 or a 
combination of both drugs. Error bars indicate SEM; n=4 biological replicates. e, 
Colony formation assay of human primary CML cells treated with DMSO, IM, 
AZD1208 or a combination of IM and AZD1208. Error bars indicate SD; n=3 
technical replicates. f, Colony formation and LTC-IC assay of post-culture 
primary CML cells treated with IM, AZD1208 or a combination of both drugs. 
Error bars indicate SEM; n=3 biological replicates. g, Relative cell viability of 
normal HSCs from healthy donors treated with DMSO, IM, AZD1208 or both 
drugs. Error bars indicate SEM; n=3 biological replicates. S denotes the 
combined drug treatment was synergistic. *P ≤ 0.05, **P ≤ 0.01. 
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Figure 3.10. FACS analyses for Figure 3.9 b and d, and synergy analysis for 
Figure 3.9 e. a, FACS analysis showing representative Annexin V/7-AAD 
staining of DMSO- or IM-treated human CML stem cells expressing a NS shRNA 
or one of two unrelated PIM2 shRNAs. These data provided the basis for the bar 
graph in Figure 3.9 b. b, FACS analysis showing representative Annexin V/7-
AAD staining of human CMLSCs treated with DMSO, IM, AZD1208 or a 
combination of IM and AZD1208. These data provided the basis for the bar graph 
in Figure 3.9 d. c, Colony formation assay of human primary CML cells treated 
with DMSO, IM, AZD1208 or a combination of IM and AZD1208. To perform 
synergy analysis, the data from 4 individual CML patients (shown in Figure 3.9 e) 
were combined and normalized by setting DMSO treatment to 1. Error bars 
indicate SEM; n=4 biological replicates. S denotes the combined drug treatment 
was synergistic. **P ≤ 0.01. 
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Figure 3.11. Side by side comparison of combination therapy using IM and 
PIM2 inhibitor versus p53 activator and c-Myc inhibitor in primary CML 
cells. Relative cell viability of total CD34+ CML cells, CD34+CD38- CMLSCs, 
and CD34+CD38-CD90+ CMLSCs was determined after either 48 hours (a) or 
72 hours (b) treatment with  either a combination of RITA (p53 activator) and 
CPI-203 (c-Myc inhibitor) at various concentrations or a combination of AZD 
1208 and IM.  The results were normalized to that obtained in DMSO-treated 
cells, which was set to 1. Error bars indicate SEM; n=4 biological replicates. **P ≤ 
0.01, *P ≤ 0.05, n.s means not significant.  
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Figure 3.13. Combined treatment with IM and the PIM2 inhibitor AZD1208 
significantly prolongs survival in a mouse CML model. 
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Figure 3.13. Combined treatment with IM and the PIM2 inhibitor AZD1208 
significantly prolongs survival in a mouse CML model. a, Kaplan-Meier 
survival curve of CML mice (n=5 per group) treated for two weeks (days 7-21) 
with vehicle, IM, AZD1208 or a combination of both drugs. b, Annexin-V staining 
monitoring apoptosis of CML LSK cells from CML mice treated with vehicle 
(n=10), IM (n=9), AZD1208 (n=10) or a combination of IM and AZD1208 (n=9). c-
e FACS determination of the number of CML (GFP+) LSK cells (c), CML (GFP+) 
short-term HSCs (ST-HSCs) and long-term HSCs (LT-HSCs) (d), or normal 
(GFP-) LSK cells (e) after treatment of mice with vehicle (n=6), IM (n=6), 
AZD1208 (n=6), or both IM and AZD1208 (n=5). f, Kaplan-Meier survival curve 
showing CML engraftment and progression in secondary transplant mice (n=5) 
with bone marrow cells from each group of primary transplant CML mice shown 
in (a). Error bars indicate SEM. *P ≤ 0.05, **P ≤ 0.01. 
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Figure 3.14. Combined therapy with IM and AZD1208 kills BCR-ABL 
independent IM-resistant CML cells. Apoptosis(a) or cell viability(b) of K562R 
cells expressing an NS or PIM2 shRNA and treated with DMSO or IM. Statistical 
analysis was performed between each PIM2 shRNA and NS shRNA expressing 
cells in either DMSO or IM treated condition. In (b), the results were normalized 
to that obtained in DMSO-treated NS shRNA expressing cells, which was set to 
1. Error bars indicate SD; n=4 technical replicates. c, Cell viability of K562R cells 
treated with DMSO, IM (1uM), AZD1208 (1uM) or a combination of both drugs. 
Error bars indicate SD; n=4 technical replicates. d, Cell viability of primary CML 
cells with BCR-ABL independent IM resistance upon treatment with DMSO, IM 
(5uM), AZD1208 (5uM) or a combination of both drugs. Error bars indicate SEM; 
n=3 biological replicates. In (c) and (d), statistical analysis was performed 
between IM treated group and combination treated group. **P ≤ 0.01, *P ≤ 0.05. 
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1 UMass, UMass Cancer Center Tissue Bank; OHSU, Druker Lab, OHSU Knight 
Cancer Institute. 
 
 
Table 3.1 List of human CML patient samples used in this study.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  
  		
               
 
Sample 
ID 
Source1 CML phase BCR-ABL 
mutation 
status 
Origin Application 
Single-cell 
RNA seq 
Functional 
assay 
CML1 UMass  Newly-diagnosed 
chronic phase 
Wild-type Bone marrow   
CML2 OHSU Newly-diagnosed 
chronic phase 
Wild-type Bone marrow   
CML3 UMass Newly-diagnosed 
chronic phase 
Wild-type Bone marrow   
CML4 UMass Newly-diagnosed 
chronic phase 
Wild-type Bone marrow   
CML5 UMass Newly-diagnosed 
chronic phase 
Wild-type Bone marrow   
CML6 UMass  Newly-diagnosed 
chronic phase 
Wild-type Bone marrow   
CML7 UMass Newly-diagnosed 
chronic phase 
Wild-type Bone marrow   
CML8 UMass Resistant to IM 
(Gleevec) 
Wild-type Bone marrow   
CML9 UMass Resistant to IM 
(Gleevec) 
Wild-type Bone marrow   
CML10 UMass Resistant to IM 
(Gleevec) 
Wild-type Peripheral 
Blood 
  
1 UMass, Mass C ncer en r issu  Ban ; OHSU, ruke  L  OHSU Knig t Canc r 
s i ut . 
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* Published in ref. (Chu et al., 2005) 
 
 
Table 3.2 List of primers used for qPCR and nested PCR analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  
  		
               
 
 
 
    
 
 
  
 
  
 
 
    
  
     
   
  
   
 
 
   
  
   
  
   
  
    
 
   
  
    
 
    
  
     
   
  
    
 
     
 
    
 
     
 
    
 
     
 
  
 
 
 
             
 
 
 
              
 
Gene Forward primer (5’à  3’) Reverse primer (5’à3’) 
BCR-ABL (1st round) GCAGCAGAAGAAGTGTTTCAG CCGGAGCTTTTCACCTTTAG 
BCR-ABL (2nd round)* CATTCCGCTGACCATCAATAA AACGAGCGGCTTCACTCAGA 
B2M GTATGCCTGCCGTGTGAAC AAAGCAAGCAAGCAGAATTTGG 
GAPDH TGCACCACCAACTGCTTAGC GGCATGGACTGTGGTCATGAG 
PIM2 (human) CTGACTTTGATGGGACAAGG GAATCTCCTGGTCCCTCTC 
Pim2 (mouse) ATCTCGCGACACCAGTACCAT GATTAGGGCACAGCAATCTGG 
* ub shed n r  49 	
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CHAPTER IV: CRISPR-CAS9 MEDIATED SATURATED MUTAGENESIS 
SCREEN IN BCR-ABL PREDICTS CLINICAL TKI RESISTANT MUTATIONS 
 
ABSTRACT 
Understanding the mechanism of drug resistant mutations should improve the 
ability to generate therapeutics with reduced susceptibility to resistance. In vitro 
analyses of mutations provide a promising approach, but previous analyses of 
BCR-ABL mutations inserted at stochastic locations in the genome identified 
many mutations that increased tolerance to drug but that were rarely observed in 
patients. We developed a high-throughput CRISPR-Cas9 mediated approach to 
analyze the effects of systematic libraries of BCR-ABL point mutations at a 
consistent genomic location. Using bulk competitions with a deep-sequencing 
readout, we analyzed the effects of hundreds of mutations in parallel under 
multiple drug conditions. The effects of mutations on growth with and without 
inhibitor were critical for predicting clinical resistant mutations, many of which 
were cancer adaptive in the absence of drug pressure. The strategy we have 
developed can be applied to many different oncogenes and should be more 
useful than previous approaches for interpreting patient mutations and for 
evaluating resistance susceptibility in the development of new therapeutics. 
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INTRODUCTION	
Drug resistance limits the effectiveness of many therapeutic strategies with a 
tremendous impact on patients that develop resistance (Gottesman, 2002; 
Holohan et al., 2013). Drug resistance has been challenging to address in part 
because it is difficult to predict the mutations that will contribute to patient health. 
In vitro screens of drug resistant mutations in many target proteins, including 
BCR-ABL, often identify many more resistant mutations than are observed in 
patients (Azam et al., 2003). One potential reason for the discrepancy between in 
vitro identified BCR-ABL resistant mutations and those observed in patients is 
that most previous in vitro analyses introduced mutations using viral transduction, 
which integrates mutations stochastically. The genomic location of a gene can 
have a large effect on its expression level that can in turn have a large effect on 
phenotype (Day et al., 2000). In our own previous analyses of mutations in 
oncogenic BRAF using transduction (Wagenaar et al., 2014), we observed that 
multiple independent measurements (>4) were required to confidently distinguish 
mutations that consistently caused resistance from those that exhibited 
resistance in occasional replicates.  These observations motivated us to develop 
strategies that would provide higher confidence in understanding drug resistant 
mutations, and would be improved for predicting the impacts of mutations on 
drug resistance in patients. 
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We chose to focus on BCR-ABL because inhibitors to this oncogene are effective 
at curing many patients, and where resistance has been observed it is frequently 
associated with direct mutations in BCR-ABL itself (Gorre et al., 2001; Soverini et 
al., 2011). Thus, the prediction of the impact of BCR-ABL mutations on patients 
most likely has a high potential to provide information to guide the development 
of new therapeutics. 
 
To improve the consistency and efficiency of in vitro screens, we developed an 
approach that we refer to as BIG (Barcoded Introns in the Genome) EMPIRIC 
(Exceedingly Meticulous and Parallel Investigation of Randomized Individual 
Codons). We previously developed EMPIRIC to analyze hundreds to thousands 
of mutations encoded on plasmids in yeast (Hietpas et al., 2011; Mishra et al., 
2016), as well as in reverse engineered viruses (Jiang et al., 2016), and 
randomly integrated oncogenes in mammalian cells in culture (Wagenaar et al., 
2014). EMPIRIC experiments are a type of mutational scanning approach 
(Fowler and Fields, 2014) that focuses on individual amino acid changes, which 
are often the most relevant to mammalian genetic disorders including cancer. 
 
In our previous EMPIRIC studies in yeast and reverse engineered viruses, we 
observed strong reproducibility between independent measurements of the 
impact of amino acid changes. We observed far greater variation between 
independent measurements in the analyses of randomly integrated variants of 
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BRAF in mammalian cells, and multiple independent measurements were 
necessary to distinguish signal from noise. BIG EMPIRIC was designed to 
provide both reduced variation through the targeting of mutations to a consistent 
genomic location using CRISPR-Cas9 (Cong et al., 2013; Horvath and 
Barrangou, 2010), and multiple independent measurements for each amino acid 
change by utilizing a barcoding strategy (Figure 4.1). Of note, the use of multiple 
barcodes for each amino acid variant provides internal independent 
measurements within each experimental replicate.  
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RESULTS	
Towards the goal of sampling hundreds of Bcr-Abl mutations in the same 
experiment, we extensively optimized a CRISPR-Cas9 integration strategy 
(Figure 4.1, Figure 4.2, Figure 4.3 & Methods). We utilized Ba/F3 cells because 
of their conditional dependence on Bcr-Abl function in the absence of 
exogenously supplied IL-3 (Daley and Baltimore, 1988). We transduced a non-
functional Bcr-AblΔKD (lacking the kinase domain) and utilized CRISPR-Cas9 to 
site specifically introduce the AblKD to generate full-length Bcr-Abl and induce 
expression of a GFP marker (Figure 4.1 b). We used a donor template with 
DsRed to optimize homology-directed repair (HDR) efficiency (Figure 4.1 c, 
Figure 4.3 and Methods) and were able to achieve 8% HDR efficiency, which 
represented successful genetic modification of 105 cells. For 10-fold 
representation of mutant libraries, we estimate that this would be sufficient to 
screen up to 10,000 mutations in a single reaction. As part of the HDR 
optimization process, we tested dozens of clonal cell lines to identify a clone (C7) 
that when rescued with the wildtype AblKD produced a response to TKI 
treatment that resembled the response of CML cells (Figure 4.4). In this cell line 
that we refer to as Ba/F3-BcrAblΔKD, we observed that Bcr-AblΔKD was 
integrated at a single genomic location within transcriptionally active chromatin 
(see Methods, Figure 4.5). To facilitate multiple independent measurements for 
each amino acid change in AblKD mutant libraries, we introduced a short intron 
containing a barcode (Figure 4.1). We designed the barcode sequence to avoid 
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sequences that would disturb intron splicing (see Methods, Figure 4.6). The 
frequency of mutations that we observed integrated into the genome closely 
matched the frequency in the donor library (Figure 4.1 d and Figure 4.7), 
indicating that integration was not strongly biased by the mutations.  
 
We initially investigated the experimental fitness effects of mutants at the 
gatekeeper position (Figure 4.8 a). Cells with the T315X library were grown 
without IL-3 for three days, then split and grown for a further three days with and 
without Bcr-Abl inhibitors. Based on next-generation sequencing of barcodes we 
determined the frequency of each amino acid at position 315 at the time of IL-3 
withdrawal and at the end of the experiment. The effects of mutations on growth 
without IL-3 provide a readout of Bcr-Abl function without inhibitors. Most amino 
acid changes at position 315 caused a functional defect (Figure 4.8 b). Five 
mutations increased Bcr-Abl function, including the T315I mutation that is known 
to cause resistance (Gorre et al., 2001). Supporting these observations, 
mutations corresponding to T315I and T315M have been reported to increased 
kinase function in c-Abl and/or c-Src (Azam et al., 2008).  
 
In replicate growth competitions, strong correlation (R2=0.93) was observed 
between estimates of Bcr-Abl function (Figure 4.7 b). We estimated the effects of 
mutations on drug binding by comparing relative growth of mutants in the 
presence and absence of imatinib, similar to what is done in traditional IC-50 
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measurements. All mutations at position 315 compromised drug binding based 
on this analysis (Figure 4.8 b). The observation that few gatekeeper mutations 
have been observed in patients (Zabriskie et al., 2014) indicates that alterations 
in drug binding without consideration of function may be misleading with regard 
to clinical relevance. In principle, the combined effects of mutations on Bcr-Abl 
function and drug binding will be under selection in patients. In our experiments, 
these combined effects provide the strongest advantage (Figure 4.8 b) for four 
different amino acid changes (L,M,I,E). Among these mutations, only T315I is 
accessible by a single nucleotide change, which is the most common form of 
mutation in cancer (Vogelstein et al., 2013). The T315I mutation was the most 
frequently observed mutation in imatinib resistant patients (Shah and Sawyers, 
2003), suggesting that consideration of mutational accessibility and combined 
effects on function and drug binding can provide clinically relevant predictions. 
 
The combined effects of mutations on function and drug binding were further 
investigated with additional inhibitors at varying concentrations (Figure 4.8 c). Six 
amino acid changes at position 315 (L,M,I,V,Q,E) demonstrated greater 
combined effects than the parental Bcr-Abl. Five of these (L,M,I,Q,E) exhibited 
increasingly adaptive responses with elevated imatinib concentration (Figure 4.8 
c), indicating our measurements are capturing relevant aspects of drug selection. 
We also examined selection in the presence of dasatinib (Figure 4.9) and 
ponatinib (Figure 4.8 c), which was designed to counteract the T315I mutation 
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(O'Hare et al., 2009). Consistent with its design, we observed that T315I could be 
inhibited by ponatinib. However, four mutations(L,M,Q,E) at position 315 were 
increasingly adaptive with higher ponatinib concentrations. 
 
Next, a panel of individual mutations were analyzed in isolation (Figure 4.10) to 
further probe the relationships between our bulk analyses and traditional IC-50 
measurements. We chose mutations at position 315 that exhibited strong growth 
effects and strong combined effects (L,M,I,E), as well as the T315C mutation that 
exhibited a slight growth defect and a mild combined benefit. Of note, all of these 
mutations exhibited strong imatinib benefits in our bulk competitions (Figure 
4.10b, upper panel). Consistent with our bulk observations, all five mutants had 
IC-50’s to imatinib that were shifted by similar amounts relative to parental Bcr-
Abl. The IC-50 results alone indicate that the T315C mutation would be a viable 
resistant mutation. However, our bulk competitions indicate that T315C causes a 
negative growth effect in the absence of drug pressure (Figure 4.8 b). These 
observations highlight the potential utility of observing growth effects in 
understanding the evolution of drug resistance in cancer. 
 
To explore how these amino acid changes might evolve, we examined the 
number of nucleotide substitutions and the potential single step pathways (Figure 
4.8 d). Of the six amino acid changes at position 315 that appear adaptive to 
imatinib (L,M,I,V,Q,E), only T315I is accessible by a single base substitution, the 
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most accessible type of mutation (Vogelstein et al., 2013). In principle, the 
prevalence of T315I in patient isolates (Jones et al., 2009) could be due to 
mutational accessibility and/or adaptive potential. Our data indicate similar 
adaptive potential with imatinib for L,M, I, and E at position 315, with L, M, and E 
having slightly greater adaptive potential than I at high imatinib concentrations 
(Figure 4.8 c). These observations suggest that mutational probabilities have a 
strong influence on the evolution of drug resistance in Bcr-Abl. In high 
concentrations of both imatinib and ponatinib, T315M and T315E were the most 
adaptive (Figure 4.8 c). T315M is accessible by a fitness increase path, while 
T315E cannot be accessed by single nucleotide substitutions without going 
through a maladaptive intermediate (Figure 4.8 d). The observed advantage of M 
relative to I at position 315 is greater under ponatinib treatment compared to 
imatinib, indicating that a mutational pathway from T to I to M may be likely in 
patients transitioned from imatinib to ponatinib therapy. Consistent with this 
hypothesis, T315M has recently been reported to evolve from T315I during 
ponatinib treatment of a patient that had previously failed imatinib therapy 
(Zabriskie et al., 2014).  
 
Our findings above highlight the potential of our approach to identify clinically 
relevant resistant mutational pathways. We then examined a larger region 
encompassing positions 311-319 of Bcr-Abl that flank the gatekeeper residue 
(Figure 4.11). To assess the reliability of this higher throughput experiment, we 
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compared results for position 315 with our single position experiment. We 
observed a strong correlation between these experiments (R2=0.95, Figure 4. 7 
c) indicating that both experiments provide accurate measurements of selection 
pressures acting on these mutations. 
  
To investigate structure-function relationships in Bcr-Abl in the absence of 
inhibitors, we examined how the growth effects of mutations map to protein 
structure. Different positions exhibited strikingly distinct patterns of functional 
sensitivity to mutation. At position 316 every amino acid substitution caused a 
strong defect, while at position 319 all amino acid changes exhibited small 
impacts on function (Figure 4.11 a). These sensitivities were generally consistent 
with inferences from structure. For example, the glutamate at position 316, which 
is sensitive to amino acid changes, makes multiple hydrogen bonds (Figure 4.12) 
that cannot be recovered by any other side chain. In contrast, the side chain of 
position 319 is oriented towards solvent such that amino acid changes can be 
tolerated without directly disrupting structure (Figure 4.12). 
 
The conformational dynamics of Bcr-Abl are known to play an integral role in 
activation and inhibitor binding (Agafonov et al., 2014; Aleksandrov and 
Simonson, 2010). Additionally, mutation of the gatekeeper residue is thought to 
activate tyrosine kinases by stabilizing the hydrophobic spine, characteristic of 
the active protein conformation (Azam et al., 2008). Using molecular dynamics 
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simulations (10 ns), we tested the stability of the inactive and active kinase states 
for seven mutations identified in our screens. Five of the mutations (F311L, 
T315I, T315E, T315M, & F317L) provided a positive growth effect (Figure 4.8 b 
and Figure 4.11 a), while the other mutations (T315K & T315A) had varying 
negative growth effects (Figure 4.8 b). The simulations reveal that neither state is 
substantially perturbed by any of the mutations (Figure 4.13). These results 
suggest that the varied functional effects of these mutations are due to 
conformational dynamics, rather than gross structural incompatibilities. However, 
due to the slow kinetics of these conformational transitions (~100 µs), exploring 
the effects of these mutations on protein dynamics is beyond the scope of the 
work presented here (Shukla et al., 2014). 
 
We observed many mutations that provided a growth advantage in the absence 
of drug (Figure 4.11 a). The observation of adaptive mutations indicates that Bcr-
Abl kinase function is linked to Ba/F3 growth rate and can be increased by many 
mutations, suggesting that the parental kinase activity of Abl may not have been 
subjected to stringent positive selection. Consistent with these observations, we 
speculate that signaling proteins such as kinases may be subject to balancing 
selection when too much or too little signaling is deleterious for organism fitness. 
This idea is consistent with observations that hyperactive kinases including Bcr-
Abl often lead to senescence in primary cells (Mooi and Peeper, 2006). 
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In the presence of imatinib, the fitness advantage of Bcr-Abl mutations were 
mediated by both drug binding and growth effects (Figure 4.11 a). The mutations 
with the strongest combined effects were located at position 315, which is 
consistent with mutations at this position evolving as the most commonly 
observed imatinib resistant mutations in clinical samples (Jones et al., 2009). 
Encouraged by this observation, we investigated if the combined effects in our 
screen together with mutational probabilities could predict clinical observations of 
imatinib resistance. Amino acid changes with the greatest combined effects and 
accessible by a single base change in our screen were ranked (Figure 4.11 b). 
We developed a predictive resistance score based on the combined effects we 
observed and mutational probabilities. The predictive resistance score correlates 
with observed prevalence in patients (Figure 4.11 c). Together, these 
observations indicate that kinase mutational scans can provide clinically relevant 
information.  
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CONCLUSIONS 
Here, we have demonstrated an approach to quantitatively interrogate the effect 
of point mutations on cell fitness across various conditions by leveraging the 
advantages of saturated mutant library generation, high-fidelity CRISPR-Cas9 
mediated library integration through HDR and high-throughput sequencing 
readout. Conventional mutagenesis study typically involves viral delivery of 
mutant library. However, random or “safe-harbor” virus integration fails to 
recapitulate the native chromatin context and ensure uniform transcription 
regulation for all the mutants, leading to inconsistent and noisy gene expression 
of individual variants(Day et al., 2000). Given that gene expression level changes 
caused by factors, such as copy number variation, also significantly affect cell 
fitness(Ciriello et al., 2013; Gadzicki et al., 2005; Willyard, 2015), this 
shortcoming markedly compromises the accuracy of the resulting measurement 
of mutational impact. A saturated mutagenesis approach using CRISPR-Cas9 
was recently reported to overcome these drawbacks (Findlay et al., 2014). 
However, this works harnesses the unique feature of splicing junction and small 
size of BRCA1 exon 18 and DBR1 exon 2, which does not apply to majority of 
coding region and poses strong limits on its application. With a unique intron 
based barcoding strategy and a systematic method optimizing HDR efficiency, 
our approach significantly expanded the randomized DNA region up to 1kb, and 
offers a more flexible way to study almost any gene of interest, particularly 
oncogenes involved in cancer. 
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We showed that our approach could quantitatively interpret the functional 
consequence of hundreds of BCR-ABL mutations at once. IC50, the gold 
standard to assessing drug resistance, depicts the effect of mutations on inhibitor 
binding, and has been widely used to predict therapeutic response of mutants. 
However, the question remains unsolved how to associate resistant BCR-ABL 
mutations identified from various in vitro high throughput mutagenesis screens 
with their actual clinical relevance(Azam et al., 2003; Ray et al., 2007). IC50 itself 
seems not to be a reliable way for this purpose based on our study. In contrast, a 
combined effect of both cell growth and inhibitor binding provides better 
estimation of the likelihood of individual mutation emerging from patients under 
TKI therapy. Nevertheless, an accurate estimation could only be achieved by 
taking into account the variable nucleotide substitution rate and the number of 
accessible single-base mutational pathways. As a proof of principle, we 
assessed those mutations within 311-319 region from patients treated with 
Imatinib and obtained marked association between our prediction and clinical 
data, suggesting a predictive power of this approach.  
 
While there is sufficient clinical data on BCR-ABL mutations, such information is 
still largely missing for other oncogenes, such as EGFR and BRAF, that are 
widely associated with cancer and that could be targeted by small molecules. 
The mutations observed to cause resistance in patients are often not clear until 
drugs are utilized clinically. In the case of HIV-1 protease, it was shown 
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previously that inhibitors confined to the space that the substrate would occupy 
can reduce resistance(Nalam et al., 2013). This pioneering work demonstrates 
that research on resistance mechanism has the capability to inform drug 
development. It also highlights the need for additional approaches such as the 
one presented here to analyze drug resistance mutations (e.g., when all of the 
relevant structures are not known).   
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MATERIALS AND METHODS 
Reagents 
Px330 vector was a gift from Mike Browsky lab. pTRIPZ vector was obtained 
from shRNA core facility at UMass Medical School. PUC19 vector was a gift from 
Lucio Castilla lab. BCR antibody (cat. No. 3902) was purchased from Cell 
Signaling Technology. Imatinib (cat. No. CT-IM001) and Dasatinib (cat.no. CT-
DS001) were purchased from ChemieTek Ponatinib was purchased from LC labs 
(cat.no. P-7022). Eelectroporation kit V(cat.no. VCA-1003) was purchased from 
Lonza. Doxycycline (cat.no. D9891) was purchased from Sigma.  
 
Cell lines and cell culture 
All Ba/F3 cell lines were maintained RPMI 1640 medium containing 10% fetal 
bovine serum (FBS), 4 mM L-glutamine, 100 units/ml penicillin, and 100 µg/ml 
streptomycin. Parental Ba/F3 cell culture was supplemented with 10ng/ml IL-3, 
and clonal Ba/F3 cell containing doxycycline inducible BCR-ABL was 
supplemented with 1ug/ml of doxycycline unless otherwise stated.  
 
Reporter plasmid construction 
The reporter construct was generated by removing the BCR-ABL kinase domain, 
such that in the absence of CRISPR-Cas9 cutting there would be an in-frame 
proximal downstream stop codon, thereby producing a truncated non-functional 
protein product containing BCR and a short region of ABL (Figure 4.2 and Figure 
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4.3). A PAM element (NGG) was engineered 3 nucleotides away from the 
junction, either upstream (BCR) or downstream (ABL), to create functional target 
sites that are not present in the endogenous BCR-ABL sequence.  SgRNA-
mediated CRISPR-Cas9 cutting results in complete separation of the BCR and 
ABL fragments.  To monitor the rate of CRISPR-Cas9 double strand break (DSB) 
formation, we introduced GFP linked to ABL through a 2A peptide such that non-
homologous end joining (NHEJ)-mediated mutagenesis at this locus will create 
indels, a portion of which will lead to in-frame expression of ABL and 2A-GFP. 
The BCR-ABL fusion protein was also put under control of a doxycycline-
regulated promoter for tight and quantitative control of BCR-ABL expression. 
 
Cutting efficiency of Cas9 could be affected by the base-pairing properties of 
sgRNA and its target DNA sequence (Doench et al., 2014). Therefore, we 
constructed three different versions of BCR-ABL reporter and two sgRNAs for 
each reporter to identify the most active combination. 
 
pTRIPZ vector was re-engineered by removing shRNA and TurboRed cassette 
removed and replaced with multiple cloning sites. Two PCR reactions were 
performed using phusion polymerase (cat.no. M0530, NEB) to amplify BCR 
region and ABL (Δkinase domain) region based on the reporter design, then PCR 
product is purified and fused together into pTRIPZ vector using Gibson assembly 
(cat.no. E2611, NEB).   
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Reporter cell line generation 
pTRIPZ reporter plasmids was packaged into low-titer lentivirus and transduced 
into Ba/F3 cells.  After 3 days of culturing, cells were subjected to puromycin 
selection, and continuously expanded for ~1 week. Cells were then collected, 
stained for 7AAD and single live cell were sorted at sterile condition into each 
well in 96-well plate containing culture medium with IL-3 and extra antibiotics 
(ciprofloxin). After 7~10 days of expanding without medium change, usually~50% 
of well will have colonies growing up. Colonies were then transferred into 24 well 
plate and cultured in IL-3 supplemented medium with 1ug/ml of Doxycycline for 
additional 48 hours. ~50 colonies from each reporter construct were then 
harvested for fusion protein expression analysis using western blots. The top 5 
colonies with highest fusion protein expression were considered to be most 
accessible to Cas9/Crisper and saved for subsequent HDR analysis.   
 
HDR optimization 
To optimize HDR efficiency, we used a donor template containing an in-frame 
DsRed (~600bp) flanked by homology arms (Figure 4.3). Successful HDR events 
will lead to both in-frame DsRed and GFP expression, and therefore HDR 
efficiency could be accurately estimated by the percentage of GFP+/DsRed+ 
cells (Figure 4.3). 
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First, we generated BCR-DsRed-ABL containing donor plasmids. Specifically, we 
replaced the kinase domain region with DsRed in BCR-ABL, short linker 
sequence was added to ensure in-frame expression of BCR-DsRed-ABL. Then, 
we performed PCR reactions with primers binding on either side of DsRed at 
different distance, 0.4kb, 0.8kb, 1.2kb, 1.5kb, 2kb, and 2.5kb, to generate PCR 
products with different homology arm length. Then these PCR products were 
fused into a small PUC19 vector using Sequence and Ligation Independent 
Cloning (Klein et al.) method to achieve the final donor plasmid. 
 
We then selected three clonal lines with similar expression of BCR-ABL fusion 
protein, one clone from each reporter lines. Then used 1.2kb homology arm 
donor plasmid and 10 ug of total plasmid (1:3 ratio of Cas9/Crispr:donor plasmid), 
and we found HRC reporter and sgRNA C2 gave the highest HDR rate(Figure 
4.3). Then we further optimized the homology arm length, and found 2kb 
homology sequence on both arms offers the best HDR rate (Figure 4.3). Next, 
we tested multiple clonal HRC BCR-ABL reporter clones and found variation in 
HDR efficiency (Figure 4.3), which is likely due to chromatin accessibility of 
reporter insertion site. We selected the HRC Clone 7(C7) and further optimized 
the ratio of sgRNA and donor template. Ba/F3 cells have high tolerance to large 
amount of plasmids, however, more than 20ug of total plasmid sometimes leads 
to significant portion of cell death (Figure 4.3). Therefore, we performed all our 
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following experiments using a ratio of 1:5 of sgRNA:Donor template, with a total 
amount of 20ug. We often manage to obtain 5~8% of HDR rate.  
 
Transfection was conducted using standard electroporation reaction(Lonza Kit V) 
with 2 million cells each reaction. A library with 1x10^4 variants could be 
efficiently incorporated with a minimal 5% HDR rate and a typical 10-fold 
coverage. By scaling up the electroporation reactions and with optimal 10% HDR 
rate, confident screening of a large library of 10^5~10^6 variants could be easily 
achieved. 
 
Verification of single chromatin locus integration of reporter gene 
Genomic DNA was extracted from reporter cell line C7, digested overnight with a 
4-cutter restriction enzyme CviQI, and then ligated to adaptors. Then, nested 
PCR was performed using KAPA HiFi DNA polymerase (cat.no. KK2602.) to 
amplify the joint region of the reporter construct and genomic DNA from both 5’ 
and 3’ end (Figure 4.5). PCR product from the clone that yield single PCR band 
on agarose gel was then cloned into TA vector and sequenced to identify the 
specific genomic location. 
 
T315x and T311-319x HDR donor library construction 
Site saturation libraries were generated using a cassette ligation strategy in a 
bacterial cloning plasmid and transferred to mammalian specific plasmid 
	 189	
constructs as previously described(Wagenaar et al., 2014). The T315X site 
saturation library was generated with a NNN codon at position 315, while the 
311-319 library utilized NNK codons. 
 
To facilitate specific recovery of inserted mutants, we further modified the donor 
template plasmid by inserting the human Beta-globin intron 2(~130bp) 
downstream of the BCR-ABL kinase domain to accommodate a set of barcodes 
as an alternative for specific identification of BCR-ABL mutants using deep-
sequencing (Figure 4.6). To ensure optimal splicing context is preserved to 
guarantee efficient splicing and protein expression, we inserted the intron 
between the two guanines of the CAGG sequence at~120bp downstream of the 
kinase domain. The barcodes(NMYRMYNMYRMYNMYRMYNM) were inserted 
between the 5’ splicing donor site and branch site, and also designed to avoid 
interference of normal splicing context, i.e., the 5’ splicing donor, 3’ splicing 
acceptor and branching (A) site. (Figure 4.6).  
 
By using CRISPR-Cas9-HDR to introduce donor plasmid with or without intron 
into the reporter cell line, we can see expression of BCR-ABL in both cases, 
indicating successfully splicing has happened (Figure 4.6). Previously, it was 
reported that a mini-intron could increase protein expression, potentially by 
stabilizing pre-mRNA. However, we did not notice dramatic difference in 
expression level of BCR-ABL. 
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Library introduction and drug treatment 
Day 1, one million of BaF3 reporter cells were cultured initially in T75 flask for 3 
days in the presence of IL3 but without doxycycline. Day 4, cells were collected, 
pelleted and re-suspended in 15ml of IL3 containing fresh medium for every 10 
million cells, cultured for additional 24 hours. Day 5, cells were collected for 
electroporation using optimal parameters defined above.  
 
Day 6, cells were transferred from 12-well plate into T25 with fresh medium, and 
doxycycline was added at this moment. Day 8, cells were pelleted, washed twice 
in IL3-free medium. An aliquot of cells(1~2 million) were saved as baseline 
control sample. The remaining cells were cultured in IL-3-free and doxycycline 
containing medium in T75 for additional 3 days, unless otherwise stated. Day 11, 
cells were collected and treated with DMSO, TKI, or a combination of drugs. Day 
14, all cells were collected and saved for genomic DNA extraction.  All samples 
should be pelleted and saved at -80 if not used immediately. 
 
Genomic DNA extraction and Nested PCR 
Cell pellet were thawed and re-suspended in DNA extraction buffer(100mM Tris 
pH8.0, 5mM EDTA, 1%SDS, 200mM NaCl)+ 5ul of protease K and digested at 
55 degree for 4 hours. Then genomic DNA were extracted using phenol:cloriform 
method, and kept at -20. 
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For 1st round of PCR, 2ug of total genomic DNA was used as template, 2mM 
Mg2Cl was added to ensure the high efficiency of polymerase. 1ul of 10uM 
primer (PE1, GFP_r), the PCR reaction was carried out using KAPA HIFI DNA 
polymerase. In 25ul reaction volume. 
 
Cycling condition:  
95°C   3min 
98°C   20s 
58°C   15s 
72°C   2:30min 
additional cycles  22x 
72°C   5min 
4°C      cool 
5ul of PCR product was checked on 1% agrose gel. All samples should yield a 
~2.5kb band, the band from baseline control sample should be barely 
seen(<10% library integration), while the rest of sample should give a nice 
band(~100% library integration.) 
 
For the 2nd round of PCR, 1ul of 1st round PCR product was used as template, 
1ul of 10uM primer (Index 1,2,3,…15, PE1) (see Table 4.1 for the list of nested 
PCR primers). The PCR reaction was carried out by switching to Phusion 
polymerase to avoid further amplification of 1st round PCR. 
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Cycling condition:  
95°C   3min 
98°C   20s 
58°C   15s 
72°C   20s 
additional cycles  9x 
72°C   5min 
4°C      cool 
5ul of PCR product was checked on 2.5% agrose gel. All samples should yield a 
~200bp band, the band from baseline control sample should be visible now, but 
still relatively faint compared to other samples. Final PCR products purified by 
silica column (Zymo Research). 
 
Library preparation and deep-sequencing: 
Library sample created by blending equimolar amounts of purified PCR products 
and then purifying by silica column (Zymo Research. Concentration of the library 
sample was determined by qPCR using Illumina Library Quantification kit (KAPA 
Biosystems).  Libraries with 20% PhiX control (Illumina) were sequenced on 
either a MiSeq or NextSeq sequencer (Illumina). 
 
Fitness and drug resistance analysis 
Deep sequencing results were processed by custom perl scripts. First, 
sequences with Phred scores >10 containing the constant region of the PCR 
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products were extracted from the fastq file. Extracted sequences were then 
parsed based on the sample ID added in the 2nd round of PCR; IDs correspond 
to the growth condition the PCR product was generated from. Next, counts for 
each unique barcode were generated for each condition/sample ID. Barcodes 
were then decoded using the subassembly file described in the T315x and T311-
319x HDR donor library construction section. Finally, counts for barcodes 
corresponding to the same codon or amino acid mutation were merged. 
 
The mutant frequencies for each condition were analyzed in three ways. First, 
the ratio of the ‘Day 9, -IL-3, DMSO’ to the ‘Day 3, +IL-3’ samples were log2 
transformed and normalized to the wild-type synonyms. This analysis highlights 
the effect each mutant has solely on cell growth in the absence of any inhibitor. 
The second analysis looks at the effect each mutant has on inhibitor resistance. 
This is done by taking the ratio of the ‘Day 9, -IL-3, Inhibitor’ to the ‘Day 9, -IL-3, 
DMSO’ samples, then log 2 transforming and normalizing to wild-type synonyms. 
Finally, the ratio of the ‘Day 9, -IL-3, Inhibitor’ to the ‘Day 3, +IL-3’ looks at the 
combined growth and resistance effect of each mutant. 
 
Mutational probability for each a.a. pair in Figure 4.11c was calculated with the 
following equation:   Score of combined effects x Single base mutational rate!!   
n = Number of single base mutational paths for each a.a. pair 
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Figure 4.1. Optimized CRISPR/Cas9 strategy efficiently chromosomally 
integrates barcoded Bcr-Abl libraries. a, Prior to genomic integration, Abl 
mutations were generated by site saturation mutagenesis and specifically 
associated with unique barcodes inserted into an engineered intron through a 
paired end sequencing reaction. b, CRISPR/Cas9 strategy to insert barcoded 
libraries of Bcr-Abl mutants into a consistent genomic location. Transduction was 
used to insert a defective Bcr-Abl allele into the genome. A CRISPR/Cas9 
strategy was utilized to introduce barcoded libraries of Abl mutations. Successful 
homologous replacement generates an intact Bcr-Abl gene and rescues 
expression and rescues the expression of GFP. c, The efficiency of homologous 
replacement was increased from initial levels (step 1) by optimization of the 
synthetic guide RNA and donor template sequences (step 2), homology arm 
length (step 3), clonal cell line (step 4), and the amount of guide RNA and donor 
template (step 5). Error bars represent the standard deviation of three 
independent experiments. d, The frequency of a library of site saturation 
mutations at the gatekeeper position (T315X) integrated into the genome was 
similar to the frequency of these mutations in the donor template, indicating 
efficient incorporation of mutants into a consistent genomic location.  
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Figure 4.2. Design of CRISPR/Cas9 mediated saturated mutagenesis 
system. Illustration of doxycycline inducible BCR-ABL(ΔKinase Domain) 2A-GFP 
reporter construct for CIRSPR/Cas9 mediated saturated mutagenesis. A stop 
codon was put immediately downstream of the BCR-ABL junction to terminate 
transcription and prevent GFP expression. Three reporter constructs were 
generated, varying in the junction region as shown in the DNA sequence. Two 
separate sgRNAs of opposite orientation were designed to recognize each 
junction and mediate Cas9 cutting right at the junction as the arrow pointed. With 
supplement of a donor plasmid containing the wildtype kinase domain flanked by 
homology arms, homology directed repair(HDR) pathway could facilitate 
incorporation of the wildtype kinase domain, restoring BCR-ABL kinase function 
to promote IL-3 independent growth of Ba/F3 cells and driving GFP expression. 
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Figure 4.8. Fitness of 315 mutations under various selection pressure. a, 
Flow chart showing the experimental procedures using CRISPR-Cas9 to 
introduce 315x library into reporter Ba/F3 cell line, and subsequent selection of 
mutations under growth selection and inhibitor selection. Samples at various 
stage were collected for PCR and deep-sequencing to study mutant enrichment. 
Three comparisons were performed, Day9 + DMSO vs Day 3 represents “growth 
effect”, Day 9 + Imatinib vs day 9 + DMSO represents “inhibitor effect”, Day 9 + 
Imatinib vs Day 3 represents “combined effect”. b, Enrichment analysis of 315 
mutants in growth effect, inhibitor effect and combined effect. Mutations that are 
accessible through single base change were marked in black, two bases change 
in dark grey, and three base change in light grey. c, Enrichment analysis of 315 
mutants in combined effect at different concentration of Imatinib or Ponatinib. d, 
Single base mutational pathway from Thr to Met or Glu. Mutations with increase 
fitness were marked in green, decrease fitness in red, near neutral mutation in 
black.  
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Primer Sequence 
PE1 
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTAC
ACGACGCTCTTCCGATCT 
GFR_R TCGTCCTTGAAGAAGATGGTG 
Index 1 
CAAGCAGAAGACGGCATACGAGATattactcgTCTCTGTCTC
CACATGCCCA 
Index 2 
CAAGCAGAAGACGGCATACGAGATtccggagaTCTCTGTCTC
CACATGCCCA 
Index 3 
CAAGCAGAAGACGGCATACGAGATcgctcattTCTCTGTCTC
CACATGCCCA 
Index 4 
CAAGCAGAAGACGGCATACGAGATgagattccTCTCTGTCTC
CACATGCCCA 
Index 5 
CAAGCAGAAGACGGCATACGAGATattcagaaTCTCTGTCTC
CACATGCCCA 
Index 6 
CAAGCAGAAGACGGCATACGAGATgaattcgtTCTCTGTCTC
CACATGCCCA 
Index 7 
CAAGCAGAAGACGGCATACGAGATctgaagctTCTCTGTCTC
CACATGCCCA 
Index 8 
CAAGCAGAAGACGGCATACGAGATtaatgcgcTCTCTGTCTC
CACATGCCCA 
Index 9 
CAAGCAGAAGACGGCATACGAGATcggctatgTCTCTGTCTC
CACATGCCCA 
Index 10 
CAAGCAGAAGACGGCATACGAGATtccgcgaaTCTCTGTCTC
CACATGCCCA 
Index 11 
CAAGCAGAAGACGGCATACGAGATtctcgcgcTCTCTGTCTC
CACATGCCCA 
Index 12 
CAAGCAGAAGACGGCATACGAGATagcgatagTCTCTGTCTC
CACATGCCCA 
Index 13 
CAAGCAGAAGACGGCATACGAGATcagatccaTCTCTGTCTC
CACATGCCCA 
Index 14 
CAAGCAGAAGACGGCATACGAGATtgtgaccaTCTCTGTCTC
CACATGCCCA 
Index 15 
CAAGCAGAAGACGGCATACGAGATacagtggtTCTCTGTCTC
CACATGCCCA 
 
Table 4.1. List of primers for nested PCR 
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CHAPTER V: DISCUSSION AND FUTURE PERSPECTIVES 
In this thesis work, I have employed CML as a model, and studied three major 
aspects of drug resistance, namely, BCR-ABL mutation based resistance which 
blocks drug-target interaction, BCR-ABL independent drug resistance, which is 
caused by activation of parallel survival pathway, and drug insensitivity of cancer 
stem cells.  
 
Despite the findings from current thesis work, many interesting areas remain to 
be explored: 
Genetic screens to study drug resistant genes 
In addition to PRKCH mediated maintenance of MAPK pathway discovered from 
my work, activation or maintenance of other pro-survival or anti-apoptotic 
pathways, including PI3K/AKT(Quentmeier et al., 2011), JAK/STAT(Warsch et al., 
2011), LYN kinase(Donato et al., 2003), have been reported to contribute to 
BCR-ABL independent IM resistance. Interestingly, all these pathways are 
directly regulated by, and act downstream of BCR-ABL(Weisberg et al., 2007). 
This raises the question how many different ways CML cells could employ to 
circumvent BCR-ABL inhibition induced cell death? 
 
“Oncogene addiction” has been a long established theory behind the scene of 
current targeted therapy(Weinstein and Joe, 2006). Cell viability is a status 
maintained by equilibrium of survival and death signals. Loss of oncogenic input 
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will lead to immediate loss of activity of multiple survival pathways, which 
reduces the apoptotic threshold.  In the context of BCR-ABL, IM treatment results 
in suppression of phosphorylation of CRKL, SRC kinases, loss of MAPK, 
JAK/STAT and PI3K activity as early as 4 hour in vitro(Ma et al., 2014). When 
treated long enough, cells will pass the “point of no return” and enter apoptosis.  
 
However, each signaling pathway is not linear, but rather part of a complicated 
signaling network(Bhalla and Iyengar, 1999). It is not uncommon that change of a 
proximal or even distal signaling node will lead to alteration of dynamics and 
kinetics of signal dampening caused by rapid loss of activation signal due to 
BCR-ABL inhibition.  For example, MAPK pathway, although is known as a linear 
cascade due to the scaffold proteins(Kolch, 2005). Activation of RAF protein 
could be either through RAS(Leevers et al., 1994), or other kinases such as 
PKC(Kolch et al., 1993). Additionally, there are three different RAF proteins, 
ARAF, BRAF, and CRAF(Marais et al., 1997), and three different RAS isoforms, 
NRAS, HRAS and KRAS(Malumbres and Barbacid, 2003). Different combination 
of RAS and RAF is another layer of regulation that is not directly affected by 
BCR-ABL. Other than this positive regulatory mechanism, MAPK pathway activity 
is also maintained by serine/threonine phosphatases, such as PP2A(Silverstein 
et al., 2002). 
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RNAi based knockdown or CRISPR-Cas9 mediated knockout genetic screens 
offer unprecedented tools to reveal those negative regulators that could 
potentially lead to resistance(Moffat et al., 2006; Wang et al., 2014). Recently 
developed CRISPRa and CRISPRi technology would be useful for complete 
evaluation of both potential positive and negative regulators(Gilbert et al., 2014).  
 
One caveat is that most genetic screens could only be performed in established 
cell lines, which might have accumulated additional mutations that may not exist 
in primary cancer cells. Also, primary cancer cells are often a mixed lineage, for 
example, CML is a stem cell based malignancy, and BCR-ABL could exist in all 
hematopoietic lineages. Performing genetic screens in a single clonal cell line 
from a defined lineage may not provide the entire picture. Some types of primary 
cells are difficult to transduce, the delivery of whole genome RNAi or CRISPR 
library could be a big challenge. In this scenario, customized small size 
sublibraries, such as kinome that target all kinases, phosophatome that target all 
phosphatase, epigenome that target all epigenetic regulators could be used 
instead. Transduced primary cells could then be transplanted back to humanized 
or syngeneic mice for expansion and therapy based selection. Any gene 
revealed in this way might be more clinically relevant. 
 
Drug resistance mechanisms of Leukemic Stem Cells 
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IM insensitivity of CML stem cell is an interesting phenomenon but also represent 
a major challenge for the whole cancer therapeutic field—eliminating cancer 
stem cells(Reya et al., 2001). Mounting evidence has shown that cancer stem 
cells are resistant to a variety of therapies(Dean et al., 2005). Acquirement of 
stem cell property is enough to lead to such resistance, as exampled by the 
epithelial-mesenchymal transition (EMT) process in which cancer cells with 
epithelial morphology are sensitive to cancer drugs but become resistant once 
acquired mesenchymal morphology(Doherty et al., 2016; Tam et al., 2013). This 
phenomenon highlights the immediate need to understand the effects of stem 
cell signaling characteristics on drug resistance other than the typical properties 
such as self-renewal and quiescence.  
 
In CML stem cells, genes including Alox5 and Pim2 have been found to be up-
regulated compared to normal HSCs, however, IM treatment fails to restore their 
expression back to endogenous level(Chen et al., 2009). In contrast, PIM2 
expression is highly dependent on BCR-ABL activity in CML cell lines, inhibition 
of BCR-ABL activity by IM completely abolishes PIM2 expression. Such evidence 
indicates the presence of leukemic stem-cell specific gene regulation in CML 
stem cells, and also raises the question why some genes are deregulated in CML 
stem cells but this deregulation is unable to be reversed by inhibiting BCR-ABL 
kinase function. One hypothesis is that BCR-ABL possesses other functional 
domains that can exert kinase independent effect on gene regulation. In addition, 
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such deregulated genes are adapted and maintained by stem cell specific 
signaling pathways once stimulated by BCR-ABL.  
 
Our results using TET-off BCR-ABL transgenic mice model provides certain 
clues for this hypothesis. After withdrawal of tetracycline (TET) water and 
induction of BCR-ABL expression, mice develop CML and CML stem cells have 
increased PIM2 expression. By adding back TET water, BCR-ABL expression is 
suppressed, CML is reversed, and PIM2 expression was restored to the 
endogenous level.  However, the detailed mechanisms why inhibiting BCR-ABL 
activity alone fails to inhibit PIM2 expression, and how BCR-ABL protein 
contributes to gene regulation in CML stem cells remain open questions.  
 
Cancer cell heterogeneity and drug resistance   
Cell heterogeneity is gradually recognized as a universal feature of normal and 
cancerous tissue(Altschuler and Wu, 2010). The advent of single cell RNA-seq 
technology also greatly facilitated the process of systematically evaluating 
population heterogeneity and revealing rare cell types(Grun et al., 2015; Johnson 
et al., 2015; Narsinh et al., 2011; Patel et al., 2014). In our single cell study of 
CML stem cell versus normal HSCs, we showed that both normal HSC and CML 
stem cells possess extensive gene expression heterogeneity. Presence of BCR-
ABL is thought to cause significant changes in many gene expression patterns as 
revealed by previous transcriptome studies(Juric et al., 2007; Nowicki et al., 
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2003). However, we found in our study that both CML stem cells and normal 
HSCs from CML patients display a gene expression pattern highly consistent 
with normal HSCs (Figure 3.1 c). In MDS plot, global gene expression 
differences caused by BCR-ABL expression seems to be minimal and masked by 
the population heterogeneity, as evidence by the inability to completely separate 
BCR-ABL- cells from BCR-ABL+ cells (Figure 3.1 e). Interestingly, cells from 
each individual patient closely aggregate together, regardless of BCR-ABL status, 
indicating greater contribution of genetic background to gene expression pattern 
than BCR-ABL expression. Conventional gene expression studies often use bulk 
cell population with a mixed population of cancer and normal cells from a group 
of patients or healthy donors. Given the large effect of genetic background on 
gene expression pattern(Whitney et al., 2003), the conventional analysis for 
differential gene expression could lead to large variation(up to 50 folds variation) 
in the expression of certain genes, which could account for 30% of total 
transcriptome(Cheung et al., 2003). Therefore, we propose using single cell 
RNA-seq coupled with unique molecular markers, BCR-ABL in the case of CML, 
as a novel strategy to study cancer specific gene expression between 
phenotypically indistinguishable cancer and normal cells. This could be 
particularly useful leukemia study since the leukemic and normal cells typically 
possess the same set of pre-defined cell surface markers(Sloma et al., 2010). In 
solid tumors, laser capture microdissection(LCM) could be used to pick individual 
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cells in a confined area(Frumkin et al., 2008), and perform similar studies 
accordingly.  
 
In addition, cell heterogeneity also contributes to origination of rare resistant cells 
during drug treatment(Burrell and Swanton, 2014; Dexter and Leith, 1986). A 
well-known example in CML field is the establishment of resistant K562 cell 
line(K562R) by treating sensitive K562 cells with increasing concentration of 
IM(Donato et al., 2003). K562R cells are no longer sensitive to BCR-ABL 
inhibition, but rather shifted its dependence to Lyn kinase as shown by markedly 
Lyn overexpression in K562R cells compared to K562S cells(Donato et al., 2003). 
Importantly, the final resistant clone does not harbor BCR-ABL mutations, it 
suggests rewiring and adaption of cell signaling network during prolonged drug 
treatment. Additional examples include the establishment of LAMA84R cells(le 
Coutre et al., 2000) and KCL22R cells(Puttini et al., 2006).  The feasibility to 
establish such resistant cell lines without drug target mutation strongly argue for 
the existence of cell signaling or gene expression heterogeneity even within a 
clonal population. Recent single cell study of T cells in response to LPS also 
proposed the idea of gene expression bimodality in a homogenous 
population(Shalek et al., 2013; Shalek et al., 2014). Daniel Haber’s group 
isolated circulating breast cancer cells, and showed that even isolated single 
HER2- cell could acquire HER2+ phenotype after a minimal 4 cell 
divisions(Jordan et al., 2016). Such intrinsic heterogeneity and bimodal gene 
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expression could underlie the emergence of drug resistant population. Drug 
treatment and prolonged cell survival due to insufficient death signal likely 
enriched and promoted the expansion of a minor cell population possessing 
beneficial gene expression signatures. This could be particularly true for primary 
cancer cells that are continuously supported by additional survival signals, such 
as cytokines or secondary messengers(Chen et al., 2016), from tumor cell 
microenvironment or stem cell niche. 
 
Despite the compelling evidence of cell population heterogeneity, the underlying 
cause remains elusive. It is still under debate whether cell cycle stage has a 
large contribution to the degree of cell heterogeneity(2016; Buettner et al., 2015; 
McDavid et al., 2016). Recently developed Div-seq from Zhang and Regev lab 
presents a unique advantage in resolving this debate by studying cells at 
predefined cell cycle stages(Habib et al., 2016). Again, there remain significant 
technical challenges in most of the single cell RNA-seq protocols(Saliba et al., 
2014). One of the challenges is that many protocols, such as Smart-seq, require 
significant amount of post-amplification, which may lead to a false positive 
bimodal gene expression or exaggerated gene expression variation among 
single cells.  However, bimodal expression of many genes have also been 
confirmed by RNA-FISH in Regev and Haber’s paper(Jordan et al., 2016; Shalek 
et al., 2013), indicating this is still a true phenomenon.  
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Evolution of oncogene during drug selection 
Current cellular proteins are thought to have been subjected over millions year of 
evolution and selection(Chothia and Gough, 2009). In terms of kinases, however, 
such adaption may be different from maximal activity(Arnold, 2009). When most 
of the mutations could cause functional defects, it has been shown that mutation 
of c-Abl and c-Src at gate keeper position from T to I or M could further increase 
their kinase activity and leading to transformation of transduced Ba/F3 cells 
overtime(Azam et al., 2008). This is supported by the crystal structure study that 
such mutations could promote the assembly of active confirmation, while proteins 
with wildtype residues are subjected to extensive post-translational modifications 
as sophisticated regulation of kinase activity(Azam et al., 2008).  
 
Our saturated mutagenesis study in BCR-ABL kinase domain revealed that a 
number of such mutations could lead to increased BCR-ABL activity, and these 
mutations are typically associated with drug resistance. Those that could be 
achieved by single nucleotide substitution are also frequently observed in drug 
resistant CML or Ph+ ALL patients(Soverini et al., 2011). More interestingly, a 
couple of mutations in 311-319 region, T315I and F317L, could be identified from 
patients prior to IM treatment, indicating clonal expansion and selection due to 
increased fitness/kinase function(Shah et al., 2002).  
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Since most of drugs are designed to specifically target one particular kinase 
conformation, either by inhibiting active conformation or locking it in an inactive 
conformation, mutations that block drug binding and/or promote kinase activity 
will easily lead to drug resistance. It is surprising that around 17% of BCR-ABL 
mutations in 311-319 region have positive effect on cell growth. However, 
previous mutagenesis screening fails to reveal such properties of these 
mutations due to the inherent drawbacks of their screening technologies, 
including variable gene expression caused by random retroviral integration in the 
genome.   
 
The novel screen strategy developed in the current study harnesses the 
CRISPR-Cas9 genome editing and HDR mechanism to introduce mutant library 
into a single chromatin locus for consistent gene expression. In addition, the 
mini-intron based barcoding strategy offers a simple tool to perform up to 20 
biological replicates in a single run, thus significantly increasing the robustness 
and reproducibility of the results. This novel screening platform could be easily 
adapted for any oncogene of interest and expanded to cover the whole ORF for a 
particular oncogene. Since most of the small molecule inhibitor takes years from 
its first development to pre-clinical evaluation till final clinical trials(Novac, 2013), 
it would be of great help if we can predict clinical resistance beforehand in order 
to facilitate next-generation drug development. The screening platform we 
developed here could be employed in the pre-clinical stage to study the protein-
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drug interaction, and systematically evaluate mutation fitness during therapy. For 
example, if a group of such mutations fall into a particular category, say, that 
promote the assembly of a particular protein conformation, the next-generation 
drug development could be initiated immediately to target this unique 
conformation and suppress drug resistance. 
 
Future cancer therapy 
In the current era of targeted cancer therapy, small molecules have played a 
critical role due to its ease of manufacturing and administration(Zhang et al., 
2009). As exampled by TKI, small molecule cancer drugs have significantly 
prolonged cancer patients’ overall survival and saved millions of lives(Bower et 
al., 2016; Gerber, 2008; Robert et al., 2015; Topalian et al., 2014). However, 
targeting a single oncogene, even though it is strongly addicted by cancer cells, 
the intrinsic hypermutation rate and heterogeneity in cell signaling pathways and 
gene expression pattern in cancer cells will lead to adaption of cancer cells and 
rewired signaling network overtime(Pawson and Warner, 2007). In this case, 
drug resistance has been and will always be unavoidable. Recently, chimeric 
antigen receptor T cells(CAR-T cells) were developed to treat refractory B-ALL 
by engineering cytotoxic T cells to target B cell-specific CD19 antigen. This 
enforced engagement leads to constant T cell proliferation and activation 
cytotoxic program to kill CD19-expressing cells. CAR-T therapy showed great 
clinical efficacy and sustained maintenance of leukemia remission(Kalos et al., 
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2011). However, clinical cases resistant to CAR-T therapy have been reported, 
and the mechanism was found to be mutation or loss of CD19 expression(Sotillo 
et al., 2015), suggesting cancer cells are still finding ways to adapt and evade 
immunotherapy. Although drug-targeting specificity enhances safety, capability to 
counteract upcoming changes of cancer cells and heterogeneity is compromised.  
 
Cancer evolution is a multi-step process, and includes clonal selection and 
expansion. In light of this, targeting multiple pathways using small molecules 
could significantly increase the cell death rate and prevent cells from 
accumulating additional mutations that may lead to subsequent resistance. Such 
combination therapy will greatly reduce the chance of resistance by suppressing 
clonal expansion events in the early period. In addition, our immune system has 
evolved to recognize and fight theoretically all hazardous signals, tuning body’s 
own immune system to directly combat cancer or maintain disease remission, 
probably in combination with small molecule-based targeted therapy could also 
be a critical way to manage evolving changes of cancer.  
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